Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MRNA

Moderna Inc

Sep 06 • 04:00PM ET

72.89

Dollar change -0.55
Percentage change -0.75	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO VO QQQ VUG VOT SPY IVV IBB XLV

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-15.38	Insider Own	10.86%	Shs Outstand	382.00M	Perf Week	-6.06%
Market Cap	28.02B	Forward P/E	-	EPS next Y	-7.23	Insider Trans	-1.41%	Shs Float	342.64M	Perf Month	-10.62%
Income	-5867.00M	PEG	-	EPS next Q	-1.64	Inst Own	67.96%	Short Float	7.30%	Perf Quarter	-52.88%
Sales	5.04B	P/S	5.56	EPS this Y	26.10%	Inst Trans	0.89%	Short Ratio	6.61	Perf Half Y	-26.73%
Book/sh	30.50	P/B	2.39	EPS next Y	20.68%	ROA	-31.24%	Short Interest	25.00M	Perf Year	-32.66%
Cash/sh	22.08	P/C	3.30	EPS next 5Y	-	ROE	-40.94%	52W Range	62.55 - 170.47	Perf YTD	-26.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.02%	ROI	-45.28%	52W High	-57.24%	Beta	1.68
Dividend TTM	-	Quick Ratio	3.92	Sales past 5Y	662.08%	Gross Margin	22.47%	52W Low	16.53%	ATR (14)	3.90
Dividend Ex-Date	-	Current Ratio	4.09	EPS Y/Y TTM	-601.75%	Oper. Margin	-92.09%	RSI (14)	25.56	Volatility	4.00% 3.95%
Employees	5600	Debt/Eq	0.11	Sales Y/Y TTM	-52.22%	Profit Margin	-116.36%	Recom	2.42	Target Price	124.11
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	8.04%	Payout	-	Rel Volume	0.90	Prev Close	73.44
Sales Surprise	87.68%	EPS Surprise	0.54%	Sales Q/Q	-29.94%	Earnings	Aug 01 BMO	Avg Volume	3.78M	Price	72.89
SMA20	-10.51%	SMA50	-27.96%	SMA200	-31.40%	Trades		Volume	3,418,070	Change	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Upgrade	HSBC Securities	Reduce → Hold	$82
Aug-07-24	Upgrade	Deutsche Bank	Sell → Hold	$85 → $80
Aug-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$125 → $90
Feb-26-24	Downgrade	HSBC Securities	Hold → Reduce	$75 → $86
Jan-02-24	Upgrade	Oppenheimer	Perform → Outperform	$142
Nov-29-23	Initiated	Canaccord Genuity	Hold	$82
Nov-03-23	Upgrade	HSBC Securities	Reduce → Hold	$89 → $69
Nov-02-23	Downgrade	Deutsche Bank	Hold → Sell	$125 → $60
Aug-04-23	Downgrade	TD Cowen	Outperform → Market Perform	$145 → $125
Aug-03-23	Downgrade	Deutsche Bank	Buy → Hold	$125
Jul-24-23	Initiated	William Blair	Mkt Perform	$136.28
Jul-14-23	Initiated	HSBC Securities	Reduce	$97
Jun-26-23	Upgrade	UBS	Neutral → Buy	$221 → $191
Apr-26-23	Initiated	Guggenheim	Neutral
Mar-13-23	Upgrade	TD Cowen	Market Perform → Outperform	$150 → $180
Mar-02-23	Initiated	RBC Capital Mkts	Outperform	$200
Feb-24-23	Downgrade	SVB Securities	Market Perform → Underperform	$111 → $93
Dec-19-22	Upgrade	Jefferies	Hold → Buy	$170 → $275
Dec-14-22	Downgrade	Chardan Capital Markets	Buy → Neutral	$186 → $191
Oct-21-22	Upgrade	SVB Leerink	Underperform → Mkt Perform	$174 → $101

Show Previous Ratings

Today 04:31AM	Is It Time to Buy August's Worst-Performing Nasdaq Stocks? (Motley Fool)
Sep-06-24 02:02PM	Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows (Benzinga)
07:04AM	Moderna's updated Covid-19 vaccine receives positive EMA CHMP opinion (Pharmaceutical Business Review)
07:00AM	Pandemic Darling Moderna Needs a Reality Check (The Wall Street Journal)
Sep-05-24 01:04PM	Moderna, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information MRNA (GlobeNewswire)
11:53AM	Loading…
11:53AM	Moderna mpox mRNA vaccine shows early promise in monkey study (Pharmaceutical Technology)
08:00AM	EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 (ACCESSWIRE)
Sep-04-24 08:35PM	Lightning Round: Moderna has to clean it up or the stock isn't going to rally, says Jim Cramer (CNBC TV)
01:14PM	Moderna Stock's Three-Year Decline Is It Time To Sell, Hold Or Buy? (Investor's Business Daily)
08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
07:44AM	UK MHRA grants authorisation for Moderna's updated Covid-19 vaccine (Pharmaceutical Business Review)
07:21AM	Is It Time to Buy August's Worst-Performing S&P 500 Stocks? (Motley Fool)
Sep-03-24 11:32PM	Is Merck & Co., Inc. (MRK) the Best Cancer Stock to Buy Now? (Insider Monkey) -5.76%
08:30AM	Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1 (ACCESSWIRE)
Sep-02-24 10:53AM	Novavax wins FDA emergency approval for updated Covid-19 vaccine (Pharmaceutical Technology)
07:00AM	Loading…
07:00AM	Taiwan Food & Drug Administration Approves Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 (ACCESSWIRE)
Sep-01-24 04:12AM	Street Calls of the Week: Moderna upgraded, downgrade for Hershey (Investing.com)
Aug-30-24 04:06PM	US clears updated COVID shots from Novavax, adding a 3rd fall vaccine option (Associated Press Finance) -5.76%
Aug-29-24 12:00PM	New COVID vaccines are here. What to know about the latest shots as summer surge continues (Fortune)
08:00AM	Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination (ACCESSWIRE)
Aug-28-24 06:59PM	Moderna, Inc. (MRNA): Among The Best Medical AI Companies (Insider Monkey)
06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
Aug-27-24 05:45AM	Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA (PR Newswire)
Aug-26-24 07:16AM	Moderna's RSV vaccine mRESVIA gains EC approval (Pharmaceutical Business Review)
Aug-23-24 02:01PM	The FDA Approved New Covid Vaccines. Should You Get One? (The Wall Street Journal)
07:00AM	Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) (ACCESSWIRE)
04:12AM	FDA approves updated mRNA vaccines for Covid-19 (Pharmaceutical Technology)
01:25AM	Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1 (ACCESSWIRE)
Aug-22-24 05:19PM	S&P 500 Gains and Losses Today: Moderna Falls Despite Approval of New COVID Shot (Investopedia) -6.47%
04:46PM	FDA approves updated COVID-19 vaccines from Pfizer, Moderna (Yahoo Finance Video)
02:33PM	Loading…
02:33PM	FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot (Benzinga)
01:47PM	Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2 (ACCESSWIRE)
01:44PM	The FDA Approved a New Covid Vaccine. Should You Get It? (The Wall Street Journal)
01:41PM	FDA Approves Updated Covid-19 Shots. Wall Street Isnt Upbeat About Sales for Pfizer and Moderna. (Barrons.com)
07:00AM	Moderna to Host Investor Event - R&D Day and Business Updates (ACCESSWIRE)
Aug-21-24 01:32PM	Is Moderna Stock A Sell After Slashing Its 2024 Sales Outlook? (Investor's Business Daily)
12:42AM	Covid-19: vaccine pricing varies wildly by country and company (Pharmaceutical Technology)
12:12AM	Myocarditis risks from Covid-19 vaccines are still less than the risks from Covid-19 (Pharmaceutical Technology)
Aug-20-24 11:34AM	Top 20 biopharmas market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots (Pharmaceutical Technology)
Aug-19-24 05:32AM	Pipeline Moves: Modernas pandemic influenza vaccine trial completes (Clinical Trials Arena)
04:07AM	Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell? (Motley Fool)
Aug-16-24 04:21PM	Pfizer, BioNTech hit roadblock in COVID-flu vaccine trial (Yahoo Finance Video)
10:21AM	Pfizers Stumble on Flu and Covid Shot Is a Plus for Moderna (Barrons.com)
12:22AM	Pfizer and Moderna Covid-19 vaccines usage and updated safety labels (Pharmaceutical Technology)
Aug-14-24 07:00AM	Moderna and Coursera Launch Free Course on mRNA Technology (ACCESSWIRE)
Aug-13-24 02:43PM	Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows (Benzinga)
Aug-12-24 08:05AM	Pfizer builds case for RSV shot with data from immunocompromised adults (BioPharma Dive)
03:52AM	Hunting the holy grail: the marred history of HIV vaccine trials (Clinical Trials Arena)
Aug-10-24 08:18AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-06-24 02:42PM	When Product Launches Struggle, Biotech Investors Reward Cost Cuts (The Wall Street Journal)
06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Aug-05-24 04:35PM	Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again. (Investor's Business Daily)
11:37AM	Midday movers: Apple, Nvidia, Intel, Coinbase and Moderna fall (Investing.com)
09:40AM	PayPal, Kellanova upgraded: Wall Street's top analyst calls (The Fly)
06:55AM	Moderna plunges on downgrade amid vaccine headwinds (Investing.com)
Aug-04-24 04:15AM	Cathie Wood Bought This Stock After Its 27% Drop. Should You? (Motley Fool)
Aug-03-24 01:05AM	Decoding Moderna Inc (MRNA): A Strategic SWOT Insight (GuruFocus.com)
Aug-02-24 06:05PM	Three-Stock Lunch: Boeing, Moderna and Micron (CNBC TV) -8.06%
05:09PM	The Most Advanced Country in Biomedical Engineering (Insider Monkey)
07:17AM	Stocks sink on July jobs report, Amazon and Intel reports: Yahoo Finance (Yahoo Finance Video)
06:51AM	Fed, Intel, Apple All Updated This Week. Whats Driving the Market Selloff. (Barrons.com)
12:15AM	Q2 2024 Moderna Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 06:44PM	Analyst Report: Moderna, Inc. (Morningstar Research) -21.01%
05:09PM	S&P 500 Gains and Losses Today: Moderna Drops as Soft Vaccine Demand Prompts Guidance Cut (Investopedia)
04:36PM	Weak Economic Data Prompts Stock Selloff (The Wall Street Journal)
04:02PM	Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat (Investor's Business Daily)
03:22PM	Moderna Stock Plunges After Vaccine Maker Cuts Guidance (The Wall Street Journal)
02:31PM	Who's to blame as Moderna's stock falls amid slashed guidance? (Yahoo Finance)
01:55PM	Midday movers: Meta jumps, semi stocks Qualcomm, and Arm plunge (TheStreet)
01:19PM	Stocks fall ahead of Apple, Amazon earnings: Yahoo Finance (Yahoo Finance Video)
12:45PM	Moderna (MRNA) Q2 2024 Earnings Call Transcript (Motley Fool)
12:23PM	Top Stock Movers Now: Moderna, Western Digital, Meta Platforms, and More (Investopedia)
11:54AM	Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash (Zacks)
11:49AM	Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall (Investing.com)
11:18AM	Moderna's Revenue Warning Sends the Stock Into the Red for 2024 (Investopedia)
10:46AM	Moderna Stock Sinks On Lowered 2024 Outlook, Cites Low European Sales, Competitive RSV Vaccine Market (Benzinga)
10:02AM	Moderna cuts 2024 guidance, CEO cites pullback in Europe (Yahoo Finance Video)
10:02AM	Moderna Earnings Beat Estimates. Why the Stock Is Sinking. (Barrons.com)
08:58AM	Moderna CEO Stephane Bancel on Q2 results, slashing its full-year sales guidance (CNBC TV)
07:40AM	Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:38AM	Moderna: Q2 Earnings Snapshot (Associated Press Finance)
06:32AM	Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue (Reuters)
06:30AM	Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates (ACCESSWIRE)
06:30AM	Moderna Cuts Revenue Guidance Amid Steeper Competition (Barrons.com)
Jul-31-24 06:33AM	Leveragen and Moderna link to advance therapeutics (Pharmaceutical Technology)
Jul-29-24 09:16AM	Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS (Zacks)
07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
06:07AM	RSV vaccine makers vying for market share in second year of shots (Reuters)
Jul-26-24 08:40AM	Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy? (Zacks)
03:30AM	This Biotech Risk-Taker Created Moderna. Now Hes Harnessing AI. (Barrons.com)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-24-24 07:24AM	Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board (BioPharma Dive)
Jul-23-24 05:50PM	Why Moderna (MRNA) Dipped More Than Broader Market Today (Zacks)
07:00AM	David Rubenstein Joins Moderna's Board of Directors (ACCESSWIRE)
06:00AM	Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-17-24 05:50PM	Moderna (MRNA) Stock Moves -0.93%: What You Should Know (Zacks)
08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jul-16-24 01:33PM	3 Biotech Stocks to Buy in Case of Another Pandemic (InvestorPlace)
10:14AM	Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock? (Zacks)

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klinger Shannon Thyme	Chief Legal Officer	Sep 03 '24	Sale	76.99	114	8,777	17,566	Sep 04 05:42 PM
Hoge Stephen	President	Sep 03 '24	Sale	76.99	318	24,483	1,443,002	Sep 04 04:26 PM
Klinger Shannon Thyme	Officer	Sep 03 '24	Proposed Sale	76.99	114	8,777		Sep 03 03:58 PM
Hoge Stephen	Officer	Sep 03 '24	Proposed Sale	76.99	318	24,482		Sep 03 03:42 PM
Mock James M	Chief Financial Officer	Aug 29 '24	Sale	78.03	162	12,640	8,767	Aug 30 04:37 PM
Klinger Shannon Thyme	Chief Legal Officer	Aug 29 '24	Sale	78.03	162	12,640	17,447	Aug 30 04:34 PM
Hoge Stephen	President	Aug 29 '24	Sale	78.03	300	23,408	1,442,668	Aug 30 04:32 PM
Mock James M	Chief Financial Officer	Aug 28 '24	Sale	79.39	1,321	104,881	8,600	Aug 29 04:45 PM
Klinger Shannon Thyme	Chief Legal Officer	Aug 28 '24	Sale	79.39	1,319	104,722	17,280	Aug 29 04:03 PM
Klinger Shannon Thyme	Officer	Aug 29 '24	Proposed Sale	78.03	162	12,640		Aug 29 03:52 PM
Mock James M	Officer	Aug 29 '24	Proposed Sale	78.03	162	12,640		Aug 29 03:43 PM
Hoge Stephen	Officer	Aug 29 '24	Proposed Sale	78.03	300	23,408		Aug 29 03:38 PM
Mock James M	Officer	Aug 28 '24	Proposed Sale	79.39	1,321	104,881		Aug 28 04:47 PM
Klinger Shannon Thyme	Officer	Aug 28 '24	Proposed Sale	79.39	1,319	104,722		Aug 28 04:30 PM
Hoge Stephen	President	Aug 12 '24	Sale	84.10	254	21,363	1,442,357	Aug 13 04:33 PM
Hoge Stephen	Officer	Aug 12 '24	Proposed Sale	84.10	254	21,363		Aug 12 04:05 PM
AFEYAN NOUBAR	Director	Jul 31 '24	Sale	119.96	15,000	1,799,443	2,224,015	Aug 02 07:00 PM
NOUBAR B AFEYAN	Director	Jul 31 '24	Proposed Sale	118.84	15,000	1,782,600		Jul 31 04:18 PM
AFEYAN NOUBAR	Director	Jul 24 '24	Sale	117.80	15,000	1,766,972	2,239,015	Jul 26 07:00 PM
AFEYAN NOUBAR	Director	Jul 17 '24	Sale	122.84	15,000	1,842,651	2,254,015	Jul 19 07:00 PM
Hoge Stephen	President	Jul 15 '24	Sale	121.12	15,000	1,816,800	1,442,089	Jul 16 04:08 PM
AFEYAN NOUBAR	Director	Jul 10 '24	Sale	117.08	15,000	1,756,177	2,269,015	Jul 12 07:00 PM
Mock James M	Chief Financial Officer	Jul 08 '24	Sale	118.24	689	81,465	7,269	Jul 09 04:34 PM
AFEYAN NOUBAR	Director	Jun 26 '24	Sale	127.22	15,000	1,908,293	2,284,015	Jun 28 07:00 PM
AFEYAN NOUBAR	Director	Jun 18 '24	Sale	133.57	15,000	2,003,561	2,299,015	Jun 21 07:00 PM
Hoge Stephen	President	Jun 17 '24	Sale	138.16	15,000	2,072,400	1,457,089	Jun 18 04:05 PM
AFEYAN NOUBAR	Director	Jun 12 '24	Sale	147.20	15,000	2,208,071	2,314,015	Jun 14 07:00 PM
AFEYAN NOUBAR	Director	Jun 11 '24	Sale	148.34	202,832	30,087,339	1,528,557	Jun 11 07:01 PM
Klinger Shannon Thyme	Chief Legal Officer	Jun 10 '24	Sale	148.09	5,178	766,785	15,947	Jun 11 04:05 PM
AFEYAN NOUBAR	Director	Jun 05 '24	Sale	151.25	15,000	2,268,804	1,946,931	Jun 07 07:00 PM
Mock James M	Chief Financial Officer	Jun 03 '24	Sale	140.72	691	97,237	6,506	Jun 04 05:27 PM
Hoge Stephen	President	Jun 03 '24	Sale	140.72	339	47,704	1,472,089	Jun 04 05:20 PM
Klinger Shannon Thyme	Chief Legal Officer	Jun 03 '24	Sale	140.72	122	17,168	10,878	Jun 04 05:12 PM
AFEYAN NOUBAR	Director	May 29 '24	Sale	145.08	20,000	2,901,585	1,961,931	May 31 07:00 PM
Mock James M	Chief Financial Officer	May 29 '24	Sale	144.50	183	26,444	5,871	May 30 04:36 PM
Klinger Shannon Thyme	Chief Legal Officer	May 29 '24	Sale	144.50	183	26,444	10,768	May 30 04:27 PM
Hoge Stephen	President	May 29 '24	Sale	144.50	341	49,276	1,471,777	May 30 04:14 PM
Mock James M	Chief Financial Officer	May 28 '24	Sale	162.47	648	105,283	5,726	May 29 04:16 PM
Klinger Shannon Thyme	Chief Legal Officer	May 28 '24	Sale	162.47	1,296	210,566	10,623	May 29 04:12 PM
AFEYAN NOUBAR	Director	May 22 '24	Sale	157.57	15,000	2,363,556	1,981,931	May 24 07:00 PM
AFEYAN NOUBAR	Director	May 15 '24	Sale	127.32	15,000	1,909,863	1,996,931	May 17 07:00 PM
Hoge Stephen	President	May 15 '24	Sale	127.49	15,000	1,912,350	1,471,508	May 17 04:04 PM
Hoge Stephen	President	May 10 '24	Sale	120.96	255	30,844	1,486,508	May 13 04:03 PM
AFEYAN NOUBAR	Director	May 08 '24	Sale	121.68	15,000	1,825,220	2,011,931	May 10 07:00 PM
AFEYAN NOUBAR	Director	May 01 '24	Sale	110.92	15,000	1,663,855	2,026,931	May 03 07:00 PM
AFEYAN NOUBAR	Director	Apr 24 '24	Sale	108.32	15,000	1,624,836	2,041,931	Apr 26 07:00 PM
AFEYAN NOUBAR	Director	Apr 17 '24	Sale	103.38	15,000	1,550,703	2,056,931	Apr 19 07:00 PM
Hoge Stephen	President	Apr 15 '24	Sale	105.02	15,000	1,575,300	1,486,241	Apr 16 04:23 PM
AFEYAN NOUBAR	Director	Apr 10 '24	Sale	107.12	15,000	1,606,865	2,071,931	Apr 12 07:00 PM
Mock James M	Chief Financial Officer	Apr 08 '24	Sale	101.93	705	71,859	5,048	Apr 09 04:09 PM
AFEYAN NOUBAR	Director	Apr 03 '24	Sale	101.68	15,000	1,525,268	2,086,931	Apr 05 07:00 PM
AFEYAN NOUBAR	Director	Mar 27 '24	Sale	109.06	15,000	1,635,864	2,101,931	Mar 29 07:00 PM
AFEYAN NOUBAR	Director	Mar 20 '24	Sale	102.39	15,000	1,535,820	2,116,931	Mar 22 07:00 PM
Hoge Stephen	President	Mar 15 '24	Sale	103.17	15,000	1,547,550	1,501,241	Mar 19 04:39 PM
AFEYAN NOUBAR	Director	Mar 13 '24	Sale	108.54	15,000	1,628,031	2,131,931	Mar 15 07:00 PM
Klinger Shannon Thyme	Chief Legal Officer	Mar 08 '24	Sale	99.05	544	53,884	9,267	Mar 11 09:05 AM
Klinger Shannon Thyme	Chief Legal Officer	Mar 04 '24	Sale	94.34	117	11,038	8,673	Mar 05 05:56 PM
Hoge Stephen	President	Mar 04 '24	Sale	94.34	309	29,151	1,516,241	Mar 05 05:52 PM
Mock James M	Chief Financial Officer	Feb 29 '24	Sale	94.57	647	61,188	4,300	Mar 01 05:33 PM
Klinger Shannon Thyme	Chief Legal Officer	Feb 29 '24	Sale	94.57	670	63,363	8,557	Mar 01 05:29 PM
Hoge Stephen	President	Feb 29 '24	Sale	94.57	2,388	225,838	1,515,898	Mar 01 05:25 PM
Hoge Stephen	President	Feb 22 '24	Sale	100.00	15,000	1,500,000	1,513,433	Feb 23 04:04 PM
Hoge Stephen	President	Feb 16 '24	Sale	88.88	10,542	936,981	1,528,433	Feb 16 04:19 PM
Bancel Stephane	Chief Executive Officer	Feb 16 '24	Sale	88.88	26,351	2,342,098	5,460,224	Feb 16 04:10 PM
Hoge Stephen	President	Feb 12 '24	Sale	86.23	304	26,214	1,516,281	Feb 13 04:13 PM
Hoge Stephen	President	Jan 16 '24	Sale	103.90	15,000	1,558,500	1,516,063	Jan 17 04:12 PM
Mock James M	Chief Financial Officer	Jan 08 '24	Sale	109.75	772	84,731	3,632	Jan 09 04:08 PM
Hoge Stephen	President	Dec 27 '23	Sale	100.01	45,000	4,500,450	1,531,063	Dec 28 08:00 AM
Klinger Shannon Thyme	Chief Legal Officer	Dec 08 '23	Sale	79.09	563	44,525	7,912	Dec 11 04:03 PM
Garay Arpa	Chief Commercial Officer	Dec 06 '23	Sale	78.34	564	44,182	3,690	Dec 07 04:21 PM
Klinger Shannon Thyme	Chief Legal Officer	Dec 04 '23	Sale	79.31	111	8,804	7,336	Dec 05 04:10 PM
Hoge Stephen	President	Dec 04 '23	Sale	79.31	309	24,508	1,576,063	Dec 05 04:07 PM
Hoge Stephen	President	Nov 29 '23	Sale	79.81	1,136	90,666	1,575,721	Nov 30 04:11 PM
Hoge Stephen	President	Nov 10 '23	Sale	68.76	263	18,084	1,574,446	Nov 13 04:02 PM
AFEYAN NOUBAR	Director	Nov 01 '23	Sale	76.00	10,000	760,032	2,146,931	Nov 03 07:00 PM
AFEYAN NOUBAR	Director	Oct 25 '23	Sale	76.99	10,000	769,854	2,156,931	Oct 27 07:00 PM
AFEYAN NOUBAR	Director	Oct 11 '23	Sale	103.30	15,000	1,549,441	2,166,931	Oct 13 07:00 PM
Mock James M	Chief Financial Officer	Oct 06 '23	Sale	102.50	2,858	292,953	2,952	Oct 10 04:51 PM
AFEYAN NOUBAR	Director	Oct 04 '23	Sale	102.72	15,000	1,540,845	2,181,931	Oct 06 07:02 PM
AFEYAN NOUBAR	Director	Sep 27 '23	Sale	98.96	10,000	989,646	2,196,931	Sep 29 07:00 PM
AFEYAN NOUBAR	Director	Sep 20 '23	Sale	104.74	15,000	1,571,090	2,206,931	Sep 22 07:00 PM
Hoge Stephen	President	Sep 15 '23	Sale	112.99	15,000	1,694,850	1,574,187	Sep 18 04:06 PM
AFEYAN NOUBAR	Director	Sep 13 '23	Sale	109.70	15,000	1,645,522	2,221,931	Sep 15 07:00 PM
Klinger Shannon Thyme	Chief Legal Officer	Sep 08 '23	Sale	107.22	557	59,722	7,215	Sep 11 04:02 PM

Open in Screener

EDIT

Editas Medicine Inc

Sep 06 • 04:00PM ET

3.59

Dollar change +0.10
Percentage change 2.87	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

EDIT Editas Medicine Inc daily Stock Chart

Held by: VTI XBI IWM VXF VB VBK IWN IBB DFAT VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	0.94%	Shs Outstand	81.77M	Perf Week	-3.23%
Market Cap	296.10M	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-1.35%	Shs Float	81.70M	Perf Month	-12.65%
Income	-193.45M	PEG	-	EPS next Q	-0.78	Inst Own	69.52%	Short Float	20.68%	Perf Quarter	-33.89%
Sales	67.03M	P/S	4.42	EPS this Y	-44.83%	Inst Trans	2.32%	Short Ratio	8.84	Perf Half Y	-59.44%
Book/sh	2.81	P/B	1.28	EPS next Y	5.21%	ROA	-41.75%	Short Interest	16.90M	Perf Year	-60.64%
Cash/sh	3.38	P/C	1.06	EPS next 5Y	1.70%	ROE	-61.23%	52W Range	3.40 - 11.69	Perf YTD	-64.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.88%	ROI	-76.61%	52W High	-69.29%	Beta	1.99
Dividend TTM	-	Quick Ratio	3.85	Sales past 5Y	101.57%	Gross Margin	91.33%	52W Low	5.59%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.85	EPS Y/Y TTM	20.53%	Oper. Margin	-317.78%	RSI (14)	35.89	Volatility	5.39% 5.57%
Employees	265	Debt/Eq	0.17	Sales Y/Y TTM	247.03%	Profit Margin	-288.59%	Recom	2.11	Target Price	13.86
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-45.51%	Payout	-	Rel Volume	1.03	Prev Close	3.49
Sales Surprise	-89.27%	EPS Surprise	-16.48%	Sales Q/Q	-82.23%	Earnings	Aug 07 BMO	Avg Volume	1.91M	Price	3.59
SMA20	-6.72%	SMA50	-22.05%	SMA200	-48.13%	Trades		Volume	1,964,984	Change	2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral	$25 → $13
Sep-29-22	Initiated	BofA Securities	Neutral	$18
Oct-19-21	Initiated	SVB Leerink	Mkt Perform	$41
Sep-24-21	Initiated	Stifel	Hold	$65
Sep-10-21	Upgrade	Oppenheimer	Perform → Outperform	$42 → $80
Aug-09-21	Upgrade	Truist	Hold → Buy	$45 → $80
Aug-05-21	Upgrade	Evercore ISI	Underperform → Outperform	$20 → $60
Jun-04-21	Resumed	Robert W. Baird	Outperform	$44
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$40

Show Previous Ratings

Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)
03:39AM	Q2 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:05AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -12.18%
07:07AM	Loading…
07:07AM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Second Quarter 2024 Results and Business Updates (GlobeNewswire)
Jul-31-24 07:00AM	Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-17-24 11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace) +5.01%
Jun-29-24 08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 09:04AM	What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential? (Insider Monkey)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
04:36PM	Loading…
04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-25-24 08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-17-24 08:13AM	Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies (Zacks)
Jun-14-24 03:01AM	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.83%
03:00AM	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire)
Jun-07-24 11:30AM	Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-22-24 07:05PM	EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (GuruFocus.com) +9.26%
May-14-24 07:01PM	Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (GuruFocus.com) +5.63%
04:27PM	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing (MT Newswires)
10:00AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June (GlobeNewswire)
May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Loading…
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-22-24 04:31PM	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? (Zacks)
Mar-07-24 03:31AM	1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. (Motley Fool)
Mar-05-24 11:52PM	Insider Sells Shares of Editas Medicine Inc (EDIT) (GuruFocus.com) -7.86%
Mar-04-24 10:30AM	1 Beaten-Down Stock With 55% Upside, According to Wall Street (Motley Fool) -5.79%
Mar-02-24 09:49PM	Why Editas Medicine Stock Soared as Much as 42% Higher This Week (Motley Fool)
Feb-29-24 11:26AM	Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.12%
08:42AM	Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up (Zacks)
Feb-28-24 11:15PM	Q4 2023 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) +24.94%
08:10AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials (GuruFocus.com)
07:08AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates (GlobeNewswire)
Feb-21-24 07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Feb-19-24 09:55AM	Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade (Zacks)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 12:00PM	What Makes Editas (EDIT) a New Buy Stock (Zacks)
Jan-31-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-21-24 09:37AM	Could Editas Medicine Become the Next CRISPR Therapeutics? (Motley Fool)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-15-24 05:19AM	Down 88%, Could Editas Medicine Be a Good Investment Now? (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 08:15AM	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool)
Jan-03-24 07:00AM	Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.11%
Jan-02-24 10:15AM	Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why (Zacks)
Dec-23-23 08:02AM	Editas Just Caught a Break Thanks to Vertex Pharmaceuticals (Motley Fool)
Dec-14-23 08:32AM	Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6% (Zacks)
06:30AM	Editas cashes in on CRISPR patent with Vertex deal (BioPharma Dive)
Dec-13-23 05:12PM	S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the Fed (Investopedia) +5.69%
04:06PM	Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal (Investopedia)
12:30PM	Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss (Investopedia)
09:00AM	Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 (GlobeNewswire)
Dec-11-23 01:22PM	ASH23: Pharma branding, Editas high bar and clinical trial diversity (BioPharma Dive) -5.71%
12:00PM	Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-05-23 07:00AM	1 Promising Stock Down 66% That Could Skyrocket in 2024 (Motley Fool)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-22-23 06:30AM	Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year (InvestorPlace)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +10.84% -6.64%
05:36AM	2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street (Motley Fool)
Nov-16-23 03:25PM	3 Long-Term Growth Stocks Analysts Are Bullish On (InvestorPlace)
Nov-09-23 03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace) -6.31%
Nov-06-23 09:00AM	Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
Nov-05-23 05:51PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:45AM	Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +18.21%
08:34AM	Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ... (GuruFocus.com)
07:17AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2023 Results and Business Updates (GlobeNewswire)
Nov-02-23 09:12AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 07:00AM	Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly) +5.12%
01:53AM	The Trade Desk cleans up; DraftKings 'stronger than ever': 5 big analyst picks (Investing.com)
Oct-18-23 11:05AM	3 Gene Editing Stocks to Generate Super-Charged Gains (InvestorPlace)
09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool)
Oct-17-23 11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks) -6.20%

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Sep 04 '24	Sale	3.42	518	1,774	133,895	Sep 06 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 04 '24	Sale	3.42	1,555	5,325	313,724	Sep 06 04:18 PM
O'Neill Gilmore Neil	Officer	Sep 03 '24	Proposed Sale	3.92	3,000	11,760		Aug 29 04:19 PM
Mei Baisong	Officer	Sep 03 '24	Proposed Sale	3.92	1,000	3,920		Aug 29 04:17 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 25 '24	Sale	5.42	11,886	64,370	73,136	Jul 26 05:02 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jul 19 '24	Sale	5.21	6,619	34,456	134,413	Jul 22 05:01 PM
O'Neill Gilmore Neil	CEO	Jun 04 '24	Sale	5.50	12,191	66,997	315,279	Jun 06 04:17 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	5.50	511	2,808	141,032	Jun 06 04:16 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	May 20 '24	Sale	5.61	22,337	125,404	116,829	May 22 04:30 PM
Hopfield Jessica	Director	May 13 '24	Buy	5.64	45,000	253,868	67,700	May 14 04:17 PM
O'Neill Gilmore Neil	CEO	Mar 05 '24	Sale	9.42	77,824	732,884	327,470	Mar 05 08:00 PM
Mei Baisong	SVP, CHIEF MEDICAL OFFICER	Mar 04 '24	Sale	9.42	20,327	191,425	141,543	Mar 05 07:54 PM
Eaton Bruce	EVP, CBO AND CTO	Dec 05 '23	Sale	10.90	103	1,122	74,791	Dec 07 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 14 '23	Sale	8.21	695	5,706	74,894	Nov 16 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 07 '23	Sale	8.40	139	1,168	75,589	Nov 09 04:31 PM

Open in Screener

RGNX

Regenxbio Inc

Sep 06 • 04:00PM ET

11.48

Dollar change +0.10
Percentage change 0.88	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IJR VTI VB IWM XBI VXF VBK IWN SPSM IBB

Index	RUT	P/E	-	EPS (ttm)	-5.27	Insider Own	9.86%	Shs Outstand	49.42M	Perf Week	-4.33%
Market Cap	567.34M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-2.77%	Shs Float	44.55M	Perf Month	-4.65%
Income	-241.08M	PEG	-	EPS next Q	-1.12	Inst Own	89.90%	Short Float	12.86%	Perf Quarter	-16.57%
Sales	89.04M	P/S	6.37	EPS this Y	24.86%	Inst Trans	-3.00%	Short Ratio	9.97	Perf Half Y	-50.58%
Book/sh	7.06	P/B	1.63	EPS next Y	76.16%	ROA	-38.52%	Short Interest	5.73M	Perf Year	-35.03%
Cash/sh	5.88	P/C	1.95	EPS next 5Y	13.60%	ROE	-63.94%	52W Range	10.49 - 28.80	Perf YTD	-36.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.56%	52W High	-60.14%	Beta	1.22
Dividend TTM	-	Quick Ratio	3.53	Sales past 5Y	72.63%	Gross Margin	37.75%	52W Low	9.44%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	3.53	EPS Y/Y TTM	16.62%	Oper. Margin	-277.01%	RSI (14)	42.73	Volatility	5.77% 5.16%
Employees	344	Debt/Eq	0.46	Sales Y/Y TTM	-8.18%	Profit Margin	-270.74%	Recom	1.22	Target Price	39.44
Option/Short	Yes / Yes	LT Debt/Eq	0.34	EPS Q/Q	36.74%	Payout	-	Rel Volume	0.64	Prev Close	11.38
Sales Surprise	-2.95%	EPS Surprise	18.70%	Sales Q/Q	11.60%	Earnings	Aug 01 AMC	Avg Volume	574.81K	Price	11.48
SMA20	-3.72%	SMA50	-6.60%	SMA200	-28.42%	Trades		Volume	365,010	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$38 → $37
Jun-18-19	Reiterated	Chardan Capital Markets	Buy	$145 → $150
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy	$127.50 → $145
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform

Show Previous Ratings

Sep-04-24 09:15AM	New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth (GlobeNewswire)
Sep-03-24 01:33PM	RegenxBio touts positive data for rare disease drug RGX-121 (Pharmaceutical Technology) -7.20%
08:04AM	REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect (PR Newswire)
Aug-29-24 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-27-24 07:05AM	REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (PR Newswire)
07:05AM	Loading…
Aug-08-24 07:05AM	REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (PR Newswire)
06:00AM	7 Biotech Stocks to Buy for Their Game-Changing Potential (InvestorPlace)
Aug-06-24 09:55AM	Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet (Zacks)
Aug-01-24 05:45PM	Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.60%
04:46PM	Regenxbio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
07:03AM	REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire)
Jul-30-24 07:01PM	Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX) (GuruFocus.com)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 07:05AM	REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire) +5.50%
09:59AM	Loading…
Jul-12-24 09:59AM	Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains? (Zacks)
Jun-27-24 10:05AM	Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) -6.57%
Jun-25-24 04:32AM	Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace) +6.41%
07:05AM	REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients (PR Newswire)
Jun-21-24 04:28PM	Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy (Investor's Business Daily)
06:40AM	Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy (Investor's Business Daily)
Jun-18-24 07:05AM	REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II (PR Newswire)
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-12-24 08:00AM	Regenxbio CEO to step down after 15 years (BioPharma Dive)
07:05AM	REGENXBIO Announces Leadership Transition (PR Newswire)
Jun-05-24 07:05AM	REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-15-24 11:38AM	HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating (MT Newswires)
May-10-24 02:30PM	Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
07:05AM	Loading…
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-09-24 03:53PM	REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.94%
11:11AM	UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating (MT Newswires)
07:11AM	Q1 2024 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
03:46AM	Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ... (GuruFocus.com)
May-08-24 09:56PM	RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:40PM	Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:44PM	Regenxbio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
May-01-24 07:05AM	REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire) +5.54%
Apr-24-24 07:05AM	REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (PR Newswire)
Mar-28-24 01:09PM	REGENXBIO Sees Positive Results For Macular Degeneration Therapy (Exec Edge) -5.00%
07:05AM	REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD (PR Newswire)
Mar-27-24 04:05PM	REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days (PR Newswire)
Mar-18-24 07:00PM	Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
Mar-11-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-08-24 01:29AM	Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares (GuruFocus.com)
Mar-06-24 11:20PM	REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants (PR Newswire)
04:10PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
11:33AM	REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study (Zacks)
03:01AM	Regenxbio data suggest niche in Duchenne gene therapy (BioPharma Dive)
Mar-05-24 07:05AM	REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL (PR Newswire) +15.22%
Feb-29-24 04:57PM	REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE Trial (PR Newswire) -12.36% +21.50%
Feb-28-24 11:05AM	Q4 2023 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
09:36AM	REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:35PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +9.16%
04:41PM	Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights (GuruFocus.com)
04:32PM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-21-24 07:05AM	REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-17-24 12:07AM	Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Feb-08-24 09:36AM	REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up (Zacks) +11.81%
04:50AM	Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength? (Zacks)
Feb-07-24 11:40AM	REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint (PR Newswire) +11.65%
07:05AM	REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE Trial (PR Newswire)
Jan-31-24 07:05AM	REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 (PR Newswire)
Jan-18-24 09:01PM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Jan-16-24 02:47PM	REGENXBIO Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery (PR Newswire)
Jan-10-24 07:05AM	REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting (PR Newswire)
Jan-09-24 06:20PM	Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX) (Zacks)
Jan-08-24 07:05AM	U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit (PR Newswire) -12.22%
Dec-22-23 09:01AM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Nov-29-23 07:05AM	REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE Trial (PR Newswire)
Nov-16-23 09:55AM	Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade (Zacks)
Nov-09-23 04:46PM	REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.13%
06:37AM	'Difficult, but necessary, steps': SQZ lays off 80% of staff, Regenxbio cuts 15% (FierceBiotech.com)
Nov-08-23 04:42PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-03-23 06:53PM	REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery (PR Newswire) +8.03%
Nov-01-23 07:05AM	REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire) +10.09%
Oct-30-23 07:05AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (PR Newswire)
Oct-05-23 07:05AM	REGENXBIO to Participate in the Jefferies CNS/Neuro Summit (PR Newswire)
Oct-03-23 04:05PM	REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society (PR Newswire) -8.12%
Sep-26-23 07:05AM	REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-05-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-30-23 07:05AM	Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium (PR Newswire)
Aug-23-23 04:05PM	REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (PR Newswire)
Aug-02-23 05:55PM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.51%
04:41PM	Regenxbio: Q2 Earnings Snapshot (AP Finance)
04:05PM	REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Aug-01-23 04:05PM	REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference (PR Newswire)
Jul-26-23 07:05AM	REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Jul-24-23 04:05PM	REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting (PR Newswire)
Jul-11-23 07:05AM	REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023 (PR Newswire)
Jul-01-23 10:09AM	Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price (Simply Wall St.)
Jun-27-23 07:05AM	REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates (PR Newswire) +6.89%
Jun-21-23 08:00PM	RGNX: Lowering target price to $25.00 (Argus Research)
Jun-20-23 08:00AM	REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit (PR Newswire)

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KARABELAS ARGERIS N	Director	Sep 03 '24	Option Exercise	3.76	10,000	37,600	21,286	Sep 04 08:20 PM
KARABELAS ARGERIS N	Director	Sep 03 '24	Sale	11.56	10,000	115,588	11,286	Sep 04 08:20 PM
Mills Kenneth T.	Director	Aug 08 '24	Option Exercise	0.85	36,316	30,869	444,351	Aug 12 04:58 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Option Exercise	3.85	10,100	38,874	21,386	Aug 05 06:39 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Sale	13.51	10,100	136,454	11,286	Aug 05 06:39 PM
Simpson Curran	Chief Executive Officer	Aug 01 '24	Sale	15.00	100	1,500	170,037	Aug 05 06:39 PM
ARGERIS N KARABELAS	Director	Aug 01 '24	Proposed Sale	14.25	31,000	441,750		Aug 01 04:34 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Option Exercise	12.74	11,000	140,140	22,286	Jul 30 05:01 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Sale	15.04	11,000	165,495	11,286	Jul 30 05:01 PM
Simpson Curran	Chief Executive Officer	Jul 29 '24	Sale	15.04	9,648	145,106	170,137	Jul 30 05:01 PM
CURRAN M SIMPSON	Director	Jul 29 '24	Proposed Sale	14.33	25,106	359,769		Jul 29 04:13 PM
Mills Kenneth T.	Director	Jul 25 '24	Option Exercise	3.76	15,369	57,787	423,404	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Option Exercise	3.76	12,221	45,951	420,256	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 25 '24	Sale	13.96	15,369	214,501	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Sale	13.78	12,221	168,433	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 17 '24	Option Exercise	3.76	2,210	8,310	410,245	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Option Exercise	3.76	200	752	408,235	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 17 '24	Sale	13.77	2,210	30,440	408,035	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Sale	13.76	200	2,752	408,035	Jul 18 05:05 PM
KARABELAS ARGERIS N	Director	Jul 01 '24	Option Exercise	3.76	10,000	37,600	21,286	Jul 03 07:55 AM
KARABELAS ARGERIS N	Director	Jul 01 '24	Sale	11.27	10,000	112,691	11,286	Jul 03 07:55 AM
Mills Kenneth T.	President and CEO	May 14 '24	Option Exercise	3.76	15,000	56,400	423,035	May 16 05:06 PM
Mills Kenneth T.	President and CEO	May 14 '24	Sale	15.81	15,000	237,222	408,035	May 16 05:06 PM
Mills Kenneth T.	President and CEO	Apr 15 '24	Option Exercise	3.76	15,000	56,400	423,035	Apr 17 05:05 PM
Mills Kenneth T.	President and CEO	Apr 15 '24	Sale	18.19	15,000	272,871	408,035	Apr 17 05:05 PM
Vasista Vittal	Chief Financial Officer	Mar 19 '24	Option Exercise	3.76	20,041	75,354	246,534	Mar 21 05:20 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Mar 18 05:03 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Sale	21.86	15,000	327,942	408,035	Mar 18 05:03 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Option Exercise	22.25	12,878	286,536	120,070	Mar 07 06:05 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Sale	28.36	12,878	365,220	107,192	Mar 07 06:05 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Sale	16.76	15,000	251,349	408,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Option Exercise	3.76	45,000	169,200	453,035	Jan 18 06:39 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Sale	15.18	45,000	682,992	408,035	Jan 18 06:39 PM
PAKOLA STEVE	Chief Medical Officer	Jan 03 '24	Sale	17.39	17,237	299,789	107,192	Jan 04 04:23 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Option Exercise	3.66	45,000	164,835	400,289	Dec 21 01:38 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Sale	19.68	45,000	885,825	355,289	Dec 21 01:38 PM

Open in Screener

IMVT

Immunovant Inc

Sep 06 • 04:00PM ET

34.03

Dollar change +0.41
Percentage change 1.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VB VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.92	Insider Own	57.71%	Shs Outstand	145.58M	Perf Week	9.85%
Market Cap	4.98B	Forward P/E	-	EPS next Y	-2.32	Insider Trans	-0.23%	Shs Float	61.90M	Perf Month	26.13%
Income	-272.55M	PEG	-	EPS next Q	-0.59	Inst Own	50.55%	Short Float	19.76%	Perf Quarter	33.82%
Sales	0.00M	P/S	-	EPS this Y	-31.34%	Inst Trans	5.01%	Short Ratio	12.23	Perf Half Y	4.90%
Book/sh	3.73	P/B	9.13	EPS next Y	6.24%	ROA	-57.93%	Short Interest	12.23M	Perf Year	47.83%
Cash/sh	3.83	P/C	8.89	EPS next 5Y	3.69%	ROE	-64.54%	52W Range	19.50 - 45.58	Perf YTD	-19.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-50.04%	52W High	-25.34%	Beta	0.70
Dividend TTM	-	Quick Ratio	13.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	74.51%	ATR (14)	1.35
Dividend Ex-Date	-	Current Ratio	13.08	EPS Y/Y TTM	0.52%	Oper. Margin	0.00%	RSI (14)	67.89	Volatility	4.83% 4.17%
Employees	207	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	48.43
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-5.29%	Payout	-	Rel Volume	1.55	Prev Close	33.62
Sales Surprise	-	EPS Surprise	-0.53%	Sales Q/Q	-	Earnings	Aug 06 AMC	Avg Volume	1.00M	Price	34.03
SMA20	10.03%	SMA50	16.02%	SMA200	4.02%	Trades		Volume	1,549,499	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy	$30
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$10 → $27
Sep-26-22	Downgrade	UBS	Buy → Neutral	$7 → $5
Dec-08-21	Initiated	Wells Fargo	Equal Weight	$9
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $10
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform	$12 → $7
Jun-01-21	Downgrade	Stifel	Buy → Hold	$28 → $9
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Sep-05-24 11:31AM	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? (Zacks) +9.55%
06:30AM	Immunovant to Host Graves' Disease Program Update on September 9, 2024 (GlobeNewswire)
Aug-09-24 12:20AM	Q1 2025 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 04:05PM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 (GlobeNewswire)
Jun-28-24 11:30AM	Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
08:04AM	Loading…
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:26AM	Q4 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily) -10.69%
11:29AM	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus (Zacks)
07:22AM	Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive)
05:53AM	Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart (FierceBiotech.com)
May-29-24 09:53PM	IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 (InvestorPlace)
04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
04:01PM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 (GlobeNewswire)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
06:28PM	Loading…
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
May-13-24 09:55AM	Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet (Zacks)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-22-24 11:53AM	Here's Why You Should Add Immunovant (IMVT) to Your Portfolio (Zacks)
Apr-17-24 12:00PM	What Makes Immunovant (IMVT) a New Buy Stock (Zacks) -6.48%
Mar-25-24 03:00PM	Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily)
11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 11:30AM	Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? (Zacks)
Mar-12-24 07:30AM	Immunovant Awarded U.S. Patent for IMVT-1402 (GlobeNewswire)
Mar-08-24 09:35AM	Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks (Zacks)
03:04PM	Loading…
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
Feb-23-24 11:22PM	Immunovant Inc CFO Eva Barnett Sells 2,930 Shares (GuruFocus.com)
Feb-14-24 04:35AM	Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs (GuruFocus.com)
12:29AM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-13-24 07:26AM	Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus (Zacks)
Feb-12-24 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 (GlobeNewswire)
Feb-06-24 02:38PM	7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Jan-22-24 06:07AM	Should You Invest in Immunovant (IMVT)? (Insider Monkey)
Jan-19-24 04:39PM	3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-13-24 03:02AM	Immunovant Inc CFO Eva Barnett Sells 3,515 Shares (GuruFocus.com)
Jan-03-24 08:00AM	Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.33%
Dec-26-23 10:01AM	Immunovant (IMVT) Rose on Positive Clinical Trial (Insider Monkey) +6.53%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily) +8.07% +6.09%
11:00AM	Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data (Zacks)
10:57AM	Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% (Benzinga)
06:49AM	Immunovant stakes claim for FcRn niche, posting midphase Graves' data and plotting next steps (FierceBiotech.com)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -12.84%
04:30PM	Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire)
Dec-19-23 10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-01-23 01:01AM	Here's Why Immunovant (IMVT) Outperformed in Q3 (Insider Monkey)
Nov-29-23 10:22AM	Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data (Zacks) +6.19%
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire) +7.36%
07:00AM	Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
Nov-25-23 11:03AM	Immunovant Inc CEO Peter Salzmann Sells Over 16,000 Shares (GuruFocus.com)
Nov-14-23 12:30AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents) +6.62%
Nov-13-23 08:00AM	Immunovant to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-23 07:19AM	Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus (Zacks)
Nov-09-23 08:17AM	Immunovant Inc (IMVT) Reports Fiscal Q2 Results: R&D Investments Surge Amidst Clinical Progress (GuruFocus.com) -6.23%
07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023 (GlobeNewswire)
Oct-27-23 11:02PM	Insider Sell: Chief Legal Officer Mark Levine Sells 4,107 Shares of Immunovant Inc (GuruFocus.com)
Oct-13-23 09:50AM	Netflix downgraded, Applied Materials upgraded: Wall Street's top analyst calls (The Fly) +6.04%
Oct-11-23 11:01PM	CFO Eva Barnett Sells 4,557 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-07-23 01:00AM	CEO Peter Salzmann Sells 5,239 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-05-23 03:01AM	Sciences Roivant, Director and 10% Owner, Buys 1,526,316 Shares of Immunovant Inc (IMVT) (GuruFocus.com) +7.64%
Oct-02-23 04:52PM	Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -9.77%
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 11:41PM	Immunovant Announces Pricing of $450 Million Common Stock Financing (GlobeNewswire)
04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily)
04:06PM	Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering (Investor's Business Daily)
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
12:21PM	Why Immunovant Stock Is Bolting Higher Today (Motley Fool)
09:25AM	Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data (Zacks)
Sep-26-23 05:00PM	Immunovant Announces Proposed Offering of $300 Million of Common Stock (GlobeNewswire) +97.04%
04:13PM	Immunovant Doubles And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
04:06PM	Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations (Investopedia)
03:23PM	Why Shares of Immunovant Are Soaring on Tuesday (Motley Fool)
02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com)
10:01AM	Immunovant Soars 73% And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
09:10AM	These 2 Biotech Stocks Are Bucking a Down Market Tuesday (Motley Fool)
06:00AM	Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire)
Sep-25-23 11:01PM	Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023 (GlobeNewswire)
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey) -5.09%
Aug-12-23 08:25AM	We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate (Simply Wall St.)
Aug-11-23 11:20AM	Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus (Zacks)
Aug-10-23 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023 (GlobeNewswire) +6.69%
Aug-09-23 06:26AM	Daily Vickers Top Buyers & Sellers for 08/09/2023 (Argus Research)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 01:42AM	Q4 2023 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Jun-21-23 11:30AM	Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-23-23 09:48AM	Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus (Zacks) -6.36%
06:05AM	Estimating The Intrinsic Value Of Immunovant, Inc. (NASDAQ:IMVT) (Simply Wall St.)
May-22-23 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023 (GlobeNewswire) +11.98%
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Feb-15-23 01:14PM	Immunovant Could Potentially Be An M&A Target, Writes Analyst (Benzinga)
Feb-03-23 07:00AM	Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022 (GlobeNewswire)
Dec-29-22 11:04AM	We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth (Simply Wall St.)
Dec-19-22 07:53AM	The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant (Zacks)
Dec-16-22 08:06AM	4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023 (Zacks)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levine Mark S.	Chief Legal Officer	Aug 21 '24	Sale	31.86	3,295	104,976	330,099	Aug 23 04:15 PM
Macias William L.	Chief Medical Officer	Aug 21 '24	Sale	31.86	3,027	96,437	368,332	Aug 23 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Aug 21 '24	Sale	31.86	3,768	120,045	343,776	Aug 23 04:11 PM
Butchko Julia G.	Chief Development Officer	Aug 21 '24	Sale	31.86	3,027	96,437	440,959	Aug 23 04:10 PM
Salzmann Peter	Chief Executive Officer	Aug 21 '24	Sale	31.86	15,068	480,052	1,008,344	Aug 23 04:07 PM
Stout Jay S	Chief Technology Officer	Jul 24 '24	Sale	27.76	2,813	78,089	144,926	Jul 26 04:20 PM
Geffner Michael	Chief Medical Officer	Jul 24 '24	Sale	27.76	3,456	95,939	138,160	Jul 26 04:19 PM
Levine Mark S.	Chief Legal Officer	Jul 24 '24	Sale	27.76	4,015	111,456	333,394	Jul 26 04:17 PM
Levine Mark S.	Chief Legal Officer	Jul 17 '24	Sale	29.69	2,505	74,382	337,409	Jul 19 05:42 PM
Macias William L.	Chief Medical Officer	Jul 17 '24	Sale	29.69	3,044	90,386	371,359	Jul 19 05:41 PM
Barnett Eva Renee	Chief Financial Officer	Jul 17 '24	Sale	29.69	3,123	92,733	347,544	Jul 19 05:39 PM
Butchko Julia G.	Chief Development Officer	Jul 17 '24	Sale	29.69	2,867	85,132	443,986	Jul 19 05:38 PM
Salzmann Peter	Chief Executive Officer	Jul 17 '24	Sale	29.69	8,685	257,887	1,023,412	Jul 19 05:36 PM
Barnett Eva Renee	Chief Financial Officer	Jul 09 '24	Sale	28.06	4,747	133,201	350,667	Jul 10 05:07 PM
Butchko Julia G.	Chief Development Officer	Jul 09 '24	Sale	28.06	1,527	42,848	446,853	Jul 10 05:06 PM
Salzmann Peter	Chief Executive Officer	Jul 09 '24	Sale	28.06	4,619	129,609	1,032,097	Jul 10 05:04 PM
Barnett Eva Renee	Chief Financial Officer	May 22 '24	Sale	29.65	4,042	119,845	355,414	May 24 04:18 PM
Salzmann Peter	Chief Executive Officer	May 22 '24	Sale	29.65	16,163	479,233	1,036,716	May 24 04:15 PM
Butchko Julia G.	Chief Development Officer	May 22 '24	Sale	29.65	3,247	96,274	448,380	May 24 04:14 PM
Macias William L.	Chief Medical Officer	May 22 '24	Sale	29.65	3,247	96,274	374,403	May 24 04:13 PM
Levine Mark S.	Chief Legal Officer	May 22 '24	Sale	29.65	3,242	96,125	339,914	May 24 04:10 PM
Geffner Michael	Chief Medical Officer	Apr 24 '24	Sale	28.90	3,261	94,243	141,616	Apr 26 05:22 PM
Stout Jay S	Chief Technology Officer	Apr 24 '24	Sale	28.90	7,239	209,207	147,739	Apr 26 05:20 PM
Levine Mark S.	Chief Legal Officer	Apr 24 '24	Sale	28.90	3,963	114,531	343,156	Apr 26 05:18 PM
Levine Mark S.	Chief Legal Officer	Apr 17 '24	Sale	29.06	9,827	285,554	347,119	Apr 19 06:06 PM
Macias William L.	Chief Medical Officer	Apr 17 '24	Sale	29.06	8,280	240,602	377,650	Apr 19 06:05 PM
Barnett Eva Renee	Chief Financial Officer	Apr 17 '24	Sale	29.06	12,253	356,049	359,456	Apr 19 06:01 PM
Butchko Julia G.	Chief Development Officer	Apr 17 '24	Sale	29.06	10,115	293,923	451,627	Apr 19 05:59 PM
Salzmann Peter	Chief Executive Officer	Apr 17 '24	Sale	29.06	34,079	990,269	1,052,879	Apr 19 05:57 PM
Barnett Eva Renee	Chief Financial Officer	Apr 09 '24	Sale	31.18	3,689	115,023	371,709	Apr 10 04:18 PM
Butchko Julia G.	Chief Development Officer	Apr 09 '24	Sale	31.18	1,053	32,833	461,742	Apr 10 04:16 PM
Salzmann Peter	Chief Executive Officer	Apr 09 '24	Sale	31.18	4,807	149,882	1,086,958	Apr 10 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Feb 22 '24	Sale	36.15	2,930	105,920	320,420	Feb 23 04:21 PM
Levine Mark S.	Chief Legal Officer	Feb 22 '24	Sale	36.15	2,134	77,144	301,968	Feb 23 04:18 PM
Macias William L.	Chief Medical Officer	Feb 22 '24	Sale	36.15	2,221	80,289	330,952	Feb 23 04:16 PM
Butchko Julia G.	Chief Development Officer	Feb 22 '24	Sale	36.15	2,146	77,578	407,817	Feb 23 04:14 PM
Salzmann Peter	Chief Executive Officer	Feb 22 '24	Sale	36.15	13,454	486,362	931,231	Feb 23 04:11 PM
Levine Mark S.	Chief Legal Officer	Jan 26 '24	Sale	37.92	3,027	114,778	304,102	Jan 29 04:12 PM
Geffner Michael	Chief Medical Officer	Jan 26 '24	Sale	37.92	10,101	383,012	89,899	Jan 29 04:11 PM
Macias William L.	Chief Medical Officer	Jan 18 '24	Sale	41.03	424	17,397	333,173	Jan 19 04:04 PM
Barnett Eva Renee	Chief Financial Officer	Jan 11 '24	Sale	41.83	3,515	147,023	323,350	Jan 12 04:34 PM
Butchko Julia G.	Chief Development Officer	Jan 05 '24	Sale	38.59	1,297	50,051	409,963	Jan 09 04:20 PM
Salzmann Peter	Chief Executive Officer	Jan 05 '24	Sale	38.59	3,824	147,568	944,685	Jan 09 04:18 PM
Fromkin Andrew J.	Director	Dec 01 '23	Sale	39.73	12,350	490,697	88,658	Dec 05 04:30 PM
Pande Atul	Director	Dec 01 '23	Sale	39.73	12,350	490,667	83,158	Dec 05 04:28 PM
MIGAUSKY GEORGE V	Director	Dec 01 '23	Sale	39.73	12,700	504,567	109,808	Dec 05 04:25 PM
Salzmann Peter	Chief Executive Officer	Nov 22 '23	Sale	32.78	16,217	531,581	948,509	Nov 24 02:55 PM
Barnett Eva Renee	Chief Financial Officer	Nov 22 '23	Sale	32.78	4,055	132,920	326,865	Nov 24 02:51 PM
Butchko Julia G.	Chief Development Officer	Nov 22 '23	Sale	32.78	3,265	107,024	411,260	Nov 24 02:47 PM
Macias William L.	Chief Medical Officer	Nov 22 '23	Sale	32.78	3,265	107,024	333,597	Nov 24 02:45 PM
Levine Mark S.	Chief Legal Officer	Nov 22 '23	Sale	32.78	3,252	106,598	307,129	Nov 24 02:41 PM
Levine Mark S.	Chief Legal Officer	Oct 25 '23	Sale	34.66	4,107	142,349	310,381	Oct 27 04:04 PM
Macias William L.	Chief Medical Officer	Oct 19 '23	Sale	36.80	530	19,504	336,862	Oct 20 04:06 PM
Barnett Eva Renee	Chief Financial Officer	Oct 10 '23	Sale	36.92	4,557	168,244	330,920	Oct 11 04:11 PM
Butchko Julia G.	Chief Development Officer	Oct 05 '23	Sale	36.24	1,735	62,885	414,525	Oct 06 05:15 PM
Salzmann Peter	Chief Executive Officer	Oct 05 '23	Sale	36.24	5,239	189,887	964,726	Oct 06 05:10 PM
Roivant Sciences Ltd.	Director	Oct 02 '23	Buy	38.00	1,526,316	58,000,008	79,805,331	Oct 04 05:15 PM

Open in Screener

RXRX

Recursion Pharmaceuticals Inc

Sep 06 • 04:00PM ET

5.92

Dollar change -0.25
Percentage change -4.05	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

RXRX Recursion Pharmaceuticals Inc daily Stock Chart

Held by: ARKK ARKG VTI VB IWM XBI VXF VBK IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	23.68%	Shs Outstand	226.26M	Perf Week	-20.11%
Market Cap	1.67B	Forward P/E	-	EPS next Y	-1.72	Insider Trans	-1.55%	Shs Float	215.41M	Perf Month	-7.06%
Income	-374.93M	PEG	-	EPS next Q	-0.33	Inst Own	77.36%	Short Float	25.14%	Perf Quarter	-34.30%
Sales	49.63M	P/S	33.67	EPS this Y	1.11%	Inst Trans	3.80%	Short Ratio	9.49	Perf Half Y	-46.91%
Book/sh	2.08	P/B	2.85	EPS next Y	-10.01%	ROA	-51.98%	Short Interest	54.15M	Perf Year	-34.59%
Cash/sh	1.69	P/C	3.51	EPS next 5Y	12.00%	ROE	-71.18%	52W Range	4.97 - 15.74	Perf YTD	-39.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.41%	ROI	-57.01%	52W High	-62.39%	Beta	0.85
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	132.77%	Gross Margin	-31.81%	52W Low	19.11%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	-17.59%	Oper. Margin	-817.09%	RSI (14)	35.50	Volatility	7.43% 6.89%
Employees	-	Debt/Eq	0.15	Sales Y/Y TTM	-0.70%	Profit Margin	-755.37%	Recom	2.50	Target Price	10.14
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-5.72%	Payout	-	Rel Volume	0.80	Prev Close	6.17
Sales Surprise	20.46%	EPS Surprise	-4.09%	Sales Q/Q	30.86%	Earnings	Aug 08 BMO	Avg Volume	5.70M	Price	5.92
SMA20	-14.33%	SMA50	-19.90%	SMA200	-34.73%	Trades		Volume	4,561,976	Change	-4.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Sep-03-24 08:00AM	Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability (GlobeNewswire) -16.62%
07:11AM	AI specialist Recursion says lead drug is safe, but efficacy less clear (BioPharma Dive)
Aug-30-24 04:10AM	Is Recursion Pharmaceuticals a Warren Buffett Stock? (Motley Fool)
Aug-28-24 07:04PM	Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies (Insider Monkey)
Aug-18-24 12:34PM	The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. (Motley Fool)
09:53AM	Loading…
Aug-17-24 09:53AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-16-24 06:36PM	These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter (Investopedia) +6.08%
Aug-14-24 09:45AM	How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates (GlobeNewswire)
Aug-13-24 07:05AM	Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks (Motley Fool) +8.46%
Aug-12-24 09:15AM	Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move (Motley Fool)
Aug-11-24 04:59AM	Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? (Motley Fool)
Aug-08-24 05:37PM	AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals (Benzinga) -5.27%
02:41PM	CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:45AM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:39AM	Loading…
07:39AM	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities (GlobeNewswire)
07:30AM	Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:07AM	Biotech firm Recursion to buy smaller peer Exscientia for $688 million (Reuters)
01:32AM	Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT (GlobeNewswire)
Aug-06-24 06:00AM	Is Recursion Pharmaceuticals a Millionaire-Maker? (Motley Fool)
Aug-05-24 04:01PM	Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th (GlobeNewswire)
Jul-31-24 05:06AM	99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks (Motley Fool)
Jul-29-24 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why (Zacks)
Jul-27-24 05:41AM	Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? (Motley Fool)
Jul-26-24 09:55AM	Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know (Zacks)
Jul-18-24 06:10AM	3 Millionaire-Maker Artificial Intelligence (AI) Stocks (Motley Fool) -5.75%
Jul-14-24 06:25AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Jul-13-24 09:29AM	1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell (Motley Fool)
06:26AM	3 Healthcare Stocks Injecting AI for Big Gains (InvestorPlace)
Jul-12-24 05:50AM	These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street (Motley Fool) +8.85%
07:09PM	Loading…
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-28-24 10:28AM	Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
03:48AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
Jun-27-24 08:15AM	3 AI Stocks on the Edge of a Massive Surge (InvestorPlace) -13.53%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 10:07PM	Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock (GlobeNewswire) -6.61%
04:06PM	Recursion Announces Proposed Offering of Class A Common Stock (GlobeNewswire)
Jun-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jun-24-24 09:00AM	Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data (Business Wire) +5.54%
08:00AM	Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day (GlobeNewswire)
Jun-13-24 02:40PM	3 Stocks Under $10 Set to Quadruple by 2025: June Edition (InvestorPlace)
Jun-08-24 11:37AM	Nvidia Owns These 4 Stocks. Heres How Theyre Doing. (Barrons.com)
Jun-07-24 09:00AM	Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim (Motley Fool) -5.55%
Jun-05-24 06:26AM	Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance (InvestorPlace) +8.09%
Jun-03-24 09:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:15AM	Cathie Wood Owns These 2 AI Stocks. Should You? (Motley Fool)
Jun-02-24 03:40AM	Is Recursion Pharmaceuticals Stock a Millionaire-Maker? (Motley Fool)
May-31-24 02:46AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com) -6.65%
May-30-24 04:46AM	Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock (Insider Monkey)
04:32AM	7 Best Under-The-Radar AI Stocks Hedge Funds are Buying (Insider Monkey)
May-29-24 03:27PM	Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool (GlobeNewswire)
May-24-24 04:30PM	Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board (GlobeNewswire)
06:30AM	2 Stocks That Could 10x by 2035 (Motley Fool)
May-23-24 09:00AM	Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock (Zacks)
May-17-24 02:36AM	Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
May-15-24 08:45AM	What's the Difference Between Biotech Stocks and TechBio Stocks? (Motley Fool)
May-13-24 09:59AM	Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed (MT Newswires) +10.23%
05:00AM	Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry (GlobeNewswire)
May-12-24 08:15AM	Cathie Wood Is Buying This Under-the-Radar AI Stock (Motley Fool)
May-10-24 08:05PM	Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer (CNBC TV) +10.23%
01:26PM	Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ... (GuruFocus.com)
12:36PM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:04PM	Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
05:25PM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 11:41AM	Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? (Zacks)
May-03-24 05:50PM	Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
May-02-24 09:00AM	Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know (Zacks) +5.40%
08:00AM	Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 (GlobeNewswire)
May-01-24 08:01AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.65%
Apr-30-24 08:00AM	Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program (GlobeNewswire)
07:29AM	Jim Cramer is Recommending These 10 Stocks Heading Into May 2024 (Insider Monkey)
Apr-27-24 08:58AM	Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves (Motley Fool)
07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
08:01AM	AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 (PR Newswire)
Apr-17-24 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
07:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
Apr-16-24 08:00AM	Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer (GlobeNewswire)
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -7.37%
08:00AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-10-24 05:50AM	Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. (Motley Fool) -5.61%
Apr-08-24 09:00AM	The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation (Motley Fool)
Apr-04-24 08:45AM	Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
01:31AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares (GuruFocus.com)
Apr-03-24 09:35AM	Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround (Zacks)
Apr-02-24 08:00AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire) -6.40%
Apr-01-24 12:00PM	All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy (Zacks) -6.02%
Mar-26-24 08:00AM	Recursion Publishes Annual Environmental, Social and Governance Report (GlobeNewswire)
Mar-22-24 01:29AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
Mar-18-24 01:00PM	New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence (Benzinga)
Mar-15-24 04:54PM	Since Nvidia Disclosed Stakes in These Stocks, They've Soared (Investopedia)
01:49AM	Recursion Pharmaceuticals Inc CFO Michael Secora Sells 50,000 Shares (GuruFocus.com)
Mar-11-24 04:00AM	Recursion Announces Plans to Open New Office in London (GlobeNewswire) -7.33%
Mar-07-24 10:28AM	Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 02:58PM	Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community (GlobeNewswire)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Chief Executive Officer	Sep 05 '24	Sale	6.14	20,000	122,800	762,656	Sep 06 04:57 PM
Gibson Christopher	Chief Executive Officer	Sep 04 '24	Sale	6.04	20,000	120,800	762,656	Sep 06 04:57 PM
Borgeson Blake	Director	Sep 03 '24	Sale	6.27	11,447	71,718	7,121,322	Sep 05 05:25 PM
Gibson Christopher	Officer	Sep 05 '24	Proposed Sale	6.14	20,000	122,800		Sep 05 11:43 AM
Gibson Christopher	Officer	Sep 04 '24	Proposed Sale	6.04	20,000	120,800		Sep 04 01:16 PM
Marriott Tina	President and COO	Aug 29 '24	Option Exercise	1.06	6,000	6,360	527,138	Sep 03 04:48 PM
Marriott Tina	President and COO	Aug 29 '24	Sale	7.56	6,000	45,376	521,138	Sep 03 04:48 PM
Borgeson Blake	Director	Sep 03 '24	Proposed Sale	6.27	11,447	71,717		Sep 03 04:27 PM
Gibson Christopher	Chief Executive Officer	Aug 30 '24	Option Exercise	2.48	5,000	12,400	762,656	Aug 30 04:26 PM
Marriott Tina	Officer	Aug 29 '24	Proposed Sale	7.56	6,000	45,376		Aug 29 04:53 PM
Gibson Christopher	Chief Executive Officer	Aug 29 '24	Option Exercise	2.48	5,000	12,400	757,656	Aug 29 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 28 '24	Option Exercise	2.48	5,000	12,400	752,656	Aug 28 04:12 PM
Gibson Christopher	Chief Executive Officer	Aug 27 '24	Option Exercise	2.48	5,000	12,400	747,656	Aug 27 04:10 PM
Gibson Christopher	Chief Executive Officer	Aug 26 '24	Option Exercise	2.48	5,000	12,400	742,656	Aug 26 04:42 PM
Gibson Christopher	Chief Executive Officer	Aug 23 '24	Option Exercise	2.48	5,000	12,400	737,656	Aug 23 05:25 PM
Borgeson Blake	Director	Aug 20 '24	Sale	7.12	11,447	81,532	7,132,769	Aug 22 06:48 PM
Borgeson Blake	Director	Aug 20 '24	Proposed Sale	7.12	11,447	81,533		Aug 20 04:25 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Option Exercise	2.22	39,375	87,413	1,355,968	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Option Exercise	2.22	39,375	87,413	1,380,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Sale	6.35	15,000	95,252	1,365,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Sale	6.35	15,000	95,182	1,340,968	Aug 15 05:24 PM
Secora Michael	Officer	Aug 14 '24	Proposed Sale	6.35	15,000	95,251		Aug 14 04:35 PM
Secora Michael	Officer	Aug 13 '24	Proposed Sale	6.35	15,000	95,183		Aug 13 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 07 '24	Sale	7.10	30,000	213,000	758,738	Aug 09 04:56 PM
Gibson Christopher	Chief Executive Officer	Aug 08 '24	Sale	6.50	20,000	130,000	758,738	Aug 09 04:56 PM
Borgeson Blake	Director	Aug 06 '24	Sale	6.82	11,447	78,083	7,144,216	Aug 08 05:23 PM
Gibson Christopher	Officer	Aug 08 '24	Proposed Sale	6.50	20,000	130,000		Aug 08 12:56 PM
Gibson Christopher	Officer	Aug 07 '24	Proposed Sale	7.10	30,000	213,000		Aug 07 01:34 PM
Borgeson Blake	Director	Aug 06 '24	Proposed Sale	6.82	11,447	78,083		Aug 06 04:50 PM
Marriott Tina	President and COO	Jul 25 '24	Option Exercise	1.06	6,000	6,360	541,457	Jul 29 06:16 PM
Marriott Tina	President and COO	Jul 25 '24	Sale	8.13	6,000	48,809	535,457	Jul 29 06:16 PM
Borgeson Blake	Director	Jul 23 '24	Sale	8.48	11,447	97,041	7,155,663	Jul 25 06:15 PM
Gibson Christopher	Chief Executive Officer	Jul 10 '24	Sale	7.48	50,000	374,000	758,738	Jul 12 06:54 PM
Gibson Christopher	Chief Executive Officer	Jul 11 '24	Sale	7.47	50,000	373,500	758,738	Jul 12 06:54 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Option Exercise	2.22	39,375	87,413	1,307,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Option Exercise	2.22	39,375	87,413	1,331,593	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Sale	7.32	15,000	109,778	1,292,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Sale	7.24	15,000	108,576	1,316,593	Jul 11 04:51 PM
Borgeson Blake	Director	Jul 09 '24	Sale	7.32	11,447	83,735	7,167,110	Jul 11 04:51 PM
Marriott Tina	President and COO	Jun 27 '24	Option Exercise	1.06	6,000	6,360	541,457	Jun 28 05:14 PM
Marriott Tina	President and COO	Jun 27 '24	Sale	7.21	6,000	43,290	535,457	Jun 28 05:14 PM
Borgeson Blake	Director	Jun 25 '24	Sale	9.51	11,447	108,806	7,177,116	Jun 27 07:13 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Option Exercise	2.22	39,375	87,413	1,258,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Option Exercise	2.22	39,375	87,413	1,282,843	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Sale	9.32	15,000	139,798	1,243,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Sale	9.27	15,000	139,082	1,267,843	Jun 17 05:46 PM
Borgeson Blake	Director	Jun 11 '24	Sale	8.45	11,447	96,763	7,188,563	Jun 13 05:36 PM
Gibson Christopher	Chief Executive Officer	Jun 06 '24	Sale	9.00	50,000	450,000	708,738	Jun 07 04:01 PM
Gibson Christopher	Chief Executive Officer	Jun 05 '24	Sale	8.42	50,000	421,000	758,738	Jun 07 04:01 PM
Marriott Tina	President and COO	May 30 '24	Option Exercise	1.06	3,000	3,180	538,457	Jun 03 06:31 PM
Marriott Tina	President and COO	May 30 '24	Sale	8.78	3,000	26,325	535,457	Jun 03 06:31 PM
Borgeson Blake	Director	May 28 '24	Sale	9.17	11,447	104,943	7,186,913	May 30 06:41 PM
Borgeson Blake	Director	May 14 '24	Sale	10.12	20,054	202,934	7,198,360	May 16 04:35 PM
Gibson Christopher	Chief Executive Officer	May 02 '24	Sale	8.47	50,000	423,500	834,820	May 03 06:24 PM
Gibson Christopher	Chief Executive Officer	May 01 '24	Sale	7.73	50,000	386,500	863,524	May 03 06:24 PM
Borgeson Blake	Director	Apr 30 '24	Sale	7.95	11,447	90,964	7,218,414	May 02 05:41 PM
Marriott Tina	President and COO	Apr 25 '24	Option Exercise	1.06	3,000	3,180	546,231	Apr 29 06:41 PM
Marriott Tina	President and COO	Apr 25 '24	Sale	7.67	3,000	23,020	543,231	Apr 29 06:41 PM
Borgeson Blake	Director	Apr 16 '24	Sale	7.66	11,447	87,725	7,229,861	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Option Exercise	2.22	37,500	83,250	1,241,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Option Exercise	2.22	37,500	83,250	1,254,179	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Sale	7.67	25,000	191,658	1,216,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Sale	7.58	23,124	175,349	1,231,055	Apr 18 05:12 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	40,000	360,800	938,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	40,000	353,600	978,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	25,000	225,500	0	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	25,000	221,000	0	Apr 05 05:44 PM
Borgeson Blake	Director	Apr 02 '24	Sale	8.82	11,447	100,942	7,241,308	Apr 03 05:42 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	40,000	404,000	1,043,524	Apr 01 06:40 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	25,000	252,500	0	Apr 01 06:40 PM
Marriott Tina	President and COO	Mar 21 '24	Option Exercise	1.06	8,000	8,480	647,982	Mar 25 06:39 PM
Marriott Tina	President and COO	Mar 21 '24	Sale	10.75	8,000	85,980	639,982	Mar 25 06:39 PM
Borgeson Blake	Director	Mar 19 '24	Sale	10.79	20,054	216,423	7,252,755	Mar 21 05:38 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Option Exercise	2.22	37,500	83,250	1,216,679	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Option Exercise	2.22	37,500	83,250	1,229,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Sale	11.03	25,000	275,815	1,204,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Sale	10.46	25,000	261,375	1,191,679	Mar 14 07:28 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Option Exercise	4.42	39,924	176,384	1,144,843	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.86	36,319	430,682	1,108,524	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.55	25,000	288,823	0	Mar 08 07:08 PM
Borgeson Blake	Director	Mar 05 '24	Sale	12.06	20,054	241,805	7,272,809	Mar 07 06:53 PM
Marriott Tina	President and COO	Feb 22 '24	Option Exercise	1.06	8,000	8,480	647,982	Feb 23 07:22 PM
Marriott Tina	President and COO	Feb 22 '24	Sale	14.89	8,000	119,160	639,982	Feb 23 07:22 PM
Borgeson Blake	Director	Feb 20 '24	Sale	12.32	20,054	247,125	7,292,863	Feb 21 05:37 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Option Exercise	2.22	37,500	83,250	1,198,851	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Option Exercise	2.22	37,500	83,250	1,211,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Sale	10.46	25,000	261,425	1,186,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Sale	9.86	25,000	246,560	1,173,851	Feb 15 06:00 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Option Exercise	2.48	31,250	77,500	822,975	Feb 09 05:34 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Sale	9.22	48,272	444,981	774,703	Feb 09 05:34 PM
Borgeson Blake	Director	Feb 06 '24	Sale	9.30	11,447	106,489	7,312,917	Feb 08 06:54 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Option Exercise	1.06	8,000	8,480	422,584	Jan 29 06:52 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Sale	10.35	8,000	82,762	414,548	Jan 29 06:52 PM
Borgeson Blake	Director	Jan 23 '24	Sale	10.58	20,054	212,083	7,324,364	Jan 25 06:13 PM
Virani Shafique	Chief Business Officer	Jan 16 '24	Option Exercise	2.22	18,000	39,960	154,748	Jan 18 06:39 PM
Virani Shafique	Chief Business Officer	Jan 16 '24	Sale	10.93	18,000	196,740	136,748	Jan 18 06:39 PM
Secora Michael	Chief Financial Officer	Jan 16 '24	Option Exercise	2.22	37,500	83,250	993,514	Jan 18 06:37 PM
Secora Michael	Chief Financial Officer	Jan 17 '24	Option Exercise	2.22	37,500	83,250	1,006,014	Jan 18 06:37 PM
Secora Michael	Chief Financial Officer	Jan 16 '24	Sale	10.45	25,000	261,160	968,514	Jan 18 06:37 PM
Secora Michael	Chief Financial Officer	Jan 17 '24	Sale	10.25	25,000	256,348	981,014	Jan 18 06:37 PM

Open in Screener

IPSC

Century Therapeutics Inc

Sep 06 • 04:00PM ET

1.46

Dollar change +0.02
Percentage change 1.39	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

IPSC Century Therapeutics Inc daily Stock Chart

Held by: VXF IWM VTI IWN VTWO SCHA VHT IWC VTWV SCHB

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	61.74%	Shs Outstand	60.34M	Perf Week	-15.61%
Market Cap	123.69M	Forward P/E	-	EPS next Y	-1.86	Insider Trans	-0.16%	Shs Float	32.41M	Perf Month	-15.61%
Income	-131.39M	PEG	-	EPS next Q	-0.45	Inst Own	26.49%	Short Float	6.90%	Perf Quarter	-51.66%
Sales	2.04M	P/S	60.63	EPS this Y	23.48%	Inst Trans	-1.45%	Short Ratio	6.66	Perf Half Y	-72.53%
Book/sh	2.63	P/B	0.56	EPS next Y	-5.59%	ROA	-31.52%	Short Interest	2.23M	Perf Year	-40.16%
Cash/sh	2.32	P/C	0.63	EPS next 5Y	-	ROE	-55.95%	52W Range	1.28 - 5.51	Perf YTD	-56.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.24%	ROI	-47.81%	52W High	-73.50%	Beta	1.40
Dividend TTM	-	Quick Ratio	10.62	Sales past 5Y	-14.25%	Gross Margin	-488.98%	52W Low	14.06%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	10.62	EPS Y/Y TTM	5.99%	Oper. Margin	-6321.69%	RSI (14)	36.05	Volatility	11.62% 11.94%
Employees	165	Debt/Eq	0.25	Sales Y/Y TTM	-55.26%	Profit Margin	-6434.23%	Recom	1.33	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	32.34%	Payout	-	Rel Volume	0.89	Prev Close	1.44
Sales Surprise	79.30%	EPS Surprise	16.45%	Sales Q/Q	678.79%	Earnings	Aug 08 BMO	Avg Volume	335.70K	Price	1.46
SMA20	-14.27%	SMA50	-31.08%	SMA200	-52.73%	Trades		Volume	300,198	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy	$6
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$28 → $5
Dec-27-22	Initiated	Chardan Capital Markets	Buy	$19
Oct-31-22	Initiated	Guggenheim	Buy	$15
Oct-10-22	Initiated	Canaccord Genuity	Buy	$28
May-23-22	Initiated	H.C. Wainwright	Buy	$27
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	Piper Sandler	Overweight	$38
Jul-13-21	Initiated	JP Morgan	Overweight	$40
Jul-13-21	Initiated	BofA Securities	Buy	$34

Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Loading…
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
01:52PM	Loading…
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Loading…
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 10:02AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39% (Simply Wall St.)
Nov-22-22 07:00AM	Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.24%
Nov-11-22 07:00AM	Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) -5.01%
Nov-10-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +15.11%
07:30AM	Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-02-22 07:05AM	Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 (GlobeNewswire)
Oct-05-22 04:05PM	Century Therapeutics to Present at the SITC 37th Annual Meeting (GlobeNewswire)
Oct-03-22 07:00AM	Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors (GlobeNewswire)
Sep-26-22 07:00AM	Century Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:30AM	Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection (GlobeNewswire)
Aug-11-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-07-22 01:43PM	Century Therapeutics nearly tripling planned space at One uCity Square (American City Business Journals)
Jul-01-22 09:18AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 13% this week, taking one-year losses to 71% (Simply Wall St.)
Jun-24-22 04:30PM	Century Therapeutics Announces Its Addition to the Russell Microcap® Index (GlobeNewswire) -6.39% -8.37%
Jun-21-22 04:30PM	Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.60%
Jun-06-22 07:30AM	Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022 (GlobeNewswire)
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-16-22 07:30AM	Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +9.79%
May-03-22 04:30PM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-22 04:30PM	Century Therapeutics to Present at the ASGCT 25th Annual Meeting (GlobeNewswire)
Apr-18-22 04:30PM	Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-06-22 04:30PM	Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-22 04:30PM	Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference (GlobeNewswire) +5.97%
Mar-17-22 07:30AM	Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-09-22 04:05PM	Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-22-22 11:29AM	What's Behind Bristol Myers Squibb's Latest Partnership? (Motley Fool)
Jan-14-22 06:50AM	Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-deal (American City Business Journals)
Jan-10-22 12:27PM	Century Therapeutics shares soar on potential multibillion-dollar deal with Bristol Myers Squibb (American City Business Journals) +14.52%
11:12AM	Century Therapeutics Rallies On Bristol Myers Squibb Strategic Collaboration (Investing.com)
08:08AM	Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies (Benzinga)
06:59AM	Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies (GlobeNewswire)
Jan-04-22 04:30PM	Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.24%
Dec-17-21 07:00AM	Century Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire) +8.91%
Dec-16-21 06:30AM	Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates (GlobeNewswire)
Nov-22-21 08:00AM	Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire) -17.56%
Nov-10-21 07:30AM	Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-21 09:00AM	Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update (GlobeNewswire)
Oct-07-21 07:30AM	Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering (GlobeNewswire)
Sep-17-21 04:01PM	Century Therapeutics Announces Its Addition to the Russell 2000® Index (GlobeNewswire) -15.35% -12.24%
Aug-12-21 08:00AM	Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jun-22-21 04:01PM	Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farid Adrienne	Chief Operations Officer	Aug 05 '24	Sale	1.83	1,073	1,960	136,163	Aug 07 04:06 PM
Carr Douglas	SVP Finance & Operations	Aug 05 '24	Sale	1.83	289	528	334,041	Aug 07 04:06 PM
Farid Adrienne	Officer	Aug 05 '24	Proposed Sale	1.83	1,073	1,960		Aug 05 03:06 PM
Russotti Gregory	See Remarks	Jul 26 '24	Sale	2.50	586	1,465	274,933	Jul 31 09:08 AM
Russotti Gregory	Officer	Jul 26 '24	Proposed Sale	2.50	586	1,465		Jul 26 05:03 PM
Russotti Gregory	See Remarks	Jul 24 '24	Sale	2.52	1,600	4,029	275,519	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jul 23 '24	Sale	2.50	200	500	277,119	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jun 20 '24	Sale	2.84	5,000	14,178	277,319	Jun 24 04:49 PM
Russotti Gregory	See Remarks	Jun 05 '24	Sale	3.00	5,000	14,989	282,319	Jun 06 04:53 PM
Russotti Gregory	See Remarks	May 20 '24	Sale	3.00	5,000	14,978	287,319	May 21 04:09 PM
Russotti Gregory	See Remarks	May 06 '24	Sale	3.12	5,000	15,619	292,319	May 07 05:13 PM
Carr Douglas	SVP Finance & Operations	May 03 '24	Sale	3.11	257	798	317,323	May 07 05:13 PM
Farid Adrienne	Chief Operations Officer	May 03 '24	Sale	3.11	913	2,836	137,236	May 07 05:13 PM
Russotti Gregory	See Remarks	Apr 22 '24	Sale	3.10	5,000	15,490	297,319	Apr 24 04:17 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Option Exercise	1.03	30,684	31,605	144,833	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Option Exercise	1.03	22,831	23,516	136,980	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Sale	4.96	30,684	152,340	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Sale	5.14	22,831	117,342	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Option Exercise	1.03	485	500	114,634	Feb 21 04:10 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Sale	4.86	485	2,358	114,149	Feb 21 04:10 PM
Carr Douglas	SVP Finance & Operations	Feb 06 '24	Sale	4.49	557	2,499	303,580	Feb 07 05:21 PM
Carr Douglas	SVP Finance & Operations	Feb 05 '24	Sale	3.84	643	2,470	304,137	Feb 07 05:21 PM
Farid Adrienne	Chief Operations Officer	Feb 06 '24	Sale	4.49	1,784	8,005	114,149	Feb 07 05:21 PM
Farid Adrienne	Chief Operations Officer	Feb 05 '24	Sale	3.84	2,035	7,816	115,933	Feb 07 05:21 PM

Open in Screener

TWST

Twist Bioscience Corp

Sep 06 • 04:00PM ET

36.72

Dollar change -3.30
Percentage change -8.25	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

TWST Twist Bioscience Corp daily Stock Chart

Held by: ARKK ARKG VTI VB IWM VXF XBI VBK IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-3.81	Insider Own	4.30%	Shs Outstand	57.56M	Perf Week	-18.22%
Market Cap	2.15B	Forward P/E	-	EPS next Y	-2.39	Insider Trans	-1.61%	Shs Float	56.07M	Perf Month	-17.58%
Income	-220.31M	PEG	-	EPS next Q	-0.70	Inst Own	106.35%	Short Float	16.43%	Perf Quarter	-30.72%
Sales	295.21M	P/S	7.29	EPS this Y	4.32%	Inst Trans	2.41%	Short Ratio	9.16	Perf Half Y	-3.34%
Book/sh	8.39	P/B	4.38	EPS next Y	30.61%	ROA	-30.42%	Short Interest	9.21M	Perf Year	49.33%
Cash/sh	4.94	P/C	7.43	EPS next 5Y	-	ROE	-38.36%	52W Range	14.42 - 60.90	Perf YTD	-0.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.09%	ROI	-39.08%	52W High	-39.70%	Beta	1.77
Dividend TTM	-	Quick Ratio	4.52	Sales past 5Y	60.13%	Gross Margin	40.53%	52W Low	154.65%	ATR (14)	2.65
Dividend Ex-Date	-	Current Ratio	4.91	EPS Y/Y TTM	-3.16%	Oper. Margin	-63.17%	RSI (14)	31.69	Volatility	6.38% 5.00%
Employees	919	Debt/Eq	0.18	Sales Y/Y TTM	25.37%	Profit Margin	-74.63%	Recom	1.83	Target Price	51.80
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-46.26%	Payout	-	Rel Volume	1.18	Prev Close	40.02
Sales Surprise	5.25%	EPS Surprise	-92.43%	Sales Q/Q	27.81%	Earnings	Aug 02 BMO	Avg Volume	1.01M	Price	36.72
SMA20	-15.32%	SMA50	-24.32%	SMA200	-7.22%	Trades		Volume	1,185,330	Change	-8.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-24	Initiated	Guggenheim	Buy	$53
Jan-17-24	Upgrade	Goldman	Neutral → Buy	$25 → $45
Sep-27-23	Initiated	Berenberg	Buy	$27
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-03-23	Upgrade	Evercore ISI	In-line → Outperform	$28 → $36
Mar-02-22	Resumed	Cowen	Outperform
Oct-15-21	Resumed	Cowen	Outperform
Jun-29-21	Initiated	William Blair	Outperform
Jun-04-21	Initiated	Goldman	Neutral	$110
Apr-12-21	Initiated	Piper Sandler	Overweight	$150
Feb-05-21	Downgrade	JP Morgan	Neutral → Underweight	$100
Jan-04-21	Downgrade	Evercore ISI	Outperform → In-line
Oct-20-20	Initiated	SVB Leerink	Mkt Perform	$90
May-31-19	Initiated	Evercore ISI	Outperform
Nov-26-18	Initiated	JP Morgan	Neutral	$27

Show Previous Ratings

Aug-27-24 08:00AM	Twist Bioscience to Present at Baird Global Healthcare Conference 2024 (Business Wire)
Aug-14-24 09:45AM	How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates (GlobeNewswire)
Aug-08-24 08:00AM	Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb (Business Wire)
Aug-07-24 06:47AM	3 Healthcare AI Stocks Positioned for Potential Breakthroughs (InvestorPlace)
Aug-06-24 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
11:20AM	Loading…
Aug-05-24 11:20AM	The 3 Best Med Tech Stocks to Buy Now (InvestorPlace) +5.49%
08:00AM	Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis (Business Wire)
Aug-02-24 08:40AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -19.00%
07:37AM	Twist Bioscience: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results (Business Wire)
Jul-30-24 02:17AM	Is Twist Bioscience Corporation (TWST) in the Pole Position? (Insider Monkey)
Jul-26-24 10:00AM	Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Jul-18-24 08:00AM	Twist Bioscience Announces Clinical Progression of Pure Biologics Antibody Candidate Discovered Using Twists Antibody Libraries (Business Wire)
Jul-11-24 08:00AM	Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024 (Business Wire)
Jul-10-24 08:00AM	Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies (Business Wire)
08:00AM	Loading…
Jul-09-24 08:00AM	Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A (Business Wire)
Jul-01-24 07:08PM	Is Twist Bioscience Corporation (TWST) a Good Stock to Buy and Hold for 5 Years? (Insider Monkey)
02:31PM	10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood (Insider Monkey)
Jun-06-24 08:00AM	Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor (Business Wire)
Jun-04-24 08:00AM	Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety (Business Wire) +6.75%
May-24-24 04:58PM	IBD 50 Stock Reverses Badly As Weight-Loss Boost Fades Fast; Cathie Wood Stock Falls Hard (Investor's Business Daily)
May-23-24 08:00AM	Twist Bioscience to Present at Upcoming Investor Conferences (Business Wire)
May-22-24 12:00PM	What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now? (Zacks)
May-13-24 08:00AM	Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications (Business Wire) +11.94%
May-10-24 06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-08-24 08:00AM	Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-03-24 03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires) +28.74%
01:58PM	Sector Update: Health Care Stocks Mixed in Afternoon Trading (MT Newswires)
01:22PM	Twist Bioscience Shares Jump After Fiscal Q2 Beat, Fiscal 2024 Revenue Guidance Raised (MT Newswires)
10:02AM	Twist Bioscience Corporation (NASDAQ:TWST) Q2 2024 Earnings Call Transcript (Insider Monkey)
06:47AM	Loading…
06:47AM	Q2 2024 Twist Bioscience Corp Earnings Call (Thomson Reuters StreetEvents)
04:05AM	Twist Bioscience Corp (TWST) Q2 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
May-02-24 09:00PM	TWST Stock Earnings: Twist Bioscience Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:35PM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Twist Bioscience: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results (Business Wire)
Apr-30-24 03:20PM	3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition (InvestorPlace)
Apr-25-24 11:31AM	5 Fastest Growing Health Tech Companies in the World (Insider Monkey)
Apr-18-24 08:00AM	Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024 (Business Wire)
Mar-28-24 08:00AM	Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations (Business Wire)
Mar-05-24 08:00AM	Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing (Business Wire)
Feb-22-24 08:00AM	Twist Bioscience to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-24 01:59PM	7 Stocks Cathie Wood Is Still Loading Up On in Q1 (InvestorPlace) -8.86%
Feb-10-24 05:28AM	Twist Bioscience Corp Director Robert Chess Sells 4,110 Shares (GuruFocus.com)
Feb-07-24 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.41%
Feb-06-24 08:05AM	Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System (Business Wire)
08:00AM	Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications (Business Wire)
Feb-05-24 08:09AM	Twist Bioscience Corporation (NASDAQ:TWST) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT (Business Wire)
Feb-02-24 11:42PM	Q1 2024 Twist Bioscience Corp Earnings Call (Thomson Reuters StreetEvents) +10.01%
07:55AM	Twist Bioscience Corp Reports Strong Revenue Growth in Q1 Fiscal 2024 (GuruFocus.com)
07:36AM	Twist Bioscience: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results (Business Wire)
Jan-24-24 08:00AM	Twist Bioscience Expands Express Genes Rapid Synthesis Service (Business Wire) -5.03%
Jan-16-24 08:00AM	Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024 (Business Wire)
Jan-08-24 08:00AM	Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-05-24 08:00AM	Twist Bioscience Appoints Adam Laponis as Chief Financial Officer (Business Wire)
Dec-19-23 12:44PM	3 Genomics Stocks to Unlock the Future of Medicine (InvestorPlace) +10.91%
Dec-18-23 08:00AM	Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-23 08:11AM	Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock? (Zacks)
Nov-20-23 08:55AM	Twist Bioscience Corporation (NASDAQ:TWST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Nov-18-23 01:29AM	Q4 2023 Twist Bioscience Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-17-23 04:03PM	DNA-Maker Twist Bioscience Catapults 26% On 'Solid' Outlook That Tops Its Peers (Investor's Business Daily) +25.90%
08:40AM	Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:28AM	Twist Bioscience Corp (TWST) Reports 20% Revenue Growth in Fiscal 2023 (GuruFocus.com)
07:47AM	Twist Bioscience: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results (Business Wire)
Nov-14-23 08:00AM	Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service (Business Wire) +13.96%
Nov-13-23 08:00AM	Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-08-23 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Nov-02-23 04:05PM	Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023 (Business Wire) +10.82% +7.80%
Oct-31-23 08:00AM	Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-06-23 12:08PM	Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery (Zacks)
11:44AM	Twist Bioscience (TWST) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards (GuruFocus.com)
Oct-05-23 08:00AM	Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million (Business Wire)
Oct-03-23 08:00AM	Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations (Business Wire)
Sep-27-23 08:00AM	Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases (Business Wire)
Sep-26-23 01:02PM	Twist Bioscience Corp (TWST): A Deep Dive into Its Performance Potential (GuruFocus.com) -5.20%
12:40PM	Twist Bioscience (TWST) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards (GuruFocus.com)
Sep-20-23 12:11PM	Twist Bioscience Corp (TWST): A Deep Dive into Its Performance Potential (GuruFocus.com)
Sep-14-23 12:56PM	Is Twist Bioscience (TWST) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
12:31PM	Twist Bioscience Corp (TWST): A Deep Dive into Its Performance Potential (GuruFocus.com)
Sep-05-23 08:00AM	Twist Bioscience to Present at Upcoming Investor Conferences (Business Wire)
Aug-31-23 03:10AM	Should You Add Twist Bioscience Corporation (TWST) to Your Portfolio? (Insider Monkey)
03:00AM	Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases (Business Wire)
Aug-22-23 08:00AM	Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene (Business Wire)
Aug-11-23 01:39PM	Biotech Bonanza: 3 Top DNA Stocks With Revolutionary Potential (InvestorPlace)
Aug-07-23 09:53AM	Twist Bioscience Corporation (NASDAQ:TWST) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023 (Business Wire)
Aug-04-23 01:21PM	Why Shares of Twist Bioscience Are Up Friday (Motley Fool) +11.18%
08:45AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:37AM	Twist Bioscience: Fiscal Q3 Earnings Snapshot (AP Finance)
07:30AM	Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results (Business Wire)
Jul-20-23 08:00AM	Twist Bioscience to Report Fiscal 2023 Third Quarter Financial Results on Friday, August 4, 2023 (Business Wire) -10.00%
Jul-18-23 09:50AM	2 Cathie Wood Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research (Business Wire)
Jun-26-23 08:10AM	Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism (Business Wire)
Jun-20-23 08:00AM	Twist Bioscience Appoints Chet Gandhi as Chief Information Officer (Business Wire)
Jun-04-23 09:46AM	We're Hopeful That Twist Bioscience (NASDAQ:TWST) Will Use Its Cash Wisely (Simply Wall St.)

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WERNER ROBERT F.	Officer	Sep 06 '24	Proposed Sale	39.16	240	9,399		Sep 06 03:27 PM
Green Paula	Officer	Sep 06 '24	Proposed Sale	39.16	912	35,715		Sep 06 03:26 PM
Cho Dennis	Officer	Sep 06 '24	Proposed Sale	39.16	275	10,769		Sep 06 03:19 PM
Leproust Emily M.	Officer	Sep 06 '24	Proposed Sale	39.16	2,340	91,636		Sep 06 03:16 PM
WERNER ROBERT F.	Chief Accounting Officer	Aug 23 '24	Sale	43.14	813	35,074	38,964	Aug 27 04:05 PM
WERNER ROBERT F.	Officer	Aug 23 '24	Proposed Sale	43.14	813	35,075		Aug 23 03:21 PM
Cho Dennis	See Remarks	Aug 05 '24	Sale	39.93	709	28,308	78,996	Aug 07 04:05 PM
Finn Patrick John	President and COO	Aug 05 '24	Sale	39.93	2,885	115,187	168,327	Aug 07 04:05 PM
Leproust Emily M.	Chief Executive Officer	Aug 05 '24	Sale	39.93	5,139	205,180	499,593	Aug 07 04:05 PM
Green Paula	SVP of Human Resources	Aug 05 '24	Sale	39.93	1,137	45,396	88,837	Aug 07 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Aug 05 '24	Sale	39.93	168	6,708	39,777	Aug 07 04:05 PM
Banyai William	Officer	Aug 06 '24	Proposed Sale	45.30	1,176	53,273		Aug 06 10:13 AM
WERNER ROBERT F.	Officer	Aug 05 '24	Proposed Sale	39.93	168	6,708		Aug 05 03:47 PM
Cho Dennis	Officer	Aug 05 '24	Proposed Sale	39.93	709	28,307		Aug 05 03:35 PM
Leproust Emily M.	Officer	Aug 05 '24	Proposed Sale	39.93	5,139	205,179		Aug 05 03:25 PM
Green Paula	Officer	Aug 05 '24	Proposed Sale	39.93	1,137	45,396		Aug 05 03:23 PM
Finn Patrick John	Officer	Aug 05 '24	Proposed Sale	39.93	2,885	115,186		Aug 05 03:14 PM
Banyai William	Officer	Aug 05 '24	Proposed Sale	39.93	1,415	56,495		Aug 05 03:10 PM
Banyai William	Officer	Aug 01 '24	Proposed Sale	55.34	18,777	1,039,119		Aug 01 10:39 AM
Finn Patrick John	President and COO	Jul 23 '24	Sale	56.62	2,207	124,971	171,212	Jul 25 04:05 PM
Laponis Adam	Chief Financial Officer	Jul 09 '24	Sale	48.91	842	41,185	73,602	Jul 11 04:05 PM
Cho Dennis	See Remarks	Jul 02 '24	Sale	48.00	126	6,048	79,705	Jul 05 04:05 PM
Leproust Emily M.	Chief Executive Officer	Jul 02 '24	Sale	48.00	1,114	53,474	504,732	Jul 05 04:05 PM
Green Paula	SVP of Human Resources	Jul 02 '24	Sale	48.00	322	15,457	89,974	Jul 05 04:05 PM
Finn Patrick John	President and COO	Jul 02 '24	Sale	48.00	476	22,849	173,419	Jul 05 04:05 PM
Leproust Emily M.	Chief Executive Officer	Jun 20 '24	Sale	49.41	1,732	85,578	505,846	Jun 24 04:05 PM
Green Paula	SVP of Human Resources	Jun 20 '24	Sale	49.41	297	14,675	90,296	Jun 24 04:05 PM
Cho Dennis	See Remarks	Jun 20 '24	Sale	49.41	234	11,562	79,831	Jun 24 04:05 PM
Cho Dennis	See Remarks	Jun 14 '24	Sale	51.04	95	4,848	80,065	Jun 18 04:05 PM
Cho Dennis	See Remarks	Jun 06 '24	Sale	51.33	276	14,167	80,160	Jun 10 04:05 PM
Green Paula	SVP of Human Resources	Jun 06 '24	Sale	51.33	918	47,120	90,593	Jun 10 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Jun 06 '24	Sale	51.33	242	12,422	39,945	Jun 10 04:05 PM
Leproust Emily M.	Chief Executive Officer	Jun 06 '24	Sale	51.33	2,408	123,600	507,578	Jun 10 04:05 PM
Banyai William	See Remark	May 03 '24	Sale	37.13	798	29,633	345,188	May 07 04:05 PM
Cho Dennis	See Remarks	May 03 '24	Sale	37.13	568	21,092	80,436	May 07 04:05 PM
Green Paula	SVP of Human Resources	May 03 '24	Sale	37.13	910	33,792	91,511	May 07 04:05 PM
Leproust Emily M.	Chief Executive Officer	May 03 '24	Sale	37.13	4,163	154,589	509,986	May 07 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	May 03 '24	Sale	37.13	132	4,902	43,548	May 07 04:05 PM
Finn Patrick John	President and COO	May 03 '24	Sale	37.13	2,311	85,817	173,895	May 07 04:05 PM
Finn Patrick John	President and COO	Apr 23 '24	Sale	30.12	2,174	65,483	176,206	Apr 25 04:05 PM
Laponis Adam	Chief Financial Officer	Apr 09 '24	Sale	33.16	556	18,434	74,444	Apr 11 04:05 PM
Finn Patrick John	President and COO	Apr 02 '24	Sale	32.74	492	16,106	178,380	Apr 04 04:05 PM
Banyai William	See Remark	Apr 02 '24	Sale	32.74	327	10,705	345,986	Apr 04 04:05 PM
Leproust Emily M.	Chief Executive Officer	Apr 02 '24	Sale	32.74	1,132	37,057	514,149	Apr 04 04:05 PM
Cho Dennis	See Remarks	Apr 02 '24	Sale	32.74	129	4,223	81,004	Apr 04 04:05 PM
Green Paula	SVP of Human Resources	Apr 02 '24	Sale	32.74	229	7,497	92,421	Apr 04 04:05 PM
Cho Dennis	See Remarks	Mar 20 '24	Sale	33.52	230	7,709	81,133	Mar 22 04:05 PM
Banyai William	See Remark	Mar 20 '24	Sale	33.52	442	14,814	346,313	Mar 22 04:05 PM
Leproust Emily M.	Chief Executive Officer	Mar 20 '24	Sale	33.52	1,128	37,806	515,281	Mar 22 04:05 PM
Green Paula	SVP of Human Resources	Mar 20 '24	Sale	33.52	200	6,703	92,650	Mar 22 04:05 PM
Cho Dennis	See Remarks	Mar 14 '24	Sale	34.60	93	3,218	81,363	Mar 18 04:05 PM
Cho Dennis	See Remarks	Mar 06 '24	Sale	37.43	272	10,181	81,456	Mar 08 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Mar 06 '24	Sale	37.43	181	6,775	43,680	Mar 08 04:05 PM
Leproust Emily M.	Chief Executive Officer	Mar 06 '24	Sale	37.43	1,487	55,658	516,409	Mar 08 04:05 PM
Green Paula	SVP of Human Resources	Mar 06 '24	Sale	37.43	600	22,458	92,850	Mar 08 04:05 PM
Banyai William	See Remark	Mar 06 '24	Sale	37.43	549	20,549	346,755	Mar 08 04:05 PM
CHESS ROBERT	Director	Feb 08 '24	Sale	34.98	4,110	143,784	64,169	Feb 09 04:10 PM

Open in Screener

HALO

Halozyme Therapeutics Inc.

Sep 06 • 04:00PM ET

59.21

Dollar change -1.84
Percentage change -3.01	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

HALO Halozyme Therapeutics Inc. daily Stock Chart

Held by: IJH VTI IWM VB VXF VBK XBI IWO MDY IBB

Index	RUT	P/E	22.95	EPS (ttm)	2.58	Insider Own	1.08%	Shs Outstand	126.77M	Perf Week	-7.11%
Market Cap	7.50B	Forward P/E	12.36	EPS next Y	4.79	Insider Trans	-14.12%	Shs Float	125.31M	Perf Month	9.41%
Income	337.29M	PEG	0.82	EPS next Q	1.00	Inst Own	97.25%	Short Float	7.72%	Perf Quarter	15.10%
Sales	873.30M	P/S	8.59	EPS this Y	43.05%	Inst Trans	3.82%	Short Ratio	6.90	Perf Half Y	41.96%
Book/sh	2.29	P/B	25.89	EPS next Y	20.92%	ROA	17.85%	Short Interest	9.67M	Perf Year	44.34%
Cash/sh	4.18	P/C	14.18	EPS next 5Y	28.00%	ROE	153.16%	52W Range	32.83 - 65.53	Perf YTD	60.20%
Dividend Est.	-	P/FCF	18.37	EPS past 5Y	-	ROI	18.82%	52W High	-9.65%	Beta	1.28
Dividend TTM	-	Quick Ratio	6.21	Sales past 5Y	41.16%	Gross Margin	71.52%	52W Low	80.35%	ATR (14)	1.85
Dividend Ex-Date	-	Current Ratio	7.41	EPS Y/Y TTM	50.71%	Oper. Margin	46.04%	RSI (14)	48.88	Volatility	3.51% 3.01%
Employees	373	Debt/Eq	5.30	Sales Y/Y TTM	12.88%	Profit Margin	38.62%	Recom	1.73	Target Price	59.10
Option/Short	Yes / Yes	LT Debt/Eq	5.19	EPS Q/Q	28.90%	Payout	0.00%	Rel Volume	0.76	Prev Close	61.05
Sales Surprise	12.89%	EPS Surprise	23.17%	Sales Q/Q	4.67%	Earnings	Aug 06 AMC	Avg Volume	1.40M	Price	59.21
SMA20	-2.02%	SMA50	5.08%	SMA200	33.87%	Trades		Volume	1,061,676	Change	-3.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $27
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform	$17 → $24

Show Previous Ratings

Sep-05-24 11:31AM	Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-24 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-28-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-27-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-23-24 03:03PM	Halozyme Earnings, Guidance Point to Bullish Future (FX Empire)
07:01PM	Loading…
Aug-14-24 07:01PM	Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-07-24 04:11PM	How These Two Lesser-Known Biotech Names Obliterated Sales Expectations (Investor's Business Daily)
10:39AM	Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up (Zacks)
Aug-06-24 06:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:50PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:45PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:19PM	Halozyme And Ligand Two Leading Biotechs Smash Quarterly Forecasts (Investor's Business Daily)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Aug-05-24 09:16AM	Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
01:33PM	Loading…
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Jul-26-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Jul-23-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:30AM	Halozyme to Report Second Quarter 2024 Financial and Operating Results (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-16-24 05:11PM	Big Money Eyes Halozyme for Strong Growth (FX Empire)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)
Jul-09-24 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Jul-08-24 12:42PM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-03-24 08:00AM	How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin (Investor's Business Daily)
Jul-01-24 10:02AM	3 Breakout Biotech Stocks on Track to Double by 2032 (InvestorPlace)
Jun-25-24 01:15AM	Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Jun-21-24 05:15PM	Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
Jun-17-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
04:00PM	Loading…
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-13-24 07:00PM	Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Jun-11-24 01:13PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler (Insider Monkey)
09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 01:52PM	Halozyme Therapeutics Scores RS Rating Jump To 91 (Investor's Business Daily)
08:59AM	Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13% (Zacks)
Jun-06-24 11:31AM	Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks) +12.68%
09:31AM	Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU (Zacks)
08:30AM	Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook (PR Newswire)
Jun-05-24 04:05PM	Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform (PR Newswire)
Jun-04-24 04:30PM	Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-31-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-21-24 07:15AM	Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE (PR Newswire)
May-20-24 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
May-16-24 02:55PM	Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating (Investor's Business Daily)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
May-10-24 12:39PM	Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout (Investor's Business Daily)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:10PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:34AM	Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates (Zacks)
08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
07:05AM	Q1 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:52AM	Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-07-24 09:00PM	HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:49PM	Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth (GuruFocus.com)
05:48PM	Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed (MT Newswires)
05:25PM	Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates (Zacks)
04:23PM	Halozyme Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
May-06-24 09:16AM	Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-03-24 04:17AM	How Novo-Catalent Deal Affects Halozyme (HALO)? (Insider Monkey)
Apr-30-24 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-24 04:45PM	Mahesh Krishnan Elected to Halozyme's Board of Directors (PR Newswire)
06:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition (InvestorPlace)
Apr-24-24 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Apr-23-24 08:30AM	Halozyme to Report First Quarter 2024 Financial and Operating Results (PR Newswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-04-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-29-24 06:40AM	The 3 Best Biotech Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-21-24 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? (Zacks)
Mar-19-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Mar-14-24 01:24AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 02:05AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 03:15AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Feb-27-24 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-24 11:26AM	Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag (Zacks) +6.56%
09:00AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 05:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates (Zacks)
04:36PM	Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ... (GuruFocus.com)
04:15PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Feb-14-24 09:15AM	Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
06:49AM	Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook (Insider Monkey)
Feb-13-24 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-08-24 04:30PM	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results (PR Newswire)
Jan-29-24 04:15PM	Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jan-26-24 09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-24-24 12:10PM	Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-22-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-18-24 05:01PM	Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares (GuruFocus.com)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Jan 03 '24	Option Exercise	0.00	7,611	0	12,418	Jan 05 04:04 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Option Exercise	13.55	10,000	135,547	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Option Exercise	12.07	10,000	120,700	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Sale	40.39	10,000	403,940	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Sale	39.63	10,000	396,322	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Option Exercise	14.32	10,000	143,173	160,203	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Option Exercise	13.81	10,000	138,100	161,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Sale	39.79	10,000	397,880	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Sale	39.08	10,000	390,790	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Option Exercise	19.98	10,000	199,800	161,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Sale	36.52	10,000	365,200	151,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Option Exercise	19.98	10,000	199,800	161,911	Sep 19 04:09 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Sale	39.10	10,000	390,980	151,911	Sep 19 04:09 PM

Open in Screener

PCVX

Vaxcyte Inc

Sep 06 • 04:00PM ET

111.58

Dollar change -0.52
Percentage change -0.46	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI VB VXF XBI VBK IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.76	Insider Own	4.26%	Shs Outstand	111.61M	Perf Week	40.74%
Market Cap	12.45B	Forward P/E	-	EPS next Y	-4.95	Insider Trans	-4.41%	Shs Float	106.86M	Perf Month	58.22%
Income	-497.19M	PEG	-	EPS next Q	-1.12	Inst Own	106.93%	Short Float	10.52%	Perf Quarter	53.88%
Sales	0.00M	P/S	-	EPS this Y	-4.84%	Inst Trans	5.42%	Short Ratio	12.32	Perf Half Y	55.49%
Book/sh	17.96	P/B	6.21	EPS next Y	-14.12%	ROA	-27.70%	Short Interest	11.24M	Perf Year	119.65%
Cash/sh	13.02	P/C	8.57	EPS next 5Y	-	ROE	-29.08%	52W Range	44.20 - 119.27	Perf YTD	77.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.98%	ROI	-24.80%	52W High	-6.45%	Beta	0.84
Dividend TTM	-	Quick Ratio	17.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	152.44%	ATR (14)	5.27
Dividend Ex-Date	-	Current Ratio	17.88	EPS Y/Y TTM	-41.53%	Oper. Margin	0.00%	RSI (14)	83.72	Volatility	6.30% 3.64%
Employees	254	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	137.86
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-57.50%	Payout	-	Rel Volume	2.56	Prev Close	112.10
Sales Surprise	-	EPS Surprise	-12.75%	Sales Q/Q	-	Earnings	Aug 06 AMC	Avg Volume	912.56K	Price	111.58
SMA20	34.06%	SMA50	37.73%	SMA200	59.77%	Trades		Volume	2,332,437	Change	-0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Loading…
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:02PM	Loading…
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)
12:08PM	Loading…
Feb-28-24 12:08PM	Q4 2023 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents) -7.33%
12:00PM	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know (Zacks)
09:57AM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-24 08:32AM	Why Vaxcyte (PCVX) Might Surprise This Earnings Season (Zacks)
Feb-25-24 11:05AM	5 Best Russell 2000 Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-22-24 11:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Feb-15-24 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-02-24 11:12PM	Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
06:39PM	Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-01-24 11:02PM	Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +5.75%
04:05PM	Vaxcyte to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:37PM	Vaxcyte Announces Pricing of $750 Million Public Offering (GlobeNewswire) +6.04%
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-29-24 08:30AM	Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older (GlobeNewswire) +6.52%
Jan-19-24 08:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Jan-16-24 04:01PM	Vaxcyte Appoints Whitney Jones as Chief People Officer (GlobeNewswire)
Jan-04-24 04:01PM	Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise (GlobeNewswire) -7.07%
Dec-21-23 05:01PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Dec-04-23 06:35PM	VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Nov-28-23 08:30AM	Vaxcyte Appoints Jacks Lee to Board of Directors (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire)
Nov-23-23 11:04AM	Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Nov-09-23 08:30AM	Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire) -5.06%
Nov-06-23 05:19PM	Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:03PM	Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 11:54PM	Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +6.17%
Oct-31-23 04:05PM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 09:55PM	Insider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Oct-19-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Oct-16-23 08:00AM	Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) (GlobeNewswire)
Oct-04-23 11:00PM	Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Sep-19-23 04:05PM	Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 08:21AM	Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up (Zacks)
Sep-08-23 04:44PM	Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic (American City Business Journals)
Aug-08-23 04:03PM	Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 08:30AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jul-01-23 09:05AM	Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-01-23 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-29-23 09:55AM	Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet (Zacks)
May-12-23 09:55AM	Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade (Zacks)
May-08-23 04:03PM	Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 04:05PM	Vaxcyte to Present at the BofA Securities 2023 Health Care Conference (GlobeNewswire) +5.21%
Apr-21-23 05:25PM	Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-19-23 11:36AM	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates (Zacks)
12:26AM	Vaxcyte Announces Pricing of $500 Million Public Offering (GlobeNewswire)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 04:05PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +16.00%
06:30AM	Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies (GlobeNewswire)
Apr-16-23 05:00PM	Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies (GlobeNewswire)
Mar-30-23 08:30AM	Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Mar-12-23 11:55PM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-27-23 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Feb-16-23 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (GlobeNewswire)
Feb-07-23 04:05PM	Vaxcyte to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-22-23 07:39AM	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely (Simply Wall St.)
Jan-05-23 08:30AM	Vaxcytes VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Jan-03-23 12:34PM	This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst (Benzinga)
Dec-20-22 04:05PM	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract (GlobeNewswire)
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Nov-07-22 04:10PM	Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 08:30AM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire) +5.41%
Oct-31-22 02:58PM	Drugmakers Fight Over Lucrative Pneumonia Vaccines (The Wall Street Journal)
Oct-30-22 09:13AM	Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week (Simply Wall St.)
Oct-29-22 11:03AM	Why Shares of Vaxcyte Rose 110.7% This Week (Motley Fool)
Oct-28-22 04:01PM	Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.40%
Oct-26-22 02:13PM	Vaxcyte's New Vaccine Might Beat Pfizer (TheStreet.com) +17.04%
10:55AM	First came good vaccine data. Now this company plans to raise $600 million. (American City Business Journals)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Option Exercise	2.42	10,000	24,200	217,503	Sep 05 05:19 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Sale	111.93	10,000	1,119,252	207,503	Sep 05 05:19 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Option Exercise	25.92	5,000	129,600	17,723	Sep 05 05:15 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Sale	107.67	5,000	538,350	12,723	Sep 05 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Option Exercise	21.41	1,667	35,690	32,493	Sep 05 05:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Sale	112.11	1,667	186,880	30,826	Sep 05 05:13 PM
Cowan Elvia	Officer	Sep 03 '24	Proposed Sale	107.67	5,000	538,350		Sep 03 04:08 PM
Wassil Jim	Officer	Sep 03 '24	Proposed Sale	107.67	10,000	1,076,700		Sep 03 04:07 PM
Eydelman Mikhail	Officer	Sep 03 '24	Proposed Sale	107.67	1,667	179,485		Sep 03 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Aug 26 04:58 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Sale	78.98	15,000	1,184,767	478,888	Aug 26 04:58 PM
PICKERING GRANT	Officer	Aug 23 '24	Proposed Sale	78.89	15,000	1,183,350		Aug 23 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Option Exercise	5.35	8,000	42,800	104,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Sale	78.58	8,000	628,650	96,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	Officer	Aug 19 '24	Proposed Sale	78.91	8,000	631,280		Aug 19 04:05 PM
Wassil Jim	CHIEF OPERATING OFFICER	Aug 01 '24	Sale	78.84	3,000	236,527	207,503	Aug 05 04:10 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 01 '24	Sale	78.79	2,616	206,122	142,130	Aug 05 04:08 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Aug 05 04:06 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Sale	78.85	1,667	131,449	30,826	Aug 05 04:06 PM
PICKERING GRANT	Officer	Aug 01 '24	Proposed Sale	78.80	2,616	206,141		Aug 01 04:04 PM
Wassil Jim	Officer	Aug 01 '24	Proposed Sale	78.80	3,000	236,400		Aug 01 04:02 PM
Eydelman Mikhail	Officer	Aug 01 '24	Proposed Sale	78.80	1,667	131,360		Aug 01 04:01 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Jul 24 05:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Sale	84.26	15,000	1,263,912	478,888	Jul 24 05:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jul 22 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Sale	81.17	8,000	649,325	96,720	Jul 22 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Sale	85.00	5,000	425,000	12,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 09 05:15 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Sale	80.00	5,000	400,000	12,723	Jul 09 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Jul 02 04:17 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Sale	76.37	1,667	127,304	30,826	Jul 02 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jul 01 '24	Sale	76.34	3,000	229,013	210,503	Jul 02 04:16 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 01 '24	Sale	76.33	2,616	199,690	143,438	Jul 02 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Option Exercise	2.03	15,000	30,450	493,888	Jun 25 04:43 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Sale	75.64	15,000	1,134,579	478,888	Jun 25 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jun 20 08:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Sale	71.92	8,000	575,375	96,720	Jun 20 08:30 PM
Gilbert Halley E	Director	Jun 03 '24	Option Exercise	5.35	18,200	97,370	23,825	Jun 05 04:59 PM
Gilbert Halley E	Director	Jun 03 '24	Sale	73.00	18,200	1,328,600	5,625	Jun 05 04:59 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Option Exercise	21.41	1,667	35,690	32,828	Jun 05 04:58 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Sale	72.06	1,667	120,127	31,161	Jun 05 04:58 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jun 03 '24	Sale	71.99	3,000	215,961	213,503	Jun 05 04:57 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 03 '24	Sale	72.06	2,616	188,512	144,746	Jun 05 04:56 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Option Exercise	2.03	15,000	30,450	492,847	May 28 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Sale	69.43	15,000	1,041,408	477,847	May 28 04:22 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Option Exercise	5.35	8,000	42,800	103,679	May 22 05:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Sale	74.99	8,000	599,909	95,679	May 22 05:03 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Option Exercise	21.41	1,667	35,690	32,264	May 03 04:20 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Sale	61.74	1,667	102,921	30,597	May 03 04:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	May 01 '24	Sale	61.65	3,000	184,942	215,462	May 03 04:19 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	61.70	2,616	161,419	146,054	May 03 04:18 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Option Exercise	1.79	15,000	26,850	492,847	Apr 25 04:52 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Sale	61.92	15,000	928,845	477,847	Apr 25 04:52 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Apr 22 04:42 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Sale	61.27	8,000	490,199	95,679	Apr 22 04:42 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 17 '24	Option Exercise	5.35	3,551	18,998	221,840	Apr 19 04:31 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Option Exercise	21.41	1,667	35,690	32,264	Apr 03 04:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Sale	66.73	1,667	111,234	30,597	Apr 03 04:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 01 '24	Sale	66.69	3,000	200,066	218,289	Apr 03 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	66.71	2,616	174,502	147,362	Apr 03 04:21 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Option Exercise	1.79	15,000	26,850	492,847	Mar 27 04:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Sale	66.93	15,000	1,003,978	477,847	Mar 27 04:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Mar 20 04:29 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Sale	69.02	8,000	552,144	95,679	Mar 20 04:29 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 11 '24	Option Exercise	2.03	65,000	131,950	477,847	Mar 13 04:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 01 '24	Sale	73.71	3,000	221,134	220,852	Mar 04 09:23 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Option Exercise	25.92	11,000	285,120	24,158	Mar 04 09:22 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Sale	74.08	11,678	865,070	12,480	Mar 04 09:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Option Exercise	21.41	1,667	35,690	32,877	Mar 04 09:21 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Sale	73.73	1,667	122,907	31,210	Mar 04 09:21 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 01 '24	Sale	73.70	2,616	192,799	148,670	Mar 04 09:19 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Option Exercise	1.79	30,000	53,700	405,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Option Exercise	1.79	15,000	26,850	390,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Sale	79.03	30,000	2,370,900	375,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Sale	76.21	15,000	1,143,206	375,814	Feb 27 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Option Exercise	5.35	8,000	42,800	87,474	Feb 22 04:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Sale	74.53	8,000	596,232	79,474	Feb 22 04:30 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 15 '24	Option Exercise	2.42	27,917	67,559	203,852	Feb 20 04:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Option Exercise	21.41	1,667	35,690	22,377	Feb 05 05:39 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Sale	73.87	1,667	123,144	20,710	Feb 05 05:39 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Option Exercise	2.42	3,000	7,260	178,935	Feb 05 05:37 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Sale	73.88	3,000	221,626	175,935	Feb 05 05:37 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	73.91	2,616	193,353	149,978	Feb 05 05:33 PM
Lukatch Heath	Director	Jan 31 '24	Option Exercise	16.00	5,000	80,000	10,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 31 '24	Sale	71.50	5,000	357,500	5,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 29 '24	Option Exercise	16.00	4,000	64,000	9,625	Jan 31 04:12 PM
Lukatch Heath	Director	Jan 29 '24	Sale	67.50	4,000	270,000	5,625	Jan 31 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Option Exercise	1.79	30,000	53,700	405,814	Jan 31 04:11 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Sale	66.03	30,000	1,980,900	375,814	Jan 31 04:11 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Option Exercise	1.44	15,000	21,600	390,814	Jan 25 05:50 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	63.92	15,000	958,783	375,814	Jan 25 05:50 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 18 '24	Option Exercise	5.35	8,000	42,800	87,474	Jan 19 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 18 '24	Sale	60.73	8,000	485,879	79,474	Jan 19 04:17 PM
Lukatch Heath	Director	Jan 02 '24	Option Exercise	16.00	13,000	208,000	18,625	Jan 04 04:26 PM
Lukatch Heath	Director	Jan 02 '24	Sale	63.76	13,000	828,915	5,625	Jan 04 04:26 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Jan 02 '24	Option Exercise	21.41	1,667	35,690	22,377	Jan 04 04:26 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Jan 02 '24	Sale	63.93	1,667	106,579	20,710	Jan 04 04:26 PM
Wassil Jim	Chief Operating Officer	Jan 02 '24	Option Exercise	2.42	3,000	7,260	178,935	Jan 04 04:25 PM
Wassil Jim	Chief Operating Officer	Jan 02 '24	Sale	63.91	3,000	191,741	175,935	Jan 04 04:25 PM

Open in Screener

ATYR

Atyr Pharma Inc

Sep 06 • 04:00PM ET

1.88

Dollar change +0.13
Percentage change 7.43	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFUS

Index	-	P/E	-	EPS (ttm)	-0.91	Insider Own	2.87%	Shs Outstand	75.80M	Perf Week	-0.53%
Market Cap	142.50M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	9.02%	Shs Float	73.62M	Perf Month	5.62%
Income	-57.90M	PEG	-	EPS next Q	-0.22	Inst Own	63.45%	Short Float	0.47%	Perf Quarter	1.08%
Sales	0.59M	P/S	241.53	EPS this Y	6.21%	Inst Trans	0.55%	Short Ratio	0.91	Perf Half Y	13.25%
Book/sh	1.08	P/B	1.75	EPS next Y	11.34%	ROA	-48.51%	Short Interest	0.35M	Perf Year	13.94%
Cash/sh	1.04	P/C	1.82	EPS next 5Y	13.00%	ROE	-61.64%	52W Range	1.08 - 2.50	Perf YTD	33.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.36%	ROI	-61.41%	52W High	-24.80%	Beta	1.22
Dividend TTM	-	Quick Ratio	7.63	Sales past 5Y	436.18%	Gross Margin	-334.18%	52W Low	74.06%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	7.63	EPS Y/Y TTM	26.39%	Oper. Margin	-10633.50%	RSI (14)	52.34	Volatility	7.16% 6.47%
Employees	59	Debt/Eq	0.17	Sales Y/Y TTM	-94.34%	Profit Margin	-9846.43%	Recom	1.00	Target Price	22.00
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-0.85%	Payout	-	Rel Volume	2.02	Prev Close	1.75
Sales Surprise	-100.00%	EPS Surprise	9.20%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	381.62K	Price	1.88
SMA20	1.38%	SMA50	4.47%	SMA200	11.21%	Trades		Volume	772,336	Change	7.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-05-24	Initiated	Jefferies	Buy	$9
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	JP Morgan	Overweight	$44
Jun-01-15	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Aug-21-24 08:00AM	aTyr Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-24 04:00PM	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update (GlobeNewswire) +6.32%
Aug-06-24 08:00AM	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations (GlobeNewswire)
Jul-30-24 08:00AM	aTyr Pharma Announces Research Study with Stanford Medicine (GlobeNewswire) -6.60%
Jul-22-24 08:00AM	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) +13.41%
09:40AM	Loading…
Jun-18-24 09:40AM	Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year? (Zacks) -6.78%
Jun-10-24 10:52AM	ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023 (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
Jun-03-24 08:00AM	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR (GlobeNewswire) +6.94%
May-24-24 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 07:00AM	aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference (GlobeNewswire) +5.22%
May-14-24 08:00AM	aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +7.06%
May-06-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)
Nov-09-23 04:07PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.74%
04:00PM	Loading…
04:00PM	aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	aTyr Pharma to Present at November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD (GlobeNewswire)
Sep-11-23 08:00AM	aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes (GlobeNewswire)
Aug-30-23 09:35AM	Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE) (Zacks)
Aug-24-23 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 05:30PM	Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Jul-20-23 07:30AM	aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56% (Simply Wall St.)
Jun-28-23 07:00AM	7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 (InvestorPlace)
Jun-22-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Systemic Sclerosis (GlobeNewswire)
Jun-20-23 08:00AM	aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference (GlobeNewswire)
Jun-09-23 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 08:00AM	aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023) (GlobeNewswire)
May-25-23 08:00AM	aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 08:00AM	aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference (GlobeNewswire)
07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com)
May-13-23 08:06AM	aTyr Pharma Independent Director Acquires 25% More Stock \ (Simply Wall St.)
May-11-23 04:00PM	aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-10-23 06:11AM	aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) +6.10%
May-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Atyr Pharma: Q1 Earnings Snapshot (AP Finance)
04:00PM	aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
May-07-23 04:00AM	3 Stocks and Cryptos With the Highest Potential Returns (InvestorPlace)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-17-23 08:00AM	aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-30-23 08:00AM	aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +9.64%
Mar-23-23 07:10AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 08:00AM	aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution (GlobeNewswire)
Mar-20-23 08:00AM	aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies (GlobeNewswire)
Mar-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.18%
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	aTyr Pharma to Present at March Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results (GlobeNewswire)
Mar-01-23 08:00AM	aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application (GlobeNewswire)
Feb-17-23 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-10-23 05:21AM	With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-09-23 08:00AM	aTyr Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.56%
Feb-08-23 04:11PM	aTyr Pharma Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-06-23 08:00AM	aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd. (GlobeNewswire) +6.52%
Jan-31-23 08:00AM	aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference (GlobeNewswire)
Jan-19-23 08:00AM	aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis (GlobeNewswire)
Jan-18-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Sarcoidosis (GlobeNewswire)
Dec-29-22 06:59PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript (Insider Monkey) +5.29%
Dec-15-22 08:00AM	aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment (GlobeNewswire)
Nov-18-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:15PM	Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:00PM	aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-09-22 08:00AM	aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST (GlobeNewswire)
Nov-03-22 08:02AM	aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-25-22 08:00AM	aTyr Pharma to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-11-22 08:00AM	aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets (GlobeNewswire)
Oct-04-22 08:00AM	aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (GlobeNewswire) +6.64%
Sep-29-22 08:00AM	aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies (GlobeNewswire)
Sep-27-22 08:00AM	aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire)
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -6.73%
Sep-13-22 08:00AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
Sep-12-22 08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Sep-09-22 11:52AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
08:00AM	aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th (GlobeNewswire)
Sep-06-22 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Sep-01-22 08:00AM	aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022 (GlobeNewswire)
Aug-15-22 04:00PM	aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update (GlobeNewswire) +14.01%
Aug-12-22 04:05PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-22 08:03AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis (GlobeNewswire)
Aug-04-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-24-22 02:22PM	Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year (Simply Wall St.)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHIMMEL PAUL	Director	Jul 24 '24	Buy	1.93	52,300	101,038	413,023	Jul 24 05:29 PM
SCHIMMEL PAUL	Director	Jul 22 '24	Buy	1.74	41,052	71,500	354,075	Jul 24 05:29 PM
SCHIMMEL PAUL	Director	Jul 23 '24	Buy	1.82	6,648	12,075	360,723	Jul 24 05:29 PM
DENYES NANCY	General Counsel	Jun 05 '24	Buy	1.86	5,000	9,276	22,267	Jun 06 08:26 AM
COUGHLIN TIMOTHY	Director	May 30 '24	Buy	1.75	50,000	87,500	56,000	Jun 03 04:21 PM
Broadfoot Jill Marie	Chief Financial Officer	May 31 '24	Buy	1.79	5,000	8,950	27,960	Jun 03 08:38 AM
Shukla Sanjay	President and CEO	May 31 '24	Buy	1.81	20,000	36,140	136,548	Jun 03 08:34 AM
Broadfoot Jill Marie	Chief Financial Officer	Feb 06 '24	Sale	1.69	1,590	2,687	20,821	Feb 06 08:18 PM
Shukla Sanjay	President and CEO	Dec 12 '23	Buy	1.18	12,000	14,136	106,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Dec 11 '23	Buy	1.17	3,000	3,510	94,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Nov 13 '23	Buy	1.11	13,578	15,085	91,173	Nov 13 04:11 PM
Shukla Sanjay	President and CEO	Nov 10 '23	Buy	1.14	1,422	1,618	77,595	Nov 13 04:11 PM

Open in Screener

ARTV

Artiva Biotherapeutics Inc

Sep 06 • 04:00PM ET

12.02

Dollar change +0.11
Percentage change 0.92	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

ARTV Artiva Biotherapeutics Inc daily Stock Chart

Held by: VTI VXF VTWO VTWG VTWV

Index	-	P/E	-	EPS (ttm)	-	Insider Own	50.80%	Shs Outstand	17.58M	Perf Week	6.37%
Market Cap	291.97M	Forward P/E	-	EPS next Y	-	Insider Trans	111.43%	Shs Float	11.95M	Perf Month	6.37%
Income	-	PEG	-	EPS next Q	-0.83	Inst Own	41.37%	Short Float	0.47%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.45	Perf Half Y	-
Book/sh	-234.70	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf Year	-
Cash/sh	1.92	P/C	6.27	EPS next 5Y	-	ROE	-	52W Range	9.71 - 16.00	Perf YTD	0.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.82%	ROI	-	52W High	-24.87%	Beta	-
Dividend TTM	-	Quick Ratio	4.59	Sales past 5Y	181.38%	Gross Margin	-	52W Low	23.79%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	4.59	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	59.68	Volatility	8.64% 6.18%
Employees	77	Debt/Eq	0.62	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.25
Option/Short	No / Yes	LT Debt/Eq	0.47	EPS Q/Q	-3282.42%	Payout	-	Rel Volume	0.52	Prev Close	11.91
Sales Surprise	-100.00%	EPS Surprise	-1579.39%	Sales Q/Q	-100.00%	Earnings	Aug 29 AMC	Avg Volume	127.03K	Price	12.02
SMA20	9.63%	SMA50	6.73%	SMA200	6.73%	Trades		Volume	65,745	Change	0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '24	Buy	12.00	8,333,333	99,999,996	8,693,579	Jul 24 04:27 PM
5AM Partners VI, LLC	10% Owner	Jul 22 '24	Buy	12.00	833,333	9,999,996	1,182,054	Jul 24 04:15 PM
venBio Global Strategic Fund I	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,936,637	Jul 22 08:26 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	1,666,666	19,999,992	3,306,900	Jul 22 08:25 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,260,512	Jul 22 08:25 PM
Huh Yong-Jun	Director	Jul 22 '24	Buy	12.00	2,083,332	24,999,984	3,306,900	Jul 22 08:22 PM

Open in Screener

BCLI

Brainstorm Cell Therapeutics, Inc.

Sep 06 • 04:00PM ET

0.2575

Dollar change -0.0195
Percentage change -7.04	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

BCLI Brainstorm Cell Therapeutics, Inc. daily Stock Chart

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	9.15%	Shs Outstand	79.73M	Perf Week	-19.15%
Market Cap	20.53M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	-0.86%	Shs Float	72.43M	Perf Month	-6.33%
Income	-12.75M	PEG	-	EPS next Q	-0.04	Inst Own	15.32%	Short Float	2.23%	Perf Quarter	-37.67%
Sales	0.00M	P/S	-	EPS this Y	62.50%	Inst Trans	-0.71%	Short Ratio	2.96	Perf Half Y	-25.98%
Book/sh	-0.04	P/B	-	EPS next Y	-10.00%	ROA	-223.03%	Short Interest	1.62M	Perf Year	-83.81%
Cash/sh	0.04	P/C	5.92	EPS next 5Y	-	ROE	-1121.89%	52W Range	0.13 - 1.65	Perf YTD	-5.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.57%	ROI	-	52W High	-84.39%	Beta	0.36
Dividend TTM	-	Quick Ratio	0.50	Sales past 5Y	0.00%	Gross Margin	-	52W Low	92.16%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.50	EPS Y/Y TTM	62.05%	Oper. Margin	0.00%	RSI (14)	33.95	Volatility	9.94% 12.77%
Employees	29	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	73.40%	Payout	-	Rel Volume	0.88	Prev Close	0.28
Sales Surprise	-	EPS Surprise	214.29%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	545.99K	Price	0.26
SMA20	-18.12%	SMA50	-23.86%	SMA200	-32.64%	Trades		Volume	480,292	Change	-7.04%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-21	Upgrade	Maxim Group	Hold → Buy	$12
Nov-17-20	Downgrade	Maxim Group	Buy → Hold
Dec-19-16	Reiterated	Maxim Group	Buy	$5 → $6
Dec-22-15	Reiterated	Maxim Group	Buy	$14 → $5

Aug-14-24 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-24 06:00AM	BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update (PR Newswire)
Jul-24-24 08:30AM	BCLI Update - Progress Supports Our 10x Plus Value Range Potential (PR Newswire) +6.10%
Jul-01-24 06:00AM	BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program (PR Newswire) +5.47%
Jun-27-24 09:15AM	BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering (PR Newswire) -7.87%
08:00AM	Loading…
Jun-26-24 08:00AM	BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial (PR Newswire)
Jun-20-24 06:00AM	BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer (PR Newswire)
Jun-14-24 12:01PM	BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation (PR Newswire) +6.09%
May-20-24 06:00AM	BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn (PR Newswire) +9.02%
May-14-24 10:53PM	BCLI Stock Earnings: Brainstorm Cell Reported Results for Q1 2024 (InvestorPlace) -8.74%
04:30PM	BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-01-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +15.10%
Apr-16-24 06:30PM	BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn (PR Newswire)
Apr-11-24 06:00AM	BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule (PR Newswire)
Apr-10-24 06:00AM	BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS (PR Newswire)
06:00AM	Loading…
Apr-09-24 06:00AM	BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS (PR Newswire) -20.21%
Apr-08-24 06:00AM	BrainStorm Cell Therapeutics to Provide Update on NurOwn Program (PR Newswire) +12.14%
Apr-01-24 08:05AM	BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +31.03%
Feb-27-24 06:30AM	BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference (PR Newswire)
Feb-23-24 06:00AM	BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS (PR Newswire) +5.60%
Feb-13-24 06:30AM	BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum (PR Newswire) -5.63%
Dec-27-23 09:30AM	BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options (GlobeNewswire) +24.35%
Dec-26-23 07:30AM	BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments (PR Newswire) +16.40%
Dec-20-23 09:00AM	BrainStorm Issues 2023 Letter to Shareholders (PR Newswire)
Dec-07-23 08:40AM	BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn in ALS (PR Newswire) -25.33%
Nov-20-23 08:10AM	BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS (PR Newswire)
Nov-17-23 07:00AM	BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia (PR Newswire)
Nov-15-23 01:53PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript (Insider Monkey)
03:29AM	Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
08:00AM	Loading…
Nov-08-23 08:00AM	BRAINSTORM SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options (PR Newswire)
Nov-07-23 06:00AM	BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire) +10.82%
Oct-24-23 07:00AM	BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS (PR Newswire) -8.28%
Oct-23-23 10:05AM	BCLI: Meeting with FDA to Discuss Development Plan for NurOwn® (Zacks) -5.67%
Oct-18-23 08:01AM	BrainStorm, after setbacks, withdraws approval application for ALS drug (BioPharma Dive)
06:00AM	BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS (PR Newswire)
Oct-02-23 07:00AM	BCLI: Advisory Panel Votes Against Recommending Approval of NurOwn® (Zacks)
Sep-27-23 10:48PM	BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS (PR Newswire)
06:15PM	FDA advisers vote against experimental ALS treatment pushed by patients (Associated Press Finance)
07:00AM	BrainStorm Cell Therapeutics Stock Trading Halted Today (PR Newswire)
Sep-26-23 12:17PM	BCLI: Public Support for NurOwn® from Prominent ALS Specialists (Zacks) -8.35%
Sep-25-23 08:13AM	FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (Reuters) -47.57%
Aug-18-23 08:34AM	BCLI: Preparing for AdCom on September 27, 2023 (Zacks)
Aug-15-23 03:11AM	Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.59%
Aug-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 04:05PM	BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Jul-17-23 09:15AM	Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering (PR Newswire) -5.58%
Jul-12-23 07:00AM	BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer (PR Newswire)
Jul-07-23 07:00AM	BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration (PR Newswire)
Jun-20-23 09:06AM	BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair (PR Newswire) -14.12%
Jun-16-23 07:00AM	BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference (PR Newswire)
Jun-06-23 06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 (PR Newswire)
May-23-23 11:35AM	BCLI: Awaiting Adcom Date for NurOwn® (Zacks Small Cap Research)
May-19-23 07:30AM	BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit (PR Newswire)
May-18-23 08:55AM	While institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are its largest shareholders with 59% ownership (Simply Wall St.)
May-17-23 02:41PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 07:05AM	BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:00AM	BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Apr-24-23 07:00AM	BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (PR Newswire)
Apr-07-23 07:30AM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Apr-05-23 07:46PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.62%
Apr-04-23 09:12AM	BCLI: Preparing for Adcom for NurOwn® (Zacks Small Cap Research) -10.70%
Mar-30-23 07:05AM	BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-27-23 09:15AM	BCLI: FDA Grants Adcom for NurOwn® (Zacks Small Cap Research)
06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS (PR Newswire)
Mar-21-23 08:18AM	BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update (PR Newswire)
Jan-10-23 07:00AM	BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study (PR Newswire)
Jan-05-23 07:30AM	BrainStorm Cell Therapeutics to Present at Biotech Showcase 2023 (PR Newswire) -5.52%
Jan-04-23 07:30AM	BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer (PR Newswire)
Dec-27-22 06:00AM	BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® (PR Newswire) -12.35%
Dec-12-22 07:00AM	BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration (PR Newswire) +35.77%
Nov-17-22 06:56AM	The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen (Zacks) -8.33%
06:15AM	BCLI: Receives a Refusal to File Letter from the FDA for NurOwn® BLA (Zacks Small Cap Research)
Nov-16-22 11:28AM	Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More (Zacks)
Nov-14-22 07:05AM	BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire) +7.89%
Nov-10-22 11:01AM	FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis (Benzinga) -42.21%
08:30AM	BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS (PR Newswire)
Nov-07-22 04:10PM	BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update (PR Newswire)
06:00AM	BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting (PR Newswire)
Oct-20-22 06:00AM	BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress (PR Newswire) -8.09%
Oct-07-22 12:00PM	BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium (PR Newswire) -8.52%
Oct-04-22 06:00AM	BCLI: Relvyrio Approval Shows FDA Flexibility for ALS Treatments (Zacks Small Cap Research)
Sep-15-22 06:00AM	BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal (PR Newswire)
Aug-30-22 08:20AM	We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-17-22 10:16AM	BCLI: Filing a BLA for NurOwn® for the Treatment of ALS (Zacks Small Cap Research) +11.92%
Aug-15-22 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire)
Aug-01-22 06:00AM	BrainStorm to Announce Second Quarter Results and Provide a Corporate Update (PR Newswire) +6.25%
May-31-22 06:00AM	BrainStorm Announces Presentations at June 2022 Scientific Conferences (PR Newswire)
May-24-22 07:10AM	BCLI: Anticipating News on How NurOwn® Will be Advanced Forward (Zacks Small Cap Research)
May-16-22 08:00AM	Edited Transcript of BCLI.OQ earnings conference call or presentation 16-May-22 12:00pm GMT (Thomson Reuters StreetEvents)
07:05AM	BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire)
May-12-22 08:02AM	BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal (PR Newswire)
May-04-22 06:00AM	BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting (PR Newswire)
May-03-22 06:00AM	BrainStorm Announces Upcoming Scientific Conference Presentations (PR Newswire)
May-02-22 06:00AM	BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update (PR Newswire)
Apr-04-22 06:20AM	BCLI: Awaiting Clarity on Regulatory Environment Before Deciding on Next Steps for NurOwn® (Zacks Small Cap Research)
Mar-28-22 09:00AM	Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT (PR Newswire)
07:05AM	BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-23-22 12:56PM	Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-14-22 06:00AM	BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update (PR Newswire)

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dagher Ibrahim B.	Chief Medical Officer	Jul 19 '24	Sale	0.35	63,000	22,069	0	Jul 24 04:05 PM

Open in Screener

ALVR

AlloVir Inc

Sep 06 • 04:00PM ET

0.7642

Dollar change +0.0028
Percentage change 0.37	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA FESM

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	49.77%	Shs Outstand	113.97M	Perf Week	-1.33%
Market Cap	88.16M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	-0.18%	Shs Float	57.95M	Perf Month	5.84%
Income	-140.34M	PEG	-	EPS next Q	-0.10	Inst Own	40.51%	Short Float	9.57%	Perf Quarter	-1.04%
Sales	0.00M	P/S	-	EPS this Y	72.86%	Inst Trans	24.76%	Short Ratio	17.05	Perf Half Y	3.72%
Book/sh	1.04	P/B	0.73	EPS next Y	41.61%	ROA	-67.85%	Short Interest	5.55M	Perf Year	-74.78%
Cash/sh	1.12	P/C	0.68	EPS next 5Y	29.50%	ROE	-80.33%	52W Range	0.58 - 3.13	Perf YTD	12.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-70.96%	ROI	-109.11%	52W High	-75.58%	Beta	0.76
Dividend TTM	-	Quick Ratio	55.08	Sales past 5Y	-37.09%	Gross Margin	-	52W Low	31.76%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	55.08	EPS Y/Y TTM	32.62%	Oper. Margin	0.00%	RSI (14)	51.29	Volatility	3.46% 4.29%
Employees	112	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	4.00	Target Price	0.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	88.96%	Payout	-	Rel Volume	0.09	Prev Close	0.76
Sales Surprise	-	EPS Surprise	51.50%	Sales Q/Q	-	Earnings	Aug 01	Avg Volume	325.21K	Price	0.76
SMA20	1.41%	SMA50	0.85%	SMA200	-14.64%	Trades		Volume	27,670	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-26-23	Downgrade	BofA Securities	Buy → Underperform	$17 → $1
Dec-22-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-22-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-22-23	Downgrade	JP Morgan	Overweight → Underweight
Aug-18-23	Initiated	BofA Securities	Buy	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$48
Aug-24-20	Initiated	SVB Leerink	Outperform	$41
Aug-24-20	Initiated	Morgan Stanley	Overweight	$49
Aug-24-20	Initiated	JP Morgan	Overweight	$50

Aug-09-24 02:52PM	ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024 (InvestorPlace)
May-14-24 08:53AM	ALVR Stock Earnings: AlloVir Misses EPS for Q1 2024 (InvestorPlace)
Mar-18-24 03:53PM	ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023 (InvestorPlace) -6.03%
Mar-13-24 11:53AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights ALVR (GlobeNewswire)
10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir (PR Newswire)
05:50AM	Loading…
Mar-12-24 05:50AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR (PR Newswire)
Mar-06-24 06:17PM	ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire)
Mar-04-24 05:37PM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-28-24 01:06AM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-26-24 12:27PM	AlloVir, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALVR (GlobeNewswire)
Feb-23-24 10:30AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-29-24 09:40AM	Are Medical Stocks Lagging AlloVir (ALVR) This Year? (Zacks)
Jan-24-24 09:45AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-12-24 09:35AM	Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR) (Zacks) +5.30%
11:03AM	Loading…
Jan-05-24 11:03AM	AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts (InvestorPlace)
08:37AM	Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce (FierceBiotech.com)
Dec-26-23 10:04AM	Karuna downgraded, Arm target raised: Wall Street's top analyst calls (The Fly)
Dec-22-23 09:31AM	Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls (The Fly) -67.15%
08:30AM	AlloVir's shares plunge 64% as cell therapy biotech weighs options in wake of triple phase 3 disaster (FierceBiotech.com)
07:10AM	AlloVir scraps late-stage studies testing antiviral cell therapy (Reuters)
07:00AM	AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-16-23 07:00AM	AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-02-23 10:04AM	AlloVir Inc (ALVR) Reports Q3 2023 Financial Results (GuruFocus.com) +13.64%
07:00AM	AlloVir Reports Third Quarter 2023 Financial Results (Business Wire)
Sep-21-23 02:44PM	Why AlloVir Stock Dropped Today (Motley Fool)
Sep-14-23 09:59AM	These 2 Strong Buy Penny Stocks Could Soar to $17 (Or Higher), Say Analysts (TipRanks) +9.72%
Aug-28-23 07:00AM	AlloVir to Present at Upcoming Investor Conferences (Business Wire) +7.00%
Aug-03-23 07:00AM	AlloVir Reports Second Quarter 2023 Financial Results (Business Wire)
07:17AM	Loading…
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) +7.55%
Jul-12-23 03:12AM	Gilead Just Bought $30 Million More of 2 Biotech Stocks (Barrons.com) +6.76%
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jul-03-23 03:59AM	5 hot insider trades & hedge fund hits: Buffett picks up more Occidental shares (Investing.com)
Jun-27-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why (Zacks)
Jun-23-23 01:56PM	Why Shares of AlloVir Plummeted This Week (Motley Fool)
Jun-21-23 09:20PM	AlloVir Announces Pricing of Public Offering of Common Stock (Business Wire) -35.70%
04:18PM	AlloVir Announces Proposed Public Offering of Common Stock (Business Wire)
Jun-09-23 11:04AM	Why Shares of AlloVir Jumped This Week (Motley Fool) -7.83%
Jun-05-23 07:00AM	AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023) (Business Wire) +12.63%
May-16-23 07:00AM	AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer (Business Wire)
May-04-23 07:00AM	AlloVir Reports First Quarter 2023 Financial Results (Business Wire) +10.36%
May-01-23 07:00AM	AlloVir to Present at the BofA Securities 2023 Health Care Conference (Business Wire) +8.14%
Apr-26-23 05:12PM	AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections (Benzinga)
07:00AM	AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023 (Business Wire)
Mar-30-23 11:12AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.) -5.67%
Feb-23-23 04:15PM	AlloVir Appoints Derek Adams, Ph.D., to Board of Directors (Business Wire) +7.14%
Feb-15-23 10:05AM	AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall (Benzinga) -5.17%
07:07AM	AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook (Business Wire)
07:00AM	AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia (Business Wire)
Feb-10-23 09:55AM	Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks)
Feb-07-23 10:17AM	Sage and Biogen's NDA for Depression Drug Gets Priority Review (Zacks)
Feb-01-23 07:00AM	AlloVir to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-25-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% (Zacks)
09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Jan-09-23 07:00AM	AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 (Business Wire)
Jan-03-23 07:00AM	AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-10-22 05:15PM	AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition (Business Wire)
Nov-15-22 07:00AM	AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference (Business Wire) -5.21%
Nov-03-22 09:07AM	Final Data from AlloVirs Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting (Business Wire)
07:00AM	AlloVir Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-21-22 08:30AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-06-22 09:55AM	Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High? (Zacks) -5.10%
Aug-31-22 07:00AM	AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) +19.97%
Aug-19-22 09:55AM	Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect? (Zacks)
Aug-04-22 07:00AM	AlloVir Reports Second Quarter 2022 Financial Results (Business Wire) +12.22%
Aug-03-22 09:55AM	Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks) +5.06%
Aug-01-22 08:09AM	Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares? (Simply Wall St.)
Jul-27-22 07:00AM	AlloVir Announces $126.6 Million Registered Direct Offering (Business Wire) +11.93%
Jun-07-22 12:07PM	AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients (Benzinga)
08:30AM	AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients (Business Wire)
May-05-22 07:00AM	AlloVir Reports First Quarter 2022 Financial Results (Business Wire)
Apr-21-22 11:35AM	AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel (Zacks) -13.28%
Apr-20-22 07:00AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +15.53%
Apr-04-22 07:40PM	Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation (Simply Wall St.) -6.37%
Mar-31-22 07:00AM	AlloVir Appoints Shawn Tomasello to Its Board of Directors (Business Wire) -6.77%
Mar-23-22 09:56AM	AlloVir (ALVR) Begins Study to Prevent Six Viral Infections (Zacks)
Mar-22-22 07:00AM	AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +7.25%
Feb-11-22 07:00AM	AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-10-22 07:00AM	AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook (Business Wire)
Jan-05-22 07:30AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation (Business Wire)
Jan-03-22 04:05PM	AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.07%
Dec-16-21 04:05PM	AlloVir Announces Departure of Chief Medical Officer Augustin Melian (Business Wire) -6.32%
Dec-11-21 01:00PM	AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting (Business Wire)
Nov-17-21 11:57AM	Allovir Insider Sold Over $465K In Company Stock (Benzinga)
Nov-15-21 07:00AM	AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (Business Wire)
Nov-10-21 11:48AM	Allovir Insider Trades $300K In Company Stock (Benzinga)
Nov-05-21 07:00AM	AlloVir Reports Third Quarter 2021 Financial Results (Business Wire)
Oct-29-21 09:47AM	Morgan Stanley: These 2 Strong Buy Stocks Could Double From Here (TipRanks)
Oct-06-21 11:31AM	Notable Allovir Insider Makes $445K Sale (Benzinga)
Oct-05-21 06:48AM	Companies Like AlloVir (NASDAQ:ALVR) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-04-21 07:00AM	FDA Grants Orphan Drug Designation (ODD) to AlloVirs Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis (Business Wire) -12.20%
Sep-29-21 02:09PM	Hedge Funds Are Buying AlloVir, Inc. (ALVR) (Insider Monkey)
07:00AM	Data Presented at IDWeek 2021 Demonstrate that ALVR109, AlloVirs Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta (Business Wire)
Sep-07-21 07:00AM	AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (Business Wire)
Sep-03-21 08:19AM	Biotech Is Due for a Comeback. 5 Stocks That Could Lead a Revival. (Barrons.com)
Aug-26-21 01:41PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Avalara, Inc. - ALVR (Newsfile)
Aug-06-21 07:00AM	AlloVir Reports Second Quarter 2021 Financial Results (Business Wire)
Jun-27-21 03:19AM	Should You Take Comfort From Insider Transactions At AlloVir, Inc. (NASDAQ:ALVR)? (Simply Wall St.)

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brainard Diana	Chief Executive Officer	Aug 20 '24	Sale	0.74	5,390	3,996	753,923	Aug 22 04:15 PM
Brainard Diana	Officer	Aug 20 '24	Proposed Sale	0.74	5,390	3,996		Aug 21 11:14 AM
Miller Edward	General Counsel	Aug 19 '24	Sale	0.76	422	321	215,981	Aug 20 04:15 PM
Sinha Vikas	See Remarks	Aug 19 '24	Sale	0.76	3,159	2,399	1,153,584	Aug 20 04:15 PM
Hagen Brett R	Chief Accounting Officer	Aug 19 '24	Sale	0.76	544	413	71,981	Aug 20 04:15 PM
Brainard Diana	Chief Executive Officer	Aug 19 '24	Sale	0.76	3,091	2,348	759,313	Aug 20 04:15 PM
Sinha Vikas	Owner	Aug 19 '24	Proposed Sale	0.76	3,159	2,399		Aug 19 08:00 PM
Brainard Diana	Officer	Aug 19 '24	Proposed Sale	0.76	3,091	2,348		Aug 19 08:00 PM
Hagen Brett R	Officer	Aug 19 '24	Proposed Sale	0.76	544	413		Aug 19 08:00 PM
Miller Edward	Officer	Aug 19 '24	Proposed Sale	0.76	422	321		Aug 19 08:00 PM
Miller Edward	General Counsel	Aug 05 '24	Sale	0.73	2,323	1,707	216,403	Aug 07 04:15 PM
Brainard Diana	Chief Executive Officer	Aug 05 '24	Sale	0.73	10,847	7,970	762,404	Aug 07 04:15 PM
Sinha Vikas	See Remarks	Aug 05 '24	Sale	0.73	5,251	3,858	1,156,743	Aug 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	Aug 05 '24	Sale	0.73	1,692	1,243	72,525	Aug 07 04:15 PM
Brainard Diana	Officer	Aug 05 '24	Proposed Sale	0.73	10,847	7,970		Aug 06 08:00 PM
Sinha Vikas	Owner	Aug 05 '24	Proposed Sale	0.73	5,251	3,858		Aug 06 08:00 PM
Hagen Brett R	Officer	Aug 05 '24	Proposed Sale	0.73	1,692	1,243		Aug 06 08:00 PM
Miller Edward	Officer	Aug 05 '24	Proposed Sale	0.73	2,323	1,707		Aug 06 08:00 PM
Hagen Brett R	Chief Accounting Officer	Jul 19 '24	Sale	0.75	479	359	74,698	Jul 23 04:28 PM
Hagen Brett R	Chief Accounting Officer	Jul 22 '24	Sale	0.74	481	356	74,217	Jul 23 04:28 PM
Brainard Diana	Chief Executive Officer	Jul 19 '24	Sale	0.75	9,731	7,299	773,251	Jul 23 04:28 PM
Sinha Vikas	See Remarks	Jul 22 '24	Sale	0.74	1,858	1,373	1,161,994	Jul 23 04:27 PM
Sinha Vikas	See Remarks	Jul 19 '24	Sale	0.75	1,542	1,157	1,163,852	Jul 23 04:27 PM
Miller Edward	General Counsel	Jul 22 '24	Sale	0.74	757	560	218,726	Jul 23 04:25 PM
Miller Edward	General Counsel	Jul 19 '24	Sale	0.75	634	476	219,483	Jul 23 04:25 PM
Miller Edward	General Counsel	Jul 02 '24	Sale	0.72	379	273	220,117	Jul 03 04:14 PM
Sinha Vikas	See Remarks	Jul 02 '24	Sale	0.72	939	676	1,165,394	Jul 03 04:14 PM
Hagen Brett R	Chief Accounting Officer	Jul 02 '24	Sale	0.72	304	219	75,177	Jul 03 04:12 PM
Brainard Diana	Chief Executive Officer	Jul 02 '24	Sale	0.72	1,489	1,072	782,982	Jul 03 04:11 PM
Brainard Diana	Chief Executive Officer	May 21 '24	Sale	0.79	5,149	4,080	784,471	May 23 05:24 PM
Hagen Brett R	Chief Accounting Officer	May 17 '24	Sale	0.75	541	405	75,481	May 21 04:35 PM
Brainard Diana	Chief Executive Officer	May 17 '24	Sale	0.75	3,075	2,304	789,620	May 21 04:35 PM
Sinha Vikas	See Remarks	May 17 '24	Sale	0.75	3,143	2,355	1,129,996	May 21 04:33 PM
Miller Edward	General Counsel	May 17 '24	Sale	0.75	420	315	220,496	May 21 04:33 PM
Brainard Diana	Chief Executive Officer	May 03 '24	Sale	0.80	10,240	8,151	792,695	May 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	May 03 '24	Sale	0.80	1,597	1,271	76,022	May 07 04:15 PM
Sinha Vikas	See Remarks	May 03 '24	Sale	0.80	4,957	3,946	1,133,139	May 07 04:15 PM
Miller Edward	General Counsel	May 03 '24	Sale	0.80	2,311	1,840	220,916	May 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 22 '24	Sale	0.75	480	360	77,619	Apr 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 19 '24	Sale	0.75	473	355	78,099	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 22 '24	Sale	0.75	757	568	223,227	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 19 '24	Sale	0.75	626	470	223,984	Apr 23 04:15 PM
Brainard Diana	Chief Executive Officer	Apr 19 '24	Sale	0.75	9,601	7,207	802,935	Apr 23 04:15 PM
Sinha Vikas	See Remarks	Apr 22 '24	Sale	0.75	1,857	1,393	1,138,096	Apr 23 04:15 PM
Sinha Vikas	See Remarks	Apr 19 '24	Sale	0.75	1,521	1,142	1,139,953	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 02 '24	Sale	0.77	368	284	224,610	Apr 04 04:15 PM
Brainard Diana	Chief Executive Officer	Apr 02 '24	Sale	0.77	1,533	1,183	812,536	Apr 04 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 02 '24	Sale	0.77	281	217	78,572	Apr 04 04:15 PM
Sinha Vikas	See Remarks	Apr 02 '24	Sale	0.77	885	683	1,141,474	Apr 04 04:15 PM
Brainard Diana	Chief Executive Officer	Feb 21 '24	Sale	0.71	5,155	3,650	814,069	Feb 22 04:18 PM
Brainard Diana	Chief Executive Officer	Feb 20 '24	Sale	0.70	3,097	2,153	819,224	Feb 22 04:18 PM
Miller Edward	General Counsel	Feb 20 '24	Sale	0.70	385	268	224,978	Feb 22 04:16 PM
Sinha Vikas	See Remarks	Feb 20 '24	Sale	0.70	2,893	2,011	1,142,359	Feb 22 04:15 PM
Hagen Brett R	Chief Accounting Officer	Feb 20 '24	Sale	0.70	494	343	78,853	Feb 22 04:15 PM
Hagen Brett R	Chief Accounting Officer	Feb 08 '24	Sale	0.67	11,150	7,494	79,347	Feb 09 08:01 PM
Sinha Vikas	See Remarks	Feb 05 '24	Sale	0.67	18,331	12,282	1,145,252	Feb 06 04:46 PM
Miller Edward	General Counsel	Feb 05 '24	Sale	0.67	8,869	5,942	225,363	Feb 06 04:40 PM
Hagen Brett R	Chief Accounting Officer	Feb 05 '24	Sale	0.67	5,792	3,881	90,497	Feb 06 04:39 PM
Brainard Diana	Chief Executive Officer	Feb 05 '24	Sale	0.67	41,421	27,752	822,321	Feb 06 04:38 PM
Sinha Vikas	See Remarks	Jan 23 '24	Sale	0.67	3,205	2,150	1,163,583	Jan 25 04:15 PM
Brainard Diana	Chief Executive Officer	Jan 23 '24	Sale	0.67	9,500	6,369	863,742	Jan 25 04:15 PM
Hagen Brett R	Chief Accounting Officer	Jan 23 '24	Sale	0.67	901	604	96,289	Jan 25 04:15 PM
Miller Edward	General Counsel	Jan 23 '24	Sale	0.67	1,302	873	234,232	Jan 25 04:15 PM
Hagen Brett R	Chief Accounting Officer	Jan 04 '24	Sale	0.64	310	198	97,190	Jan 08 04:15 PM
Miller Edward	General Counsel	Jan 04 '24	Sale	0.64	424	271	235,534	Jan 08 04:15 PM
Sinha Vikas	See Remarks	Jan 04 '24	Sale	0.64	961	614	1,166,788	Jan 08 04:15 PM
Brainard Diana	Chief Executive Officer	Jan 04 '24	Sale	0.64	1,664	1,063	873,242	Jan 08 04:15 PM
Hagen Brett R	Chief Accounting Officer	Dec 27 '23	Sale	0.74	28,335	20,838	97,500	Jan 02 07:36 PM
Sinha Vikas	See Remarks	Nov 17 '23	Sale	1.63	2,490	4,061	1,167,749	Nov 21 05:00 PM
Brainard Diana	Chief Executive Officer	Nov 20 '23	Sale	1.69	4,382	7,408	874,906	Nov 21 05:00 PM
Brainard Diana	Chief Executive Officer	Nov 17 '23	Sale	1.63	2,689	4,386	879,288	Nov 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Nov 17 '23	Sale	1.63	403	657	125,835	Nov 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 19 '23	Sale	1.58	358	566	126,595	Oct 23 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 20 '23	Sale	1.54	357	550	126,238	Oct 23 05:00 PM
Brainard Diana	Chief Executive Officer	Oct 19 '23	Sale	1.58	8,581	13,558	881,977	Oct 23 05:00 PM
Sinha Vikas	See Remarks	Oct 20 '23	Sale	1.54	1,475	2,273	1,170,239	Oct 23 05:00 PM
Sinha Vikas	See Remarks	Oct 19 '23	Sale	1.58	1,232	1,947	1,171,714	Oct 23 05:00 PM
Brainard Diana	Chief Executive Officer	Oct 03 '23	Sale	1.98	1,325	2,619	890,558	Oct 05 05:00 PM
Sinha Vikas	See Remarks	Oct 03 '23	Sale	1.98	755	1,492	1,172,946	Oct 05 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 03 '23	Sale	1.98	222	439	126,953	Oct 05 05:00 PM

Open in Screener

VCEL

Vericel Corp

Sep 06 • 04:00PM ET

45.22

Dollar change -1.88
Percentage change -3.99	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VXF XBI IJT IWO SPSM IBB SLYG

Index	RUT	P/E	11305.00	EPS (ttm)	0.00	Insider Own	0.89%	Shs Outstand	49.03M	Perf Week	-12.28%
Market Cap	2.22B	Forward P/E	84.49	EPS next Y	0.54	Insider Trans	-40.62%	Shs Float	48.59M	Perf Month	-0.20%
Income	0.79M	PEG	-	EPS next Q	-0.05	Inst Own	103.55%	Short Float	6.47%	Perf Quarter	-1.29%
Sales	214.52M	P/S	10.34	EPS this Y	238.18%	Inst Trans	-2.06%	Short Ratio	8.82	Perf Half Y	0.89%
Book/sh	4.97	P/B	9.09	EPS next Y	453.31%	ROA	0.23%	Short Interest	3.14M	Perf Year	34.86%
Cash/sh	2.61	P/C	17.31	EPS next 5Y	-	ROE	0.36%	52W Range	30.18 - 54.10	Perf YTD	26.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.85%	ROI	0.24%	52W High	-16.41%	Beta	1.70
Dividend TTM	-	Quick Ratio	4.16	Sales past 5Y	17.25%	Gross Margin	70.42%	52W Low	49.83%	ATR (14)	2.02
Dividend Ex-Date	-	Current Ratio	4.50	EPS Y/Y TTM	106.81%	Oper. Margin	-1.78%	RSI (14)	39.00	Volatility	4.28% 3.74%
Employees	314	Debt/Eq	0.39	Sales Y/Y TTM	20.39%	Profit Margin	0.37%	Recom	1.00	Target Price	57.25
Option/Short	Yes / Yes	LT Debt/Eq	0.37	EPS Q/Q	8.82%	Payout	-	Rel Volume	0.53	Prev Close	47.10
Sales Surprise	0.14%	EPS Surprise	-7.64%	Sales Q/Q	14.68%	Earnings	Aug 01 BMO	Avg Volume	356.44K	Price	45.22
SMA20	-6.15%	SMA50	-6.67%	SMA200	1.01%	Trades		Volume	189,152	Change	-3.99%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6
Mar-13-17	Reiterated	Needham	Buy	$9 → $6

Show Previous Ratings

Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
12:00PM	Loading…
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
09:54AM	Loading…
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:37PM	Loading…
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance (GlobeNewswire)
Feb-27-24 08:30AM	Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 (GlobeNewswire)
Feb-22-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice (Zacks)
Feb-18-24 03:00AM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Feb-15-24 10:00AM	Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:50AM	Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 (GlobeNewswire)
Jan-30-24 11:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
08:50AM	Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why (Zacks)
Jan-25-24 09:49AM	Tesla, Boeing downgraded: Wall Street's top analyst calls (The Fly)
Jan-24-24 07:01PM	Director ZERBE ROBERT L MD Sells 8,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jan-19-24 08:28PM	Vericel Corp President and CEO Dominick Colangelo Sells 33,452 Shares (GuruFocus.com) +5.95%
Jan-09-24 08:47AM	Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last? (Zacks) +7.24%
07:55AM	Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:30AM	Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 (GlobeNewswire)
Dec-17-23 03:01AM	Insider Sell: Director Paul Wotton Offloads 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-09-23 03:05AM	Insider Sell: President and CEO Dominick Colangelo Sells 24,397 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-02-23 05:04AM	Insider Sell: COO Michael Halpin Sells 17,447 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-23-23 07:04AM	Insider Sell: Chief Medical Officer Jonathan Hopper Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-16-23 05:35PM	3 Biotech Stocks That Could Boom or Bust by 2025 (InvestorPlace)
Nov-10-23 09:52PM	3 Strong Buy Stocks Set to Take Off in the Coming Months (InvestorPlace)
Nov-09-23 03:56PM	Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.05%
Nov-08-23 03:30PM	Vericel Corp (VCEL) Reports Strong Q3 2023 Results and Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Nov-07-23 08:30AM	Vericel to Present at the Stephens Annual Investment Conference (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-25-23 08:30AM	Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-24-23 01:22AM	Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen (Zacks) +5.70%
Oct-23-23 05:59PM	Top Medical Stocks to Buy Amid Recent Market Volatility (Zacks)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +6.34%
Sep-28-23 08:30AM	Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid (GlobeNewswire)
Sep-20-23 04:30PM	Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire) +5.14%
Sep-06-23 08:30AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 01:48AM	Vericel Corp. (VCEL) Rose on Positive Trend in the Industry (Insider Monkey)
Aug-02-23 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Jul-23-23 11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jul-20-23 08:30AM	Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-10-23 09:30AM	Vericel (NASDAQ:VCEL) shareholders are still up 286% over 5 years despite pulling back 4.5% in the past week (Simply Wall St.)
Jun-21-23 08:00PM	VCEL: What does Argus have to say about VCEL? (Argus Research)
May-10-23 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
May-02-23 09:00AM	Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (PR Newswire)
Apr-26-23 08:00PM	VCEL: Lowering target price to $32.00 (Argus Research)
08:30AM	Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-24-23 02:06AM	Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains? (Zacks)
Apr-17-23 03:03PM	Little Excitement Around Vericel Corporation's (NASDAQ:VCEL) Revenues (Simply Wall St.)
Feb-28-23 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023 (GlobeNewswire)
Feb-23-23 09:45AM	Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates (Zacks) +7.29%
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance (GlobeNewswire)
Feb-09-23 08:00AM	Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Jan-31-23 07:19AM	Vericel (NASDAQ:VCEL) shareholders are still up 275% over 5 years despite pulling back 5.7% in the past week (Simply Wall St.)
Jan-11-23 10:24PM	Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains? (Zacks) +6.95%
Jan-10-23 07:55AM	Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program (GlobeNewswire) +16.27%
Jan-04-23 08:34AM	Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 (GlobeNewswire)
Dec-30-22 01:42PM	Vericel scores FDA approval for $142M burn treatment (American City Business Journals)
05:26AM	FDA Approves MediWound's NexoBrid For Burn Treatment (Benzinga)
Dec-29-22 01:46PM	MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire) +5.03%
01:45PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire)
Nov-11-22 06:09AM	Vericel Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +6.20%
Nov-10-22 09:00AM	Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference (GlobeNewswire) +26.97%
Nov-09-22 09:05AM	Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -23.43%
07:55AM	Vericel Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 08:30AM	Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Oct-10-22 11:50AM	Heres Why Vericel Corporation (VCEL) Shares Declined in the Second Quarter (Insider Monkey)
Sep-22-22 08:30AM	Vericel to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILMAN STEVEN C	Director	Sep 04 '24	Option Exercise	3.74	5,000	18,700	16,000	Sep 05 04:06 PM
GILMAN STEVEN C	Director	Sep 04 '24	Sale	48.58	5,000	242,900	11,000	Sep 05 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 03 '24	Option Exercise	10.95	10,000	109,500	68,229	Sep 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 03 '24	Sale	49.83	10,000	498,300	58,229	Sep 05 04:05 PM
GILMAN STEVEN C	Director	Sep 04 '24	Proposed Sale	48.99	5,000	244,950		Sep 04 10:25 AM
Hopper Jonathan Mark	Officer	Sep 03 '24	Proposed Sale	51.22	10,000	512,200		Sep 03 01:27 PM
Colangelo Dominick	President and CEO	Aug 14 '24	Option Exercise	3.02	17,500	52,850	238,437	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 15 '24	Option Exercise	3.02	17,500	52,850	238,437	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 15 '24	Sale	46.24	17,500	809,200	220,937	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 14 '24	Sale	45.17	17,500	790,475	220,937	Aug 16 04:05 PM
Colangelo Dominick	Officer	Aug 15 '24	Proposed Sale	46.24	17,500	809,196		Aug 15 05:03 PM
Colangelo Dominick	Officer	Aug 14 '24	Proposed Sale	45.17	17,500	790,400		Aug 14 04:17 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Option Exercise	3.74	7,000	26,180	16,900	Aug 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Sale	45.94	7,000	321,580	11,900	Aug 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Proposed Sale	45.94	7,000	321,596		Aug 07 04:11 PM
Colangelo Dominick	President and CEO	Jul 17 '24	Option Exercise	3.02	17,500	52,850	238,437	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 18 '24	Option Exercise	3.02	17,500	52,850	238,437	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 17 '24	Sale	51.55	17,500	902,125	220,937	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 18 '24	Sale	51.40	17,500	899,500	220,937	Jul 19 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jul 16 '24	Option Exercise	16.25	15,000	243,750	15,707	Jul 18 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jul 16 '24	Sale	52.18	15,000	782,700	707	Jul 18 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Jul 12 '24	Sale	50.00	5,000	250,000	14,436	Jul 16 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Jul 05 '24	Sale	45.00	545	24,525	1,033	Jul 09 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jun 21 '24	Option Exercise	16.25	6,772	110,045	7,259	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 20 '24	Option Exercise	16.25	6,754	109,752	7,241	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 24 '24	Option Exercise	16.25	1,474	23,952	1,961	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 21 '24	Sale	45.02	6,772	304,875	487	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 20 '24	Sale	45.04	6,754	304,200	487	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 24 '24	Sale	45.84	1,474	67,568	487	Jun 24 06:21 PM
Colangelo Dominick	President and CEO	Jun 12 '24	Option Exercise	3.02	17,500	52,850	238,252	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 13 '24	Option Exercise	3.02	17,500	52,850	238,252	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 12 '24	Sale	44.12	17,500	772,100	220,752	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 13 '24	Sale	43.10	17,500	754,250	220,752	Jun 14 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	May 20 '24	Option Exercise	10.95	10,000	109,500	68,116	May 21 04:07 PM
Hopper Jonathan Mark	Chief Medical Officer	May 20 '24	Sale	49.99	10,000	499,900	58,116	May 21 04:07 PM
Halpin Michael	Chief Operating Officer	May 17 '24	Option Exercise	5.39	5,195	28,017	6,284	May 21 04:05 PM
Colangelo Dominick	President and CEO	May 15 '24	Option Exercise	3.02	17,500	52,850	238,252	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 16 '24	Option Exercise	3.02	17,500	52,850	238,252	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 15 '24	Sale	49.67	17,500	869,225	220,752	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 16 '24	Sale	47.85	17,500	837,375	220,752	May 17 04:05 PM
Colangelo Dominick	President and CEO	Apr 30 '24	Option Exercise	11.79	25,445	299,977	220,752	May 01 04:05 PM
Colangelo Dominick	President and CEO	Apr 17 '24	Option Exercise	3.02	17,500	52,850	212,807	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 18 '24	Option Exercise	3.02	17,500	52,850	212,807	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 17 '24	Sale	46.47	17,500	813,225	195,307	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 18 '24	Sale	44.59	17,500	780,325	195,307	Apr 19 04:05 PM
Rubino Alan L	Director	Apr 09 '24	Option Exercise	4.12	3,000	12,360	20,594	Apr 11 04:05 PM
ZERBE ROBERT L MD	Director	Mar 27 '24	Option Exercise	3.74	3,278	12,260	26,673	Mar 29 04:05 PM
ZERBE ROBERT L MD	Director	Mar 27 '24	Sale	51.57	3,278	169,046	23,395	Mar 29 04:05 PM
Colangelo Dominick	President and CEO	Mar 13 '24	Option Exercise	3.02	17,500	52,850	212,370	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 14 '24	Option Exercise	3.02	17,500	52,850	212,370	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 13 '24	Sale	44.67	17,500	781,725	194,870	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 14 '24	Sale	44.02	17,500	770,350	194,870	Mar 15 04:07 PM
Halpin Michael	Chief Operating Officer	Mar 11 '24	Sale	44.71	7,874	352,047	949	Mar 13 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Mar 07 '24	Sale	45.00	1,634	73,530	1,400	Mar 11 04:08 PM
Flynn Sean C.	SVP, General Counsel	Mar 08 '24	Sale	45.33	8,115	367,853	167	Mar 11 04:07 PM
ZERBE ROBERT L MD	Director	Feb 20 '24	Option Exercise	3.74	722	2,700	24,117	Feb 22 04:07 PM
ZERBE ROBERT L MD	Director	Feb 20 '24	Sale	50.01	722	36,107	23,395	Feb 22 04:07 PM
Halpin Michael	Chief Operating Officer	Feb 20 '24	Option Exercise	0.00	11,887	0	10,155	Feb 22 04:07 PM
Flynn Sean C.	SVP, General Counsel	Feb 20 '24	Option Exercise	0.00	7,075	0	9,059	Feb 22 04:07 PM
Colangelo Dominick	President and CEO	Feb 20 '24	Option Exercise	0.00	38,887	0	199,013	Feb 22 04:06 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 20 '24	Option Exercise	0.00	7,380	0	20,097	Feb 22 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 20 '24	Option Exercise	0.00	2,920	0	3,900	Feb 22 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 20 '24	Option Exercise	0.00	7,075	0	58,695	Feb 22 04:06 PM
Colangelo Dominick	President and CEO	Feb 14 '24	Option Exercise	3.02	17,500	52,850	191,508	Feb 16 04:05 PM
Colangelo Dominick	President and CEO	Feb 15 '24	Option Exercise	3.02	17,500	52,850	191,508	Feb 16 04:05 PM
Colangelo Dominick	President and CEO	Feb 15 '24	Sale	48.85	17,500	854,875	174,008	Feb 16 04:05 PM
Colangelo Dominick	President and CEO	Feb 14 '24	Sale	46.99	17,500	822,325	174,008	Feb 16 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 12 '24	Option Exercise	0.00	1,625	0	54,759	Feb 13 04:06 PM
Halpin Michael	Chief Operating Officer	Feb 12 '24	Option Exercise	0.00	3,500	0	4,449	Feb 13 04:05 PM
Colangelo Dominick	President and CEO	Feb 12 '24	Option Exercise	0.00	7,500	0	177,485	Feb 13 04:05 PM
ZERBE ROBERT L MD	Director	Jan 29 '24	Sale	44.22	2,300	101,706	23,395	Jan 30 04:05 PM
ZERBE ROBERT L MD	Director	Jan 25 '24	Sale	44.02	200	8,804	25,695	Jan 29 04:05 PM
ZERBE ROBERT L MD	Director	Jan 22 '24	Option Exercise	4.12	3,000	12,360	28,895	Jan 24 04:05 PM
ZERBE ROBERT L MD	Director	Jan 22 '24	Sale	41.85	8,000	334,775	25,895	Jan 24 04:05 PM
Colangelo Dominick	President and CEO	Jan 17 '24	Option Exercise	3.02	16,726	50,513	186,711	Jan 19 04:06 PM
Colangelo Dominick	President and CEO	Jan 18 '24	Option Exercise	3.02	16,726	50,513	186,711	Jan 19 04:06 PM
Colangelo Dominick	President and CEO	Jan 18 '24	Sale	38.58	16,726	645,289	169,985	Jan 19 04:06 PM
Colangelo Dominick	President and CEO	Jan 17 '24	Sale	37.97	16,726	635,086	169,985	Jan 19 04:06 PM
ZERBE ROBERT L MD	Director	Jan 12 '24	Sale	38.09	2,200	83,798	30,895	Jan 16 04:05 PM
Flynn Sean C.	SVP, General Counsel	Dec 13 '23	Sale	34.20	1,432	48,974	4,573	Dec 15 04:07 PM
Flynn Sean C.	SVP, General Counsel	Dec 14 '23	Sale	37.45	106	3,970	4,467	Dec 15 04:07 PM
Wotton Paul K	Director	Dec 14 '23	Sale	37.31	5,000	186,550	26,802	Dec 15 04:07 PM
Colangelo Dominick	President and CEO	Dec 13 '23	Option Exercise	3.57	12,000	42,840	181,985	Dec 15 04:05 PM
Colangelo Dominick	President and CEO	Dec 14 '23	Option Exercise	3.57	12,000	42,840	181,985	Dec 15 04:05 PM
Colangelo Dominick	President and CEO	Dec 14 '23	Sale	37.12	12,000	445,440	169,985	Dec 15 04:05 PM
Colangelo Dominick	President and CEO	Dec 13 '23	Sale	34.03	12,000	408,360	169,985	Dec 15 04:05 PM
Colangelo Dominick	President and CEO	Dec 06 '23	Option Exercise	3.57	12,397	44,257	189,139	Dec 08 04:05 PM
Colangelo Dominick	President and CEO	Dec 07 '23	Option Exercise	3.57	12,000	42,840	188,742	Dec 08 04:05 PM
Colangelo Dominick	President and CEO	Dec 06 '23	Sale	34.43	12,397	426,829	176,742	Dec 08 04:05 PM
Colangelo Dominick	President and CEO	Dec 07 '23	Sale	33.84	12,000	406,080	176,742	Dec 08 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 30 '23	Option Exercise	7.20	17,447	125,618	18,274	Dec 01 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 30 '23	Sale	35.41	17,447	617,798	827	Dec 01 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Nov 20 '23	Option Exercise	10.95	5,000	54,750	58,007	Nov 22 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Nov 20 '23	Sale	36.40	5,000	182,000	53,007	Nov 22 04:05 PM
ZERBE ROBERT L MD	Director	Nov 15 '23	Sale	38.02	300	11,406	33,095	Nov 17 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Nov 15 '23	Sale	37.70	662	24,954	1,305	Nov 17 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Oct 02 '23	Option Exercise	0.00	938	0	2,134	Oct 04 04:05 PM

Open in Screener

CADL

Candel Therapeutics Inc

Sep 06 • 04:00PM ET

6.14

Dollar change -0.17
Percentage change -2.69	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

CADL Candel Therapeutics Inc daily Stock Chart

Held by: IWM VTI VXF IWO VFMO VTWO IWC VTWG RSSL URTY

Index	RUT	P/E	-	EPS (ttm)	-1.70	Insider Own	42.79%	Shs Outstand	29.21M	Perf Week	-3.76%
Market Cap	196.97M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.99%	Shs Float	18.36M	Perf Month	22.31%
Income	-49.99M	PEG	-	EPS next Q	-	Inst Own	12.91%	Short Float	8.88%	Perf Quarter	-13.76%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-0.70%	Short Ratio	4.11	Perf Half Y	301.31%
Book/sh	-0.32	P/B	-	EPS next Y	-	ROA	-117.35%	Short Interest	1.63M	Perf Year	438.60%
Cash/sh	0.67	P/C	9.18	EPS next 5Y	-	ROE	-480.68%	52W Range	0.66 - 14.30	Perf YTD	317.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.75%	ROI	-	52W High	-57.06%	Beta	-0.87
Dividend TTM	-	Quick Ratio	1.62	Sales past 5Y	-25.00%	Gross Margin	-3654.84%	52W Low	830.30%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	1.62	EPS Y/Y TTM	-52.74%	Oper. Margin	0.00%	RSI (14)	53.16	Volatility	8.88% 7.42%
Employees	42	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-123.89%	Payout	-	Rel Volume	0.36	Prev Close	6.31
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	396.37K	Price	6.14
SMA20	6.67%	SMA50	3.55%	SMA200	40.79%	Trades		Volume	142,966	Change	-2.69%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 08:00AM	Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.52%
Aug-13-24 08:00AM	Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Jun-18-24 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.93%
08:30AM	Loading…
Jun-14-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments (News Direct)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 08:00AM	Candel Therapeutics to Join Russell 3000 Index (GlobeNewswire) +7.40%
Jun-07-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers (News Direct)
Jun-03-24 08:30AM	Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer (News Direct) -5.96%
May-30-24 08:00AM	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma (GlobeNewswire)
May-28-24 11:07AM	Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why (Zacks) +9.62%
May-24-24 11:42AM	Candel (CADL) Reports Upbeat Data From Lung Cancer Study (Zacks) -27.03%
May-23-24 05:00PM	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Loading…
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-22-24 08:00AM	Candel Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -13.77%
May-20-24 08:00AM	Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire) +30.84%
May-14-24 01:53PM	CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -7.94%
Apr-25-24 08:00AM	Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire) +6.28%
Apr-12-24 10:00AM	Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag (Zacks) -8.52%
Apr-11-24 09:00AM	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire) +42.75%
Apr-09-24 08:00AM	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors (GlobeNewswire) -20.84%
Apr-05-24 12:10PM	Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study (Zacks)
Apr-04-24 12:24PM	After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study (Benzinga) +280.95%
08:00AM	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-28-24 04:05PM	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma (GlobeNewswire) +10.76%
01:53PM	Loading…
01:53PM	CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM	Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors (News Direct)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 04:30PM	Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate (GlobeNewswire)
Feb-13-24 07:30AM	CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma (GlobeNewswire) +29.50%
Feb-05-24 08:00AM	Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts (GlobeNewswire)
Dec-13-23 12:21PM	Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409 (Zacks) +17.82%
Dec-12-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer (GlobeNewswire) +16.29%
Nov-28-23 09:00AM	Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409 (GlobeNewswire) -8.16%
Nov-09-23 09:43AM	Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) -13.00%
08:00AM	Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-04-23 08:00AM	Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC (GlobeNewswire)
Nov-03-23 12:00PM	Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire) -21.50%
Oct-18-23 11:00AM	Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 (GlobeNewswire)
Sep-27-23 09:40AM	Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting (GlobeNewswire) -9.00%
Sep-26-23 08:00AM	Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) -10.71%
Sep-06-23 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 08:00AM	Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-02-23 08:00AM	Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 08:00AM	Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024 (GlobeNewswire)
Jun-08-23 08:00AM	Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors (GlobeNewswire) +5.30%
Jun-05-23 08:00AM	Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire) +9.80%
May-22-23 08:26AM	Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.) +7.64%
May-19-23 01:51PM	Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer (Benzinga) -8.15%
09:00AM	Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-02-23 08:00AM	Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO (GlobeNewswire) +15.44%
Apr-17-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) +19.01%
Mar-30-23 08:00AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research) +5.54%
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research) +6.46%
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research) -9.01%
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research) -5.28%
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research) -8.86%
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research)
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research) -6.20%
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research)
Feb-01-23 08:00AM	Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day (GlobeNewswire) -6.21%
06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research) +6.62%
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research) -9.74%
Jan-27-23 07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research) +6.80%
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research) +6.16%
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research) -11.80%
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research)
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research) +14.29%
Jan-20-23 06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research) +5.77%
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research) +8.18%
Jan-18-23 06:28AM	Daily Vickers Top Insider Picks for 01/18/2023 (Argus Research) -5.45%
Jan-17-23 06:27AM	Daily Vickers Top Insider Picks for 01/17/2023 (Argus Research) +5.77%
Jan-13-23 06:56AM	Daily Vickers Top Insider Picks for 01/13/2023 (Argus Research) +5.58%
Jan-12-23 08:00AM	Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference (GlobeNewswire)
06:50AM	Daily Vickers Top Insider Picks for 01/12/2023 (Argus Research)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tyagarajan Seshu	Chief Technology Officer	Jul 17 '24	Sale	6.47	14,851	96,125	146,049	Jul 19 08:31 AM
Tak Paul Peter	Chief Executive Officer	Jul 17 '24	Sale	6.47	22,528	145,815	330,735	Jul 19 08:29 AM
Schoch Charles	See Remarks	Jul 17 '24	Sale	6.47	9,884	63,975	62,520	Jul 19 08:28 AM
Nichols William Garrett	Chief Medical Officer	Jul 17 '24	Sale	6.47	10,875	70,390	114,482	Jul 19 08:26 AM
Barone Francesca	Chief Scientific Officer	Jul 17 '24	Sale	6.47	14,051	90,947	159,961	Jul 19 08:24 AM
Tyagarajan Seshu	Chief Technology Officer	Jul 11 '24	Sale	5.97	13,330	79,625	160,900	Jul 15 08:36 AM
Tak Paul Peter	Chief Executive Officer	Jul 11 '24	Sale	5.97	20,293	121,218	353,263	Jul 15 08:35 AM
Schoch Charles	See Remarks	Jul 11 '24	Sale	5.97	8,897	53,145	72,404	Jul 15 08:34 AM
Nichols William Garrett	Chief Medical Officer	Jul 11 '24	Sale	5.97	9,769	58,354	125,357	Jul 15 08:32 AM
Barone Francesca	Chief Scientific Officer	Jul 11 '24	Sale	5.97	12,645	75,534	174,012	Jul 15 08:30 AM

Open in Screener

ADVM

Adverum Biotechnologies Inc

Sep 06 • 04:00PM ET

6.76

Dollar change -0.06
Percentage change -0.88	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

ADVM Adverum Biotechnologies Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO IWC DFAC ITOT DFAS FESM

Index	RUT	P/E	-	EPS (ttm)	-7.99	Insider Own	32.25%	Shs Outstand	20.80M	Perf Week	-1.74%
Market Cap	140.61M	Forward P/E	-	EPS next Y	-5.08	Insider Trans	4.72%	Shs Float	14.09M	Perf Month	0.15%
Income	-99.86M	PEG	-	EPS next Q	-1.36	Inst Own	56.62%	Short Float	10.62%	Perf Quarter	-9.26%
Sales	0.00M	P/S	-	EPS this Y	54.97%	Inst Trans	2.88%	Short Ratio	4.58	Perf Half Y	-64.79%
Book/sh	8.08	P/B	0.84	EPS next Y	2.82%	ROA	-40.33%	Short Interest	1.50M	Perf Year	-61.59%
Cash/sh	8.36	P/C	0.81	EPS next 5Y	-	ROE	-66.76%	52W Range	6.38 - 29.70	Perf YTD	-10.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.36%	ROI	-43.17%	52W High	-77.24%	Beta	1.03
Dividend TTM	-	Quick Ratio	7.99	Sales past 5Y	-56.90%	Gross Margin	-249.44%	52W Low	5.96%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	7.99	EPS Y/Y TTM	40.09%	Oper. Margin	0.00%	RSI (14)	43.95	Volatility	5.00% 6.07%
Employees	121	Debt/Eq	0.44	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.25	Target Price	30.00
Option/Short	Yes / Yes	LT Debt/Eq	0.38	EPS Q/Q	71.67%	Payout	-	Rel Volume	0.31	Prev Close	6.82
Sales Surprise	-100.00%	EPS Surprise	39.36%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	326.53K	Price	6.76
SMA20	-2.06%	SMA50	-7.62%	SMA200	-35.63%	Trades		Volume	101,887	Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Initiated	Oppenheimer	Outperform	$25
Apr-30-24	Initiated	H.C. Wainwright	Buy	$30
Jul-07-22	Upgrade	Truist	Hold → Buy	$4
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Apr-29-21	Downgrade	Truist	Buy → Hold	$30 → $9
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Dec-16-20	Initiated	UBS	Neutral	$13
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform	$24
May-05-20	Upgrade	SunTrust	Hold → Buy	$13 → $21
Apr-28-20	Initiated	Goldman	Buy	$17
Mar-16-20	Initiated	SVB Leerink	Outperform	$17
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$20
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$8 → $21
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral	$6 → $10
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral	$10 → $6
Jun-14-19	Resumed	Raymond James	Mkt Perform

Show Previous Ratings

Sep-05-24 07:30AM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:05PM	Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences (GlobeNewswire)
Sep-03-24 09:55AM	Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? (Zacks)
Aug-12-24 04:35PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights (GlobeNewswire)
07:00AM	Loading…
Aug-02-24 07:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.55%
Aug-01-24 08:00AM	Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Jul-18-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.97%
Jul-17-24 02:45AM	Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet (Zacks)
Jul-10-24 08:00AM	Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting (GlobeNewswire)
Jun-18-24 08:00AM	Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit (GlobeNewswire) -9.97%
Jun-11-24 08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilard Kiss as a Member of the Board of Directors (GlobeNewswire)
08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors (GlobeNewswire)
May-10-24 03:36PM	Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress (GuruFocus.com)
09:35AM	Loading…
09:35AM	Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
May-09-24 11:55PM	ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024 (InvestorPlace)
05:45PM	Adverum Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights (GlobeNewswire)
May-03-24 08:00AM	Adverum Biotechnologies to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-02-24 10:01AM	Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 07:39AM	HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target (MT Newswires)
Apr-29-24 08:33AM	Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating (MT Newswires)
Apr-25-24 04:05PM	Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting (GlobeNewswire) -7.85%
Apr-23-24 09:40AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-19-24 09:35AM	Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Apr-04-24 09:40AM	Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? (Zacks)
08:34AM	How Adverum (ADVM) Stock Stands Out in a Strong Industry (Zacks)
Apr-03-24 09:35AM	Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround (Zacks)
Mar-27-24 09:35AM	Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
07:52AM	Loading…
Mar-21-24 07:52AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Mar-20-24 05:33AM	Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments (GuruFocus.com) -7.88%
Mar-19-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.78%
Mar-18-24 10:53PM	ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023 (InvestorPlace)
04:20PM	Adverum Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates (GlobeNewswire)
Mar-06-24 03:07PM	Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop (InvestorPlace)
Feb-28-24 04:05PM	Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-27-24 06:10AM	Stocks on the Launchpad: The Next 3 Market Sensations (InvestorPlace)
Feb-22-24 06:15AM	Unleash Massive Returns With These 3 Top Penny Stocks (InvestorPlace) +6.60%
Feb-12-24 08:00AM	Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +15.03%
Feb-08-24 07:00AM	Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD (GlobeNewswire) -29.89%
Feb-05-24 07:45AM	Adverum Biotechnologies Announces $127.5 Million Private Placement Financing (GlobeNewswire) +34.51%
Feb-01-24 05:30PM	Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 (GlobeNewswire) +13.33% +19.33%
Jan-29-24 08:00AM	Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer (GlobeNewswire) +13.89%
Jan-04-24 08:27AM	Here's Why You Should Invest in Adverum (ADVM) Stock Now (Zacks) +6.00%
Dec-07-23 04:05PM	Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society (GlobeNewswire) +9.43% -10.88%
Nov-28-23 04:05PM	Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-23 04:51PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire)
Nov-06-23 08:00AM	Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors (GlobeNewswire)
Nov-04-23 05:54PM	Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-26-23 04:05PM	Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial (GlobeNewswire) +7.50%
Sep-21-23 04:05PM	Adverum Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) +8.39%
Sep-05-23 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:05PM	Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer (GlobeNewswire)
Aug-14-23 08:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Aug-10-23 04:20PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-12-23 08:00AM	Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid (GlobeNewswire)
Jun-02-23 08:00AM	Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +6.14%
May-25-23 06:30AM	Adverum Biotechnologies Announces New Executive Leadership Roles (GlobeNewswire) +7.41%
May-18-23 09:00AM	Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vecs Phase 2 Clinical Development at ASGCT 2023 Annual Meeting (GlobeNewswire)
09:00AM	Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform (GlobeNewswire)
May-11-23 04:47PM	Adverum Biotechnologies: Q1 Earnings Snapshot (AP Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 04:05PM	Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.20%
May-02-23 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD (GlobeNewswire) -7.42%
Apr-23-23 01:00PM	Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec (GlobeNewswire)
Apr-21-23 06:03AM	After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain (Simply Wall St.) -7.00%
Apr-18-23 08:00AM	Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Apr-17-23 04:05PM	Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting (GlobeNewswire)
Apr-04-23 09:40AM	Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-23 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update (GlobeNewswire)
Mar-02-23 10:23AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
Feb-27-23 04:05PM	Adverum Biotechnologies to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-18-23 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 04:05PM	Adverum Biotechnologies Reports Third Quarter 2022 Financial Results (GlobeNewswire) +7.57%
Nov-04-22 12:08PM	Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) (GlobeNewswire)
Oct-27-22 04:05PM	Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting (GlobeNewswire)
Sep-30-22 04:45PM	Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD (GlobeNewswire) +5.26%
Sep-27-22 04:05PM	Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire) +9.94%
Sep-23-22 04:05PM	Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
11:06AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022 (GlobeNewswire)
Sep-15-22 05:19PM	Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study (Zacks)
Sep-14-22 08:00AM	Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Sep-08-22 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-26-22 04:05PM	Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-11-22 04:05PM	Adverum Biotechnologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 04:05PM	Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-01-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.48% -5.07%
Jul-25-22 07:16AM	Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders (Simply Wall St.)
Jul-15-22 09:52AM	Adverum Posts New Data From Wet AMD Gene Therapy Trial (Benzinga) -5.71%
08:32AM	Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD (GlobeNewswire)
Jul-08-22 08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022 (GlobeNewswire) +9.29%
Jul-07-22 05:14PM	Gene therapy company cuts 78 jobs as it jump-starts program in blinding eye disease (American City Business Journals) +13.82%
11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	Jul 30 '24	Buy	7.15	85,800	613,470	2,268,064	Jul 31 04:19 PM
Leonard Braden Michael	10% Owner	Jul 17 '24	Buy	7.75	135,546	1,049,926	2,101,546	Jul 18 09:16 PM
Leonard Braden Michael	10% Owner	Jul 18 '24	Buy	9.11	80,718	735,736	2,182,264	Jul 18 09:16 PM
Scopa James Paul	Director	Feb 07 '24	Buy	1.35	100,000	135,000	100,000	Feb 09 05:51 PM
Lupher, Jr. Mark L.	Director	Feb 07 '24	Buy	1.35	130,000	175,500	130,000	Feb 09 05:50 PM
Seyedkazemi Setareh	Chief Development Officer	Sep 15 '23	Sale	1.52	6,201	9,429	47,674	Sep 18 06:54 PM

Open in Screener

FDMT

4D Molecular Therapeutics Inc

Sep 06 • 04:00PM ET

15.07

Dollar change -0.44
Percentage change -2.84	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FDMT 4D Molecular Therapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IBB IWO VTWO SCHA IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	15.93%	Shs Outstand	51.97M	Perf Week	-1.18%
Market Cap	783.19M	Forward P/E	-	EPS next Y	-3.10	Insider Trans	-0.66%	Shs Float	43.69M	Perf Month	2.45%
Income	-95.93M	PEG	-	EPS next Q	-0.67	Inst Own	105.37%	Short Float	22.78%	Perf Quarter	-33.23%
Sales	21.99M	P/S	35.62	EPS this Y	-4.53%	Inst Trans	0.27%	Short Ratio	11.25	Perf Half Y	-48.93%
Book/sh	11.33	P/B	1.33	EPS next Y	-14.90%	ROA	-29.90%	Short Interest	9.95M	Perf Year	-4.92%
Cash/sh	10.43	P/C	1.45	EPS next 5Y	-	ROE	-33.00%	52W Range	9.44 - 36.25	Perf YTD	-25.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.35%	ROI	-16.02%	52W High	-58.43%	Beta	2.75
Dividend TTM	-	Quick Ratio	28.48	Sales past 5Y	111.29%	Gross Margin	74.42%	52W Low	59.64%	ATR (14)	1.03
Dividend Ex-Date	-	Current Ratio	28.48	EPS Y/Y TTM	17.81%	Oper. Margin	-477.24%	RSI (14)	43.68	Volatility	5.87% 5.58%
Employees	147	Debt/Eq	0.02	Sales Y/Y TTM	1014.45%	Profit Margin	-436.30%	Recom	1.09	Target Price	50.30
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	27.86%	Payout	-	Rel Volume	0.42	Prev Close	15.51
Sales Surprise	-99.61%	EPS Surprise	7.92%	Sales Q/Q	-98.32%	Earnings	Aug 08 AMC	Avg Volume	885.02K	Price	15.07
SMA20	0.35%	SMA50	-15.29%	SMA200	-31.81%	Trades		Volume	370,185	Change	-2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70
Jan-05-21	Initiated	BofA Securities	Buy	$47

Show Previous Ratings

Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-12-24 08:00AM	4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
05:55PM	Loading…
Aug-08-24 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-24 08:00AM	4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board (GlobeNewswire) -5.97%
Jul-17-24 05:00AM	4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity (GlobeNewswire) -31.96%
Jul-12-24 09:40AM	4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? (Zacks) +5.54%
Jul-08-24 05:52PM	4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? (Insider Monkey) +5.58%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 08:00AM	4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy (GlobeNewswire)
Jun-18-24 08:00AM	4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast (GlobeNewswire)
Jun-08-24 04:30PM	4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
07:30AM	Loading…
Jun-06-24 07:30AM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference (GlobeNewswire) -17.27%
Jun-04-24 08:00AM	4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-03-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-24 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47 European Cystic Fibrosis Conference (GlobeNewswire)
May-10-24 01:48PM	4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections (GuruFocus.com)
May-09-24 11:55PM	FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
May-07-24 08:00AM	4DMT to Participate in Upcoming Investor Conference (GlobeNewswire)
May-01-24 10:01AM	4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +6.10%
08:00AM	4DMT Announces Presentations at ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 01:30AM	4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares (GuruFocus.com)
Mar-29-24 07:01PM	4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares (GuruFocus.com)
Mar-28-24 08:00AM	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis (GlobeNewswire) -11.18%
Mar-04-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-02-24 04:32AM	4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com)
06:05PM	Loading…
Feb-29-24 06:05PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4DMT Reports Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-12-24 08:00AM	4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024 (GlobeNewswire)
Feb-08-24 03:05AM	Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc (GuruFocus.com)
Feb-06-24 11:27PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -14.97%
Feb-05-24 04:05PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +84.62%
02:50PM	Why Is 4D Molecular (FDMT) Stock Up 85% Today? (InvestorPlace)
12:36PM	4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' (Reuters)
Feb-03-24 05:00PM	4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD (GlobeNewswire)
Jan-29-24 08:00AM	4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden (GlobeNewswire)
Jan-25-24 10:04PM	4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares (GuruFocus.com) -8.28%
Jan-23-24 08:00AM	4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease (GlobeNewswire)
Jan-19-24 12:00PM	All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy (Zacks)
Jan-11-24 10:00AM	TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors (PR Newswire)
Jan-09-24 05:02AM	4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares (GuruFocus.com)
Jan-06-24 05:02AM	Andreas Halvorsen's Firm Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
05:02AM	Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
Jan-04-24 08:00AM	4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates (GlobeNewswire)
Jan-03-24 08:01AM	4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases (GlobeNewswire) -5.08%
Dec-21-23 08:00AM	4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD (GlobeNewswire) +7.35%
Dec-04-23 08:00AM	4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Nov-15-23 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-09-23 04:19PM	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire) +5.24%
Nov-01-23 04:00PM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-30-23 08:00AM	4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy (GlobeNewswire)
Oct-26-23 09:56AM	Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls (The Fly)
Oct-25-23 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-23-23 08:00AM	4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD (GlobeNewswire)
Sep-12-23 04:05PM	4DMT Appoints Uneek Mehra as Chief Financial and Business Officer (GlobeNewswire)
Sep-07-23 04:05PM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD (GlobeNewswire)
Aug-09-23 06:15PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
08:22AM	Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year (Simply Wall St.)
Jul-29-23 12:00PM	4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023 (GlobeNewswire)
Jul-17-23 04:05PM	4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data (GlobeNewswire)
Jul-10-23 07:30PM	Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets (PR Newswire) +5.33%
Jun-08-23 09:53AM	4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why (Benzinga) +6.84%
Jun-07-23 04:10PM	4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting (GlobeNewswire)
Jun-01-23 08:00AM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 08:00AM	4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting (GlobeNewswire)
May-13-23 08:27AM	Institutional investors have a lot riding on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 44% ownership (Simply Wall St.)
May-12-23 06:02PM	Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics (GuruFocus.com) +5.98%
06:02PM	Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics (GuruFocus.com)
May-11-23 08:00AM	4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-10-23 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-09-23 04:05PM	4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:25AM	Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-23 04:05PM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:27AM	4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains? (Zacks)
May-04-23 09:04PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -15.46% +5.35%
04:08PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-27-23 04:29PM	What's Going On With 4D Molecular Therapeutics Stock Today (Benzinga) -19.79% +9.15%
07:00AM	4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023 (GlobeNewswire)
Apr-24-23 08:00AM	Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas Short-Form Human Complement Factor H (GlobeNewswire)
08:00AM	4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy (GlobeNewswire)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-13-23 08:00AM	4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer (GlobeNewswire) +11.15%
Apr-12-23 08:21AM	Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Mar-22-23 08:09AM	Heres Why 4D Molecular Therapeutics (FDMT) Stock Boosted in Q4 (Insider Monkey)
Mar-15-23 05:45PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.06% +5.70%
04:05PM	4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire)
Mar-02-23 05:41AM	4D Molecular Therapeutics (NASDAQ:FDMT) shareholders have earned a 38% return over the last year (Simply Wall St.)
Feb-23-23 11:33AM	4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study (Benzinga) -6.77%
Feb-22-23 04:05PM	4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium (GlobeNewswire)
Feb-16-23 04:05PM	4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium (GlobeNewswire) +8.69%
Feb-08-23 04:05PM	4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.52%
Feb-02-23 04:05PM	4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema (GlobeNewswire) +7.31%

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bizily Scott	Chief Legal Officer	Aug 19 '24	Option Exercise	6.49	500	3,245	7,281	Aug 21 04:28 PM
Bizily Scott	Chief Legal Officer	Aug 19 '24	Sale	15.00	500	7,500	6,781	Aug 21 04:28 PM
Bizily Scott	Chief Legal Officer	Jul 16 '24	Option Exercise	7.60	1,750	13,295	8,531	Jul 18 08:22 PM
Bizily Scott	Chief Legal Officer	Jul 16 '24	Sale	27.11	1,750	47,442	6,781	Jul 18 08:22 PM
Bizily Scott	Chief Legal Officer	Jul 11 '24	Option Exercise	15.78	1,996	31,497	8,777	Jul 15 06:13 PM
Bizily Scott	Chief Legal Officer	Jul 11 '24	Sale	25.00	1,996	49,900	6,781	Jul 15 06:13 PM
Kirn David	Chief Executive Officer	Jul 10 '24	Option Exercise	14.55	12,923	188,077	1,072,076	Jul 12 05:46 PM
Kirn David	Chief Executive Officer	Jul 10 '24	Sale	22.49	12,923	290,598	1,059,153	Jul 12 05:46 PM
Bizily Scott	Chief Legal Officer	Jul 01 '24	Option Exercise	7.55	4,248	32,089	5,985	Jul 03 05:11 PM
Bizily Scott	Chief Legal Officer	Jul 01 '24	Sale	21.36	4,248	90,758	1,737	Jul 03 05:11 PM
Kirn David	Chief Executive Officer	Jun 24 '24	Option Exercise	14.42	12,930	186,451	1,072,083	Jun 26 05:07 PM
Kirn David	Chief Executive Officer	Jun 24 '24	Sale	23.10	12,930	298,711	1,059,153	Jun 26 05:07 PM
Bizily Scott	Chief Legal Officer	Jun 17 '24	Option Exercise	7.60	1,750	13,295	3,487	Jun 20 04:59 PM
Bizily Scott	Chief Legal Officer	Jun 17 '24	Sale	23.71	1,750	41,494	1,737	Jun 20 04:59 PM
Bizily Scott	Chief Legal Officer	May 16 '24	Option Exercise	7.60	1,750	13,295	3,487	May 20 08:35 PM
Bizily Scott	Chief Legal Officer	May 16 '24	Sale	25.45	1,750	44,541	1,737	May 20 08:35 PM
Bizily Scott	Chief Legal Officer	Apr 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 16 '24	Sale	25.74	1,750	45,045	1,737	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Option Exercise	12.54	8,153	102,224	9,890	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Sale	31.78	8,153	259,102	1,737	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Option Exercise	25.98	5,833	151,541	7,570	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Sale	35.04	5,833	204,410	1,737	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Option Exercise	7.60	1,750	13,295	3,487	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Sale	31.27	1,750	54,722	1,737	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Option Exercise	20.24	1,909	38,638	3,646	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Sale	30.00	1,909	57,270	1,737	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Sale	27.67	1,750	48,422	1,737	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Option Exercise	10.18	6,244	63,586	4,653	Feb 12 09:04 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Sale	27.50	6,244	171,710	1,737	Feb 12 09:04 PM
Kirn David	Chief Executive Officer	Feb 08 '24	Sale	27.13	92,001	2,495,822	1,059,153	Feb 12 08:22 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Option Exercise	15.29	24,000	366,840	13,595	Feb 07 08:32 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Sale	30.05	24,552	737,788	1,043	Feb 07 08:32 PM
Kirn David	Chief Executive Officer	Jan 23 '24	Sale	18.41	5,696	104,851	1,151,154	Jan 25 04:59 PM
Kirn David	Chief Executive Officer	Jan 04 '24	Sale	20.31	40,732	827,202	1,185,087	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Jan 05 '24	Sale	19.57	28,237	552,478	1,156,850	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 15 '23	Sale	17.27	28,632	494,432	1,230,521	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 18 '23	Sale	18.13	4,702	85,243	1,225,819	Jan 08 04:19 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 04 '24	Sale	19.53	540,000	10,546,200	4,247,914	Jan 05 05:44 PM

Open in Screener

ACLX

Arcellx Inc

Sep 06 • 04:00PM ET

71.25

Dollar change +0.88
Percentage change 1.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI XBI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	25.04%	Shs Outstand	52.28M	Perf Week	5.59%
Market Cap	3.83B	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-5.55%	Shs Float	40.29M	Perf Month	39.95%
Income	-53.89M	PEG	-	EPS next Q	-0.33	Inst Own	81.58%	Short Float	12.48%	Perf Quarter	38.78%
Sales	144.75M	P/S	26.46	EPS this Y	0.14%	Inst Trans	15.14%	Short Ratio	11.15	Perf Half Y	0.68%
Book/sh	9.08	P/B	7.84	EPS next Y	-58.49%	ROA	-7.94%	Short Interest	5.03M	Perf Year	92.83%
Cash/sh	9.61	P/C	7.41	EPS next 5Y	-	ROE	-13.80%	52W Range	30.88 - 75.10	Perf YTD	28.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.89%	ROI	-10.07%	52W High	-5.13%	Beta	0.25
Dividend TTM	-	Quick Ratio	6.01	Sales past 5Y	0.00%	Gross Margin	97.77%	52W Low	130.73%	ATR (14)	3.29
Dividend Ex-Date	-	Current Ratio	6.01	EPS Y/Y TTM	73.62%	Oper. Margin	-55.73%	RSI (14)	63.32	Volatility	5.66% 4.90%
Employees	130	Debt/Eq	0.15	Sales Y/Y TTM	349.32%	Profit Margin	-37.23%	Recom	1.12	Target Price	80.14
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-2.50%	Payout	-	Rel Volume	1.24	Prev Close	70.37
Sales Surprise	24.27%	EPS Surprise	1.72%	Sales Q/Q	91.47%	Earnings	Aug 08 AMC	Avg Volume	450.94K	Price	71.25
SMA20	9.01%	SMA50	16.20%	SMA200	21.33%	Trades		Volume	561,401	Change	1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

Show Previous Ratings

Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
04:42PM	Loading…
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Loading…
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-13-23 04:47PM	Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:00PM	Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Nov-09-23 11:14AM	There Were 181 IPOs In 2022: $1K In Either Of These Two Would Have You Up 200%+ (Benzinga)
08:30AM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks) +18.55%
09:00AM	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-26-23 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-04-23 09:55AM	Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade (Zacks)
Sep-01-23 09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-17-23 09:55AM	Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect? (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-14-23 04:00PM	Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results (PR Newswire) +6.62%
Jul-31-23 07:13AM	Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year (Simply Wall St.)
Jul-25-23 02:37AM	Should You be Bullish on Arcellx (ACLX)? (Insider Monkey)
Jun-26-23 12:48PM	Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion (Zacks)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-21-23 10:38AM	Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA (Zacks)
Jun-20-23 04:05PM	Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death (Investor's Business Daily) -7.18%
Jun-19-23 07:46PM	Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program (PR Newswire)
May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 06:11AM	Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts (Simply Wall St.)
May-08-23 05:15PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides First Quarter Financial Results (PR Newswire)
May-04-23 04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
Apr-28-23 03:34PM	Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript (Motley Fool)
Apr-25-23 12:00PM	Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy? (Zacks)
Apr-21-23 12:00PM	Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.50%
Apr-13-23 04:01PM	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire) +5.84%
Apr-11-23 10:00AM	Best Momentum Stocks to Buy for April 11th (Zacks)
Apr-05-23 09:55AM	Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know (Zacks)
Apr-04-23 12:20PM	Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? (Zacks)
Apr-03-23 08:34AM	Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't? (Zacks)
Mar-29-23 05:25PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (PR Newswire)
Mar-16-23 12:18PM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Feb-21-23 04:00PM	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire) -5.09%
Feb-02-23 04:00PM	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)
Jan-30-23 09:00AM	Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
Jan-04-23 11:45AM	Gilead's (GILD) Application for Trodelvy Gets EMA Validation (Zacks)
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-12-22 10:55AM	Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology (Zacks)
Dec-09-22 04:08PM	Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences (Investor's Business Daily) +29.24%
09:54AM	Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead (Barrons.com)
09:42AM	Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate (Benzinga)
08:46AM	Gilead to co-develop Arcellx's multiple myeloma drug (MarketWatch)
08:17AM	Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
08:17AM	Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress (PR Newswire)
08:15AM	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
Nov-30-22 11:08AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-14-22 04:00PM	Arcellx Reports Third Quarter 2022 Financial Results and Business Progress (PR Newswire)
01:13PM	The bear market rally has more room to run, Guggenheim says. Here are 2 stocks to bet on (TipRanks)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Option Exercise	15.00	3,421	51,315	12,699	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Sale	70.02	3,421	239,526	9,278	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	13.27	27,451	364,232	36,729	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	67.03	27,451	1,840,053	9,278	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Option Exercise	15.00	21,684	325,260	30,962	Aug 28 04:54 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Sale	71.12	21,684	1,542,274	9,278	Aug 28 04:54 PM
CHRISTOPHER HEERY	Officer	Aug 26 '24	Proposed Sale	69.38	48,907	3,393,168		Aug 26 04:24 PM
Patel Kavita	Director	Aug 20 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 22 04:01 PM
Patel Kavita	Director	Aug 20 '24	Sale	65.88	1,500	98,820	0	Aug 22 04:01 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Option Exercise	6.28	5,450	34,226	14,728	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Sale	65.05	5,450	354,526	9,278	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Option Exercise	10.94	20,000	218,764	29,278	Aug 02 04:02 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Sale	60.42	20,000	1,208,435	9,278	Aug 02 04:02 PM
Patel Kavita	Director	Jul 30 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 01 05:24 PM
Patel Kavita	Director	Jul 30 '24	Sale	61.97	1,500	92,949	0	Aug 01 05:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Option Exercise	6.28	10,901	68,458	20,179	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Sale	65.30	10,901	711,854	9,278	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Option Exercise	6.28	3,671	23,054	12,949	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Option Exercise	6.28	1,780	11,178	11,058	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Sale	60.01	3,671	220,302	9,278	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Sale	60.21	1,780	107,175	9,278	Jul 12 06:39 PM
Patel Kavita	Director	Jul 09 '24	Option Exercise	6.66	1,500	9,990	1,500	Jul 11 04:04 PM
Patel Kavita	Director	Jul 09 '24	Sale	56.63	1,500	84,947	0	Jul 11 04:04 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Option Exercise	11.93	20,000	238,646	29,278	Jul 03 04:05 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	55.39	20,000	1,107,763	9,278	Jul 03 04:05 PM
Patel Kavita	Director	Jun 27 '24	Option Exercise	6.66	10,000	66,600	10,000	Jun 28 04:08 PM
Patel Kavita	Director	Jun 27 '24	Sale	54.27	10,000	542,656	0	Jun 28 04:08 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	53.70	12,877	691,519	6,915	Jun 28 04:06 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Option Exercise	11.53	20,000	230,554	29,278	Jun 14 04:31 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Sale	55.13	20,000	1,102,668	9,278	Jun 14 04:31 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '24	Option Exercise	0.00	22,428	0	31,913	May 24 08:16 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 24 '24	Sale	50.71	12,121	614,656	19,792	May 24 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	6.28	18,168	114,095	27,106	May 03 05:50 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Sale	51.33	18,168	932,557	8,938	May 03 05:50 PM
Ware Olivia C	Director	Apr 16 '24	Option Exercise	7.61	9,402	71,549	9,402	Apr 18 04:01 PM
Ware Olivia C	Director	Apr 16 '24	Sale	55.55	9,402	522,260	0	Apr 18 04:01 PM
Elghandour Rami	SEE REMARKS	Apr 01 '24	Sale	67.09	23,086	1,548,887	69,253	Apr 03 04:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Option Exercise	6.28	20,000	125,600	50,303	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Option Exercise	6.28	5,450	34,226	14,388	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	70.18	41,365	2,903,066	8,938	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Sale	69.11	5,450	376,648	8,938	Mar 26 08:52 PM
Carroll Jill	Director	Mar 21 '24	Sale	70.55	504,263	35,575,755	1,479,148	Mar 25 05:30 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	69.34	6,825	473,255	9,485	Mar 18 08:49 PM
Ware Olivia C	Director	Mar 15 '24	Option Exercise	7.61	9,000	68,490	9,000	Mar 18 06:38 PM
Ware Olivia C	Director	Mar 15 '24	Sale	70.40	9,000	633,582	0	Mar 18 06:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 09 '24	Sale	63.40	3,688	233,811	33,270	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 08 '24	Sale	62.29	3,456	215,290	36,958	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 12 '24	Sale	64.46	2,967	191,251	30,303	Feb 12 07:46 PM
Elghandour Rami	SEE REMARKS	Feb 09 '24	Sale	63.40	13,886	880,340	103,508	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 08 '24	Sale	62.29	13,010	810,451	117,394	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 12 '24	Sale	64.46	11,169	719,948	92,339	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '24	Option Exercise	0.00	22,555	0	40,414	Feb 09 04:08 PM
Elghandour Rami	SEE REMARKS	Feb 07 '24	Option Exercise	0.00	70,211	0	130,404	Feb 09 04:05 PM
Heery Christopher	Chief Medical Officer	Jan 04 '24	Sale	55.27	7,598	419,926	17,859	Jan 08 04:06 PM
Gilson Michelle	Chief Financial Officer	Jan 04 '24	Sale	55.27	8,514	470,551	16,310	Jan 08 04:04 PM
Elghandour Rami	See Remarks	Jan 04 '24	Sale	55.27	29,073	1,606,804	60,193	Jan 08 04:02 PM
Heery Christopher	Chief Medical Officer	Jan 03 '24	Option Exercise	0.00	16,519	0	25,457	Jan 04 07:32 PM
Elghandour Rami	See Remarks	Jan 03 '24	Option Exercise	0.00	53,097	0	89,266	Jan 04 07:29 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Option Exercise	6.28	120,000	753,600	127,795	Dec 19 04:43 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Sale	50.17	120,000	6,020,281	7,795	Dec 19 04:43 PM
Carroll Jill	Director	Dec 14 '23	Sale	49.13	504,263	24,774,441	1,983,411	Dec 18 04:47 PM

NBIX Neurocrine Biosciences, Inc. daily Stock Chart

Held by: VTI IJH VB VXF VBK XBI MDY IBB USMV IJK

Index	-	P/E	36.30	EPS (ttm)	3.31	Insider Own	2.23%	Shs Outstand	100.98M	Perf Week	-6.43%
Market Cap	12.13B	Forward P/E	17.48	EPS next Y	6.88	Insider Trans	-13.23%	Shs Float	98.77M	Perf Month	-16.62%
Income	339.20M	PEG	1.11	EPS next Q	1.53	Inst Own	93.04%	Short Float	2.31%	Perf Quarter	-9.69%
Sales	2.12B	P/S	5.73	EPS this Y	99.31%	Inst Trans	-1.45%	Short Ratio	2.57	Perf Half Y	-11.20%
Book/sh	24.87	P/B	4.83	EPS next Y	39.67%	ROA	11.46%	Short Interest	2.29M	Perf Year	9.08%
Cash/sh	10.29	P/C	11.68	EPS next 5Y	32.80%	ROE	15.55%	52W Range	103.63 - 157.98	Perf YTD	-8.80%
Dividend Est.	-	P/FCF	24.53	EPS past 5Y	62.04%	ROI	12.27%	52W High	-23.93%	Beta	0.38
Dividend TTM	-	Quick Ratio	4.08	Sales past 5Y	34.77%	Gross Margin	97.28%	52W Low	15.96%	ATR (14)	5.35
Dividend Ex-Date	Dec 29, 1995	Current Ratio	4.19	EPS Y/Y TTM	87.53%	Oper. Margin	25.70%	RSI (14)	27.49	Volatility	3.53% 2.86%
Employees	1400	Debt/Eq	0.12	Sales Y/Y TTM	26.69%	Profit Margin	16.00%	Recom	1.46	Target Price	169.52
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-34.36%	Payout	0.00%	Rel Volume	0.98	Prev Close	121.21
Sales Surprise	8.10%	EPS Surprise	-44.16%	Sales Q/Q	30.37%	Earnings	Aug 01 BMO	Avg Volume	887.70K	Price	120.17
SMA20	-15.33%	SMA50	-16.06%	SMA200	-11.58%	Trades		Volume	868,949	Change	-0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110
Jun-06-22	Resumed	Jefferies	Buy	$126 → $112
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral	$114 → $94
Feb-25-22	Upgrade	Goldman	Neutral → Buy	$115
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$122 → $90
Nov-19-21	Initiated	BMO Capital Markets	Underperform	$76

Show Previous Ratings

Sep-02-24 10:53AM	Nxera wins $35m after Phase II schizophrenia trial success (Pharmaceutical Technology)
Aug-30-24 07:41AM	Why Neurocrine Biosciences Stock Was Tumbling This Week (Motley Fool)
Aug-29-24 01:22PM	Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock (Benzinga)
06:52AM	Neurocrine reports positive data from Phase II schizophrenia treatment trial (Clinical Trials Arena)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia) -18.87%
04:28PM	Loading…
04:28PM	Neurocrine Plummets 19% Does It Still Have A Shot At This 'Significant Market Opportunity?' (Investor's Business Daily)
04:05PM	Neurocrine Biosciences to Participate at Investor Conferences in September (PR Newswire)
11:16AM	As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors (Benzinga)
09:56AM	Neurocrine Stock Hammered After Schizophrenia Drug Lags Two Key Rivals (Investor's Business Daily)
08:17AM	Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers (Investor's Business Daily)
08:15AM	Neurocrines mixed schizophrenia data disappoint Wall Street (BioPharma Dive)
07:07AM	Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia (PR Newswire)
Aug-16-24 07:01PM	Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Aug-07-24 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
12:45PM	Loading…
Aug-06-24 12:45PM	Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Aug-02-24 06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:05AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 10:00AM	Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics (Zacks) +8.18%
08:06AM	Neurocrine Biosciences Raises 2024 INGREZZA Net Product Sales Guidance (RTT News)
08:05AM	Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates (Zacks)
07:09AM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance (PR Newswire)
Jul-31-24 09:15AM	Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:02AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-18-24 08:30AM	Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing (PR Newswire)
Jul-12-24 08:38AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Jul-11-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results (PR Newswire)
Jul-02-24 06:33AM	FDA grants priority review for Neurocrines crinecerfont NDAs (Pharmaceutical Technology)
Jul-01-24 07:30AM	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH (PR Newswire)
04:37PM	Loading…
Jun-28-24 04:37PM	How Medicare drug price negotiations could hit pharma stocks (Yahoo Finance Video)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-14-24 02:34PM	Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans (Investor's Business Daily)
Jun-03-24 08:01AM	Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 (PR Newswire)
07:35AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
May-29-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in June (PR Newswire)
May-28-24 04:14PM	Neurocrine Biosciences Announces CEO Succession Plan (PR Newswire)
08:30AM	Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 (PR Newswire)
May-21-24 04:05PM	Neurocrine Biosciences Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA (valbenazine) Capsules (PR Newswire)
May-16-24 04:47PM	Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing (MT Newswires)
May-14-24 08:30AM	Neurocrine Biosciences Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 (PR Newswire)
May-09-24 11:51AM	How Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
11:51AM	How Neurocrine Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
09:45AM	Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 (PR Newswire)
08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults (PR Newswire)
02:35AM	Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (GlobeNewswire)
May-08-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (PR Newswire)
May-07-24 04:15PM	Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference (PR Newswire)
08:30AM	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 (PR Newswire)
May-06-24 08:30AM	Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring (PR Newswire)
May-04-24 08:00AM	Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam (Investor's Business Daily)
May-03-24 01:15PM	Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 (PR Newswire)
May-02-24 11:18AM	UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating (MT Newswires)
03:01AM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
01:06AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
May-01-24 11:36PM	Q1 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
09:01PM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
04:18PM	Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech (Investor's Business Daily)
11:54AM	NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:04AM	No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win (Investor's Business Daily)
08:31AM	Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell (MT Newswires)
08:15AM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
07:18AM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 05:48PM	REFILE-UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30) (Reuters)
05:45PM	Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours (MT Newswires)
05:31PM	FDA approves Neurocrine Biosciences' Huntington's disease drug (Reuters)
05:12PM	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules (PR Newswire)
09:15AM	Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Apr-24-24 10:15AM	Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? (Investor's Business Daily)
10:01AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:30AM	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community (PR Newswire)
08:00AM	3 Red-Hot Biotech Rockets Blasting Off in 2024 (InvestorPlace)
Apr-23-24 11:50AM	No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win (Investor's Business Daily)
07:22AM	Neurocrine scores surprise win with depression drug (BioPharma Dive)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder (PR Newswire)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-16-24 04:01PM	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides (GlobeNewswire)
02:30AM	Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
Apr-10-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results (PR Newswire)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-03-24 08:30AM	Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
Mar-28-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults (PR Newswire)
Mar-24-24 09:19AM	Top 12 Stocks in George Soros' Stock Portfolio (Insider Monkey)
Mar-23-24 08:00AM	S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind (Investor's Business Daily)
Mar-16-24 08:00AM	AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base (Investor's Business Daily)
01:23AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares (GuruFocus.com)
01:23AM	Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-15-24 10:00AM	Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders (GuruFocus.com)
Mar-13-24 01:26AM	Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-11-24 04:01PM	Neurocrine Biosciences to Participate at Virtual Investor Conferences in March (PR Newswire)
01:12PM	The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher (Investor's Business Daily)
Mar-06-24 04:45PM	3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success (InvestorPlace)
Mar-01-24 12:40AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares (GuruFocus.com)
Feb-27-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in March (PR Newswire)
Feb-22-24 11:28PM	Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc (GuruFocus.com)
03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-15-24 11:36PM	Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares (GuruFocus.com)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RASTETTER WILLIAM H	Director	Aug 15 '24	Sale	146.69	14,250	2,090,332	37,491	Aug 16 05:00 PM
LYONS GARY A	Director	Aug 13 '24	Option Exercise	42.76	11,570	494,733	130,617	Aug 15 05:21 PM
LYONS GARY A	Director	Aug 13 '24	Sale	150.43	11,570	1,740,450	119,047	Aug 15 05:21 PM
ABERNETHY MATT	Chief Financial Officer	Aug 13 '24	Option Exercise	73.60	14,100	1,037,760	45,628	Aug 15 05:12 PM
ABERNETHY MATT	Chief Financial Officer	Aug 13 '24	Sale	150.38	14,100	2,120,347	31,528	Aug 15 05:12 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 13 '24	Option Exercise	103.52	3,043	315,011	9,650	Aug 15 05:06 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 13 '24	Sale	150.10	7,143	1,072,180	2,507	Aug 15 05:06 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 06 '24	Option Exercise	79.02	273	21,572	6,880	Aug 08 05:16 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 06 '24	Sale	147.70	273	40,322	6,607	Aug 08 05:16 PM
Cooke Julie	Chief Human Resources Officer	Aug 01 '24	Option Exercise	61.82	12,632	780,910	30,834	Aug 05 05:40 PM
Cooke Julie	Chief Human Resources Officer	Aug 01 '24	Sale	153.26	12,632	1,936,017	18,202	Aug 05 05:40 PM
Lippoldt Darin	Chief Legal Officer	Aug 01 '24	Option Exercise	79.02	2,996	236,744	42,736	Aug 05 05:18 PM
Lippoldt Darin	Chief Legal Officer	Aug 01 '24	Sale	154.01	2,996	461,423	39,740	Aug 05 05:18 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Option Exercise	61.82	900	55,638	19,102	Jul 18 05:12 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Sale	150.04	900	135,036	18,202	Jul 18 05:12 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Option Exercise	103.52	1,957	202,589	9,064	Jul 18 05:00 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Sale	150.03	2,857	428,627	6,607	Jul 18 05:00 PM
LYONS GARY A	Director	Jul 16 '24	Option Exercise	42.76	930	39,767	119,977	Jul 18 04:54 PM
LYONS GARY A	Director	Jul 16 '24	Sale	150.03	930	139,530	119,047	Jul 18 04:54 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Option Exercise	73.60	900	66,240	32,428	Jul 18 04:45 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Sale	150.04	900	135,037	31,528	Jul 18 04:45 PM
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Option Exercise	79.02	7,004	553,456	46,744	Jul 18 04:41 PM
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Sale	150.00	7,004	1,050,590	39,740	Jul 18 04:41 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Option Exercise	61.82	10,000	618,200	28,202	Jul 02 09:36 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Sale	140.19	10,000	1,401,864	18,202	Jul 02 09:36 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Option Exercise	79.02	272	21,493	7,779	Jul 02 09:09 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Sale	138.11	272	37,566	7,507	Jul 02 09:09 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Option Exercise	79.02	273	21,572	7,780	Jun 04 04:23 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Sale	136.55	273	37,278	7,507	Jun 04 04:23 PM
SHERWIN STEPHEN A	Director	May 29 '24	Option Exercise	44.68	40,000	1,787,350	51,504	May 30 04:38 PM
SHERWIN STEPHEN A	Director	May 29 '24	Sale	133.46	40,000	5,338,564	26,504	May 30 04:38 PM
Sharp Shalini	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:35 PM
Sharp Shalini	Director	May 17 '24	Sale	141.90	1,106	156,943	994	May 21 05:35 PM
POPS RICHARD F	Director	May 17 '24	Option Exercise	0.00	4,199	0	33,711	May 21 05:27 PM
POPS RICHARD F	Director	May 17 '24	Sale	141.84	2,100	297,860	31,611	May 21 05:27 PM
MORROW GEORGE J	Director	May 17 '24	Option Exercise	0.00	4,199	0	4,199	May 21 05:15 PM
Norwalk Leslie V	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:06 PM
Norwalk Leslie V	Director	May 17 '24	Sale	141.82	1,106	156,850	994	May 21 05:06 PM
LYONS GARY A	Director	May 17 '24	Option Exercise	0.00	2,100	0	119,047	May 21 04:57 PM
SHERWIN STEPHEN A	Director	May 17 '24	Option Exercise	0.00	4,199	0	26,504	May 21 04:51 PM
Mercier Johanna	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 04:46 PM
LYONS GARY A	Director	May 14 '24	Option Exercise	42.76	12,500	534,500	129,447	May 16 04:55 PM
LYONS GARY A	Director	May 14 '24	Sale	135.63	12,500	1,695,370	116,947	May 16 04:55 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Sale	140.24	15,000	2,103,609	31,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Sale	135.66	15,000	2,034,826	31,528	May 16 04:40 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Option Exercise	79.02	273	21,572	7,780	May 08 04:26 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Sale	140.55	273	38,370	7,507	May 08 04:26 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Option Exercise	81.21	19,818	1,609,431	53,365	Apr 17 05:19 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Sale	133.36	19,818	2,643,020	40,778	Apr 17 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Option Exercise	79.02	272	21,493	7,779	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Sale	137.30	272	37,346	7,507	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Option Exercise	103.52	5,000	517,600	12,507	Mar 25 06:02 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Sale	145.06	5,000	725,320	7,507	Mar 25 06:02 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Option Exercise	80.90	75,000	6,067,628	110,299	Mar 15 05:33 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Sale	139.38	75,000	10,453,417	40,778	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Option Exercise	39.79	40,000	1,591,600	20,000	Mar 15 05:25 PM
MORROW GEORGE J	Director	Mar 14 '24	Sale	139.42	40,000	5,576,710	0	Mar 15 05:25 PM
POPS RICHARD F	Director	Mar 13 '24	Option Exercise	42.76	23,200	992,032	52,712	Mar 15 05:19 PM
POPS RICHARD F	Director	Mar 13 '24	Sale	140.33	23,200	3,255,621	29,512	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Option Exercise	106.02	3,000	318,060	10,507	Mar 15 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Sale	140.14	3,000	420,419	7,507	Mar 15 05:15 PM
POPS RICHARD F	Director	Mar 08 '24	Option Exercise	42.76	1,700	72,692	31,212	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 11 '24	Option Exercise	42.76	100	4,276	29,612	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 08 '24	Sale	140.05	1,700	238,078	29,512	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 11 '24	Sale	140.00	100	14,000	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Option Exercise	106.02	1,800	190,836	9,307	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Option Exercise	106.02	200	21,204	7,707	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Sale	140.03	1,800	252,053	7,507	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Sale	140.00	200	28,000	7,507	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Option Exercise	79.02	6,544	517,107	10,007	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Option Exercise	79.02	273	21,572	7,780	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Sale	135.34	6,544	885,638	7,507	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Sale	135.51	273	36,994	7,507	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Option Exercise	53.67	75,000	4,025,043	93,759	Feb 29 06:55 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Sale	134.69	75,000	10,101,608	40,616	Feb 29 06:55 PM
Norwalk Leslie V	Director	Feb 27 '24	Option Exercise	84.95	8,000	679,600	8,000	Feb 29 06:50 PM
Norwalk Leslie V	Director	Feb 27 '24	Sale	135.67	8,000	1,085,388	0	Feb 29 06:50 PM
POPS RICHARD F	Director	Feb 20 '24	Option Exercise	12.98	15,000	194,700	44,512	Feb 22 05:11 PM
POPS RICHARD F	Director	Feb 20 '24	Sale	132.47	15,000	1,987,047	29,512	Feb 22 05:11 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '24	Sale	132.96	1,114	148,122	23,716	Feb 15 05:51 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '24	Sale	132.94	1,432	190,371	13,128	Feb 15 05:48 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '24	Sale	132.99	1,098	146,028	39,740	Feb 15 05:45 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Sale	133.02	2,832	376,700	514,596	Feb 15 05:43 PM
Gano Kyle	Chief Business Development Off	Feb 13 '24	Sale	132.89	1,352	179,674	135,166	Feb 15 05:40 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '24	Sale	133.03	716	95,253	7,507	Feb 15 05:38 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '24	Sale	133.04	796	105,902	17,976	Feb 15 05:35 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '24	Sale	133.07	1,811	240,996	4,895	Feb 15 05:33 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '24	Sale	133.01	1,098	146,050	40,616	Feb 15 05:29 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '24	Sale	132.85	1,352	179,612	31,528	Feb 15 05:27 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Option Exercise	39.28	5,090	199,951	512,052	Feb 14 05:17 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '24	Sale	135.41	1,328	179,830	4,895	Feb 08 07:46 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 06 '24	Sale	141.96	456	64,734	4,894	Feb 08 07:46 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '24	Sale	135.44	1,329	179,995	17,263	Feb 08 07:35 PM
Cooke Julie	Chief Human Resources Officer	Feb 06 '24	Sale	142.07	1,215	172,617	17,263	Feb 08 07:35 PM
ROBERTS EIRY	Chief Medical Officer	Feb 06 '24	Sale	142.24	1,121	159,446	21,837	Feb 08 07:28 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '24	Sale	134.21	980	131,522	22,717	Feb 08 07:28 PM
Lippoldt Darin	Chief Legal Officer	Feb 06 '24	Sale	142.17	1,041	147,995	37,939	Feb 08 07:25 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '24	Sale	134.24	911	122,289	38,755	Feb 08 07:25 PM

Open in Screener

TARA

Protara Therapeutics Inc

Sep 06 • 04:00PM ET

1.86

Dollar change -0.04
Percentage change -2.37	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

TARA Protara Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-3.19	Insider Own	10.77%	Shs Outstand	20.63M	Perf Week	-8.17%
Market Cap	38.27M	Forward P/E	-	EPS next Y	-3.20	Insider Trans	-17.84%	Shs Float	18.41M	Perf Month	-2.37%
Income	-40.69M	PEG	-	EPS next Q	-0.52	Inst Own	46.39%	Short Float	10.21%	Perf Quarter	-31.55%
Sales	0.00M	P/S	-	EPS this Y	14.22%	Inst Trans	-2.32%	Short Ratio	11.28	Perf Half Y	-51.57%
Book/sh	8.10	P/B	0.23	EPS next Y	-4.49%	ROA	-41.35%	Short Interest	1.88M	Perf Year	-14.91%
Cash/sh	4.34	P/C	0.43	EPS next 5Y	-	ROE	-45.90%	52W Range	1.04 - 5.24	Perf YTD	-1.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.98%	ROI	-42.38%	52W High	-64.60%	Beta	1.82
Dividend TTM	-	Quick Ratio	16.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	78.37%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	16.33	EPS Y/Y TTM	46.34%	Oper. Margin	0.00%	RSI (14)	34.86	Volatility	6.85% 8.84%
Employees	27	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	29.50
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	55.15%	Payout	-	Rel Volume	0.78	Prev Close	1.90
Sales Surprise	-	EPS Surprise	43.75%	Sales Q/Q	-	Earnings	Aug 06 BMO	Avg Volume	166.75K	Price	1.86
SMA20	-8.15%	SMA50	-12.74%	SMA200	-29.42%	Trades		Volume	129,635	Change	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Sep-03-24 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-06-24 08:00AM	Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jun-24-24 05:06PM	Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.83%
May-21-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Loading…
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Loading…
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
08:35AM	Loading…
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +5.44%
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)
Dec-03-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-20 07:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-12-20 07:15AM	Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Nov-11-20 07:00AM	Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-04-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-20 03:12PM	What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry? (Simply Wall St.)
Sep-22-20 08:13AM	Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire)
Sep-21-20 04:01PM	Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.97%
Sep-08-20 07:00AM	Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications (GlobeNewswire) -6.09%
Sep-02-20 05:49PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-20 07:00AM	Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Jul-28-20 07:00AM	Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) +5.29%
Jul-24-20 07:00AM	Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors (GlobeNewswire)
Jul-03-20 06:34PM	Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) (Insider Monkey)
Jul-02-20 07:59PM	CORRECTION Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-20 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.74%
May-26-20 08:30AM	Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease (GlobeNewswire) +13.98%
May-13-20 08:00AM	Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview (GlobeNewswire) -8.46%
May-11-20 08:38AM	ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics (GlobeNewswire)
May-05-20 04:05PM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-20 07:00AM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-20 08:00AM	ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Jul 16 '24	Sale	2.44	11,396	27,828	56,500	Jul 18 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 11 '24	Sale	2.40	47,993	115,346	60,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 10 '24	Sale	2.31	18,061	41,685	75,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 09 '24	Sale	2.21	8,497	18,811	80,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 01 '24	Sale	2.12	8,288	17,598	87,500	Jul 03 02:00 PM
Opaleye Management Inc.	10% Owner	Jun 27 '24	Sale	2.26	46,574	105,169	90,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 28 '24	Sale	2.07	17,994	37,334	85,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 25 '24	Sale	2.26	12,725	28,734	102,471	Jun 27 04:05 PM
Opaleye Management Inc.	10% Owner	May 30 '24	Sale	2.94	9,230	27,113	114,520	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 31 '24	Sale	2.90	5,824	16,895	108,696	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 21 '24	Sale	3.06	33,000	100,838	124,250	May 23 07:01 PM
Opaleye Management Inc.	10% Owner	May 22 '24	Sale	3.02	9,800	29,596	123,750	May 23 07:01 PM
Opaleye Management Inc.	10% Owner	May 17 '24	Sale	3.25	70,885	230,326	126,050	May 17 07:48 PM
Opaleye Management Inc.	10% Owner	May 10 '24	Sale	3.11	151,700	472,424	2,380,294	May 10 06:57 PM
Opaleye Management Inc.	10% Owner	May 09 '24	Sale	3.09	30,600	94,526	2,531,994	May 10 06:57 PM

Open in Screener

RVMD

Revolution Medicines Inc

Sep 06 • 04:00PM ET

41.84

Dollar change -1.40
Percentage change -3.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

RVMD Revolution Medicines Inc daily Stock Chart

Held by: VTI IWM VB VBK VXF XBI IBB IWO VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.65	Insider Own	16.89%	Shs Outstand	164.67M	Perf Week	0.10%
Market Cap	6.99B	Forward P/E	-	EPS next Y	-3.87	Insider Trans	-0.73%	Shs Float	138.83M	Perf Month	-1.02%
Income	-519.21M	PEG	-	EPS next Q	-0.90	Inst Own	87.07%	Short Float	12.13%	Perf Quarter	4.21%
Sales	0.74M	P/S	9444.53	EPS this Y	10.44%	Inst Trans	7.50%	Short Ratio	12.05	Perf Half Y	32.70%
Book/sh	9.77	P/B	4.28	EPS next Y	-11.91%	ROA	-36.03%	Short Interest	16.84M	Perf Year	24.97%
Cash/sh	9.52	P/C	4.39	EPS next 5Y	-	ROE	-40.73%	52W Range	15.44 - 48.61	Perf YTD	45.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-30.58%	52W High	-13.93%	Beta	1.42
Dividend TTM	-	Quick Ratio	15.42	Sales past 5Y	11.11%	Gross Margin	-1323.58%	52W Low	170.98%	ATR (14)	1.71
Dividend Ex-Date	-	Current Ratio	15.42	EPS Y/Y TTM	-16.27%	Oper. Margin	-80961.32%	RSI (14)	44.72	Volatility	4.21% 3.81%
Employees	378	Debt/Eq	0.05	Sales Y/Y TTM	-97.49%	Profit Margin	-69973.99%	Recom	1.19	Target Price	59.29
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	12.28%	Payout	-	Rel Volume	0.62	Prev Close	43.24
Sales Surprise	-100.00%	EPS Surprise	-4.56%	Sales Q/Q	-100.00%	Earnings	Aug 07 AMC	Avg Volume	1.40M	Price	41.84
SMA20	-2.80%	SMA50	-3.17%	SMA200	20.84%	Trades		Volume	861,523	Change	-3.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Aug-07-24 04:05PM	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-31-24 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 (GlobeNewswire)
Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
09:00AM	Loading…
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
04:06PM	Loading…
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38% +14.52%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.71%
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72% +8.78%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.81%
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%
Nov-09-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-22 05:55PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-02-22 10:01AM	Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
09:54AM	Harvard University Stock Portfolio: Top 10 Picks (Insider Monkey)
Nov-01-22 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022 (GlobeNewswire)
Oct-24-22 11:07AM	Who Doesnt Like a Bargain?: Oppenheimer Suggests 2 Stocks to Buy (TipRanks)
Oct-13-22 11:05AM	Loss-making Revolution Medicines (NASDAQ:RVMD) sheds a further US$68m, taking total shareholder losses to 33% over 1 year (Simply Wall St.)
Sep-22-22 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Companys First Mutant-Selective RAS(ON) Inhibitor (GlobeNewswire) +5.44%
Sep-01-22 04:05PM	Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire (GlobeNewswire)
Aug-31-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know (Zacks) +8.21%
Aug-10-22 08:35AM	Need To Know: Analysts Are Much More Bullish On Revolution Medicines, Inc. (NASDAQ:RVMD) Revenues (Simply Wall St.)
Aug-09-22 06:15PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBARA L WEBER	Officer	Aug 21 '24	Proposed Sale	44.83	1,808	81,053		Aug 21 04:14 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Aug 15 04:48 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Sale	42.98	16,667	716,389	269,073	Aug 15 04:48 PM
STEPHEN M. KELSEY	Officer	Aug 13 '24	Proposed Sale	42.98	16,667	716,348		Aug 13 04:25 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Option Exercise	4.09	10,000	40,900	321,885	Aug 02 05:35 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Sale	45.88	10,000	458,827	311,885	Aug 02 05:35 PM
MARK A GOLDSMITH	Director	Aug 01 '24	Proposed Sale	45.64	10,000	456,400		Aug 01 04:29 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Option Exercise	4.09	16,667	68,168	285,740	Jul 17 04:07 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Sale	46.47	16,667	774,516	269,073	Jul 17 04:07 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Option Exercise	4.09	25,000	102,250	336,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.05	25,000	1,126,205	311,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.01	10,000	450,117	25,424	Jul 16 05:05 PM
Cislini Jeff	General Counsel	Jul 09 '24	Sale	40.83	2,399	97,951	47,088	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Option Exercise	16.80	2,155	36,204	22,103	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Sale	44.00	2,155	94,820	19,948	Jul 10 04:36 PM
Cislini Jeff	General Counsel	Jun 26 '24	Sale	38.47	2,000	76,940	49,487	Jun 27 06:48 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Option Exercise	4.09	16,467	67,350	285,540	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Option Exercise	4.09	200	818	269,273	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Sale	39.06	16,467	643,152	269,073	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Sale	39.00	200	7,800	269,073	Jun 26 04:26 PM
GOLDSMITH MARK A	See Remarks	Jun 17 '24	Sale	37.39	11,950	446,770	311,885	Jun 20 04:14 PM
Anders Jack	Chief Financial Officer	Jun 17 '24	Sale	37.39	1,893	70,775	101,176	Jun 20 04:13 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '24	Sale	37.39	4,415	165,064	136,651	Jun 20 04:12 PM
Kelsey Stephen Michael	See Remarks	Jun 17 '24	Sale	37.39	3,349	125,209	269,073	Jun 20 04:11 PM
Cislini Jeff	General Counsel	Jun 17 '24	Sale	37.39	1,757	65,690	51,487	Jun 20 04:11 PM
Wei Lin	Chief Medical Officer	Jun 17 '24	Sale	37.39	5,589	208,954	70,851	Jun 20 04:10 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Option Exercise	4.09	7,500	30,675	329,822	Jun 05 04:18 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Sale	39.99	7,500	299,942	322,322	Jun 05 04:18 PM
Cislini Jeff	General Counsel	May 21 '24	Sale	39.11	1,500	58,671	52,874	May 22 04:11 PM
Anders Jack	Chief Financial Officer	May 03 '24	Option Exercise	2.68	10,000	26,800	111,959	May 03 07:36 PM
Anders Jack	Chief Financial Officer	May 03 '24	Sale	40.03	10,000	400,260	101,959	May 03 07:36 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.33	10,000	353,346	30,424	Apr 12 08:08 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.48	7,500	266,122	452,879	Apr 12 08:08 PM
Patel Sushil	Director	Apr 10 '24	Option Exercise	16.80	2,155	36,204	17,855	Apr 12 04:23 PM
Patel Sushil	Director	Apr 10 '24	Sale	37.00	2,155	79,735	15,700	Apr 12 04:23 PM
Cislini Jeff	General Counsel	Mar 27 '24	Sale	30.99	1,500	46,481	54,374	Mar 28 04:11 PM
Cislini Jeff	General Counsel	Mar 18 '24	Sale	31.58	1,252	39,542	55,874	Mar 20 04:45 PM
Kelsey Stephen Michael	See Remarks	Mar 18 '24	Sale	31.58	2,123	67,051	270,909	Mar 20 04:45 PM
Horn Margaret A	Chief Operating Officer	Mar 18 '24	Sale	31.58	2,914	92,033	139,553	Mar 20 04:44 PM
GOLDSMITH MARK A	See Remarks	Mar 18 '24	Sale	31.58	5,788	182,804	460,379	Mar 20 04:44 PM
Anders Jack	Chief Financial Officer	Mar 18 '24	Sale	31.58	1,261	39,826	101,959	Mar 20 04:43 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Option Exercise	4.09	15,735	64,356	158,202	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Option Exercise	4.09	7,936	32,458	150,403	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Sale	34.02	15,735	535,306	142,467	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Sale	34.07	7,936	270,345	142,467	Mar 13 04:32 PM
Cislini Jeff	General Counsel	Jan 22 '24	Sale	27.00	1,500	40,500	36,126	Jan 24 04:12 PM
Kelsey Stephen Michael	See Remarks	Jan 08 '24	Sale	29.01	3,337	96,809	221,632	Jan 10 04:26 PM
Kelsey Stephen Michael	See Remarks	Jan 02 '24	Sale	29.10	13,330	387,884	224,969	Jan 04 04:06 PM
Kelsey Stephen Michael	See Remarks	Dec 27 '23	Sale	29.01	33,334	966,996	238,299	Dec 29 04:14 PM
Anders Jack	Chief Financial Officer	Dec 18 '23	Sale	25.90	1,775	45,976	76,416	Dec 20 05:10 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '23	Sale	25.90	8,165	211,488	376,167	Dec 20 05:08 PM
Cislini Jeff	General Counsel	Dec 18 '23	Sale	25.90	1,229	31,833	37,284	Dec 20 05:08 PM
Kelsey Stephen Michael	See Remarks	Dec 18 '23	Sale	25.90	2,088	54,083	271,633	Dec 20 05:07 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Sale	26.64	5,000	133,183	104,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 18 '23	Sale	25.90	2,993	77,524	101,467	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 08 04:08 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Sale	25.00	5,000	125,000	104,460	Dec 08 04:08 PM
Cislini Jeff	General Counsel	Nov 20 '23	Sale	21.70	1,500	32,545	38,513	Nov 20 06:24 PM
Horn Margaret A	Chief Operating Officer	Oct 25 '23	Option Exercise	0.54	7,500	4,050	104,460	Oct 25 06:20 PM
GOLDSMITH MARK A	See Remarks	Oct 24 '23	Option Exercise	0.49	35,000	17,150	384,332	Oct 24 07:21 PM
Anders Jack	Chief Financial Officer	Oct 23 '23	Option Exercise	2.98	24,524	72,967	78,191	Oct 23 06:01 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Option Exercise	4.09	25,000	102,250	121,960	Oct 18 04:23 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Sale	33.95	25,000	848,806	96,960	Oct 18 04:23 PM
Kelsey Stephen Michael	See Remarks	Oct 11 '23	Sale	29.05	16,667	484,130	273,721	Oct 13 04:20 PM
Cislini Jeff	General Counsel	Sep 28 '23	Sale	28.20	2,000	56,394	40,013	Oct 02 04:12 PM
Kelsey Stephen Michael	See Remarks	Sep 18 '23	Sale	31.31	2,060	64,500	290,388	Sep 20 04:13 PM
GOLDSMITH MARK A	See Remarks	Sep 18 '23	Sale	31.31	8,054	252,175	349,332	Sep 20 04:12 PM
Cislini Jeff	General Counsel	Sep 18 '23	Sale	31.31	1,214	38,011	42,013	Sep 20 04:11 PM
Anders Jack	Chief Financial Officer	Sep 18 '23	Sale	31.31	1,427	44,680	53,667	Sep 20 04:11 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Option Exercise	4.09	5,000	20,450	104,474	Sep 19 04:17 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Sale	32.08	5,000	160,408	99,474	Sep 19 04:17 PM
Horn Margaret A	Chief Operating Officer	Sep 18 '23	Sale	31.31	2,514	78,715	96,960	Sep 19 04:17 PM

Open in Screener

KYMR

Kymera Therapeutics Inc

Sep 06 • 04:00PM ET

45.40

Dollar change -1.20
Percentage change -2.58	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

KYMR Kymera Therapeutics Inc daily Stock Chart

Held by: VTI VB IWM XBI VBK VXF IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	10.33%	Shs Outstand	63.76M	Perf Week	-5.91%
Market Cap	2.89B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-17.23%	Shs Float	57.17M	Perf Month	12.63%
Income	-157.85M	PEG	-	EPS next Q	-0.83	Inst Own	97.19%	Short Float	16.57%	Perf Quarter	38.12%
Sales	88.55M	P/S	32.69	EPS this Y	-16.28%	Inst Trans	3.48%	Short Ratio	16.14	Perf Half Y	6.32%
Book/sh	11.12	P/B	4.08	EPS next Y	-10.93%	ROA	-22.42%	Short Interest	9.47M	Perf Year	136.83%
Cash/sh	8.00	P/C	5.68	EPS next 5Y	1.90%	ROE	-28.18%	52W Range	9.60 - 50.19	Perf YTD	78.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.18%	ROI	-20.75%	52W High	-9.53%	Beta	2.22
Dividend TTM	-	Quick Ratio	8.45	Sales past 5Y	241.22%	Gross Margin	94.17%	52W Low	372.92%	ATR (14)	2.54
Dividend Ex-Date	-	Current Ratio	8.45	EPS Y/Y TTM	12.58%	Oper. Margin	-204.01%	RSI (14)	50.68	Volatility	5.34% 5.16%
Employees	187	Debt/Eq	0.13	Sales Y/Y TTM	71.38%	Profit Margin	-178.27%	Recom	1.59	Target Price	53.69
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	13.45%	Payout	-	Rel Volume	0.40	Prev Close	46.60
Sales Surprise	104.31%	EPS Surprise	14.87%	Sales Q/Q	55.33%	Earnings	Aug 07 BMO	Avg Volume	586.71K	Price	45.40
SMA20	-0.81%	SMA50	8.03%	SMA200	29.03%	Trades		Volume	232,096	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63
Mar-10-22	Initiated	JP Morgan	Neutral	$44
Feb-10-22	Initiated	Wells Fargo	Overweight	$62
Sep-30-21	Initiated	Stifel	Buy	$80
Sep-30-21	Initiated	B. Riley Securities	Neutral	$67
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral	$65 → $80
May-21-21	Initiated	UBS	Buy	$80

Show Previous Ratings

Sep-06-24 11:31AM	Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? (Zacks)
Aug-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-21-24 11:15AM	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-24 01:02PM	Kymera (KYMR) to Raise $225 Million Through Offering of Shares (Zacks)
07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
10:45PM	Loading…
Aug-19-24 10:45PM	Kymera Therapeutics Announces Pricing of $225 Million Public Offering (GlobeNewswire)
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Aug-08-24 09:55AM	Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-07-24 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 (GlobeNewswire) +7.17%
Jul-10-24 08:10AM	Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains? (Zacks) -8.09%
Jul-09-24 01:30PM	Why Kymera Therapeutics Stock Is Soaring Today (Motley Fool) +23.40%
12:22PM	Kymera Therapeutics soars as Sanofi expands phase 2 trials (Investing.com)
10:44AM	Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug (Investopedia)
09:59AM	Loading…
09:59AM	Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies (Zacks)
07:00AM	Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day (GlobeNewswire)
Jul-08-24 04:05PM	Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy (GlobeNewswire) +5.65%
Jun-20-24 08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
Jun-14-24 07:00AM	Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire)
Jun-01-24 08:00AM	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-29-24 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-23-24 05:00PM	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-22-24 11:20AM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) -8.52%
May-08-24 07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-03-24 12:23PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:57AM	Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know (Zacks)
08:44AM	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 (MT Newswires)
03:19AM	Loading…
03:19AM	Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:18PM	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
11:57AM	KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:00AM	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-19-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-18-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-16-23 07:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma (GlobeNewswire)
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-03-23 04:48PM	Why Shares of Kymera Therapeutics Jumped on Tuesday (Motley Fool) +14.30%
Sep-18-23 07:00AM	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire)
Aug-28-23 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-03-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.07%
07:00AM	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-27-23 07:00AM	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-09-23 09:09AM	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-22-23 08:30AM	Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-14-23 02:30AM	Kymera Therapeutics STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials (GlobeNewswire)
Jun-09-23 06:00PM	Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 (GlobeNewswire) +10.51%
03:00AM	Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress (GlobeNewswire)
Jun-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conference (GlobeNewswire)
May-29-23 12:24PM	Investors in Kymera Therapeutics (NASDAQ:KYMR) have seen notable returns of 95% over the past year (Simply Wall St.)
May-22-23 07:00AM	Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer (GlobeNewswire)
May-19-23 07:00AM	Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253 (GlobeNewswire)
May-18-23 07:00AM	Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium (GlobeNewswire)
May-14-23 02:57PM	7 Growth Stocks That Could Double Your Money in 2023 (InvestorPlace)
May-09-23 03:15PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.08%
07:00AM	Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Albers Jeffrey W.	Director	Aug 26 '24	Option Exercise	10.34	5,000	51,700	5,000	Aug 26 06:31 PM
Albers Jeffrey W.	Director	Aug 26 '24	Sale	49.10	5,000	245,508	0	Aug 26 06:31 PM
JOANNA HOROBIN	Director	Aug 26 '24	Proposed Sale	49.16	12,000	589,896		Aug 26 04:32 PM
JEFFREY ALBERS	Director	Aug 26 '24	Proposed Sale	47.78	5,000	238,900		Aug 26 04:25 PM
BAKER BROS. ADVISORS LP	Director	Aug 20 '24	Buy	46.41	1	46	5,516,986	Aug 22 04:03 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Option Exercise	2.08	23,145	48,142	118,885	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Option Exercise	2.08	16,455	34,226	112,195	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Sale	45.81	23,145	1,060,218	95,470	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Sale	45.15	16,455	742,925	95,740	Jul 16 06:00 PM
Booth Bruce	Director	Jul 09 '24	Sale	38.21	453,960	17,346,919	723,246	Jul 09 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '24	Option Exercise	5.33	18,773	100,060	649,959	Jul 01 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 27 '24	Option Exercise	2.08	25,000	52,000	168,554	Jun 28 08:30 AM
Mainolfi Nello	Chief Executive Officer	Jun 18 '24	Option Exercise	2.08	14,413	29,979	631,186	Jun 20 08:30 AM
Booth Bruce	Director	Jun 12 '24	Sale	35.45	16,740	593,378	803,792	Jun 14 06:01 PM
Booth Bruce	Director	Jun 13 '24	Sale	34.98	10,200	356,796	802,022	Jun 14 06:01 PM
Horobin Joanna	Director	Jun 07 '24	Option Exercise	2.08	8,500	17,680	8,500	Jun 07 06:36 PM
Horobin Joanna	Director	Jun 07 '24	Sale	32.99	8,500	280,400	0	Jun 07 06:36 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '24	Sale	34.99	2,575	90,105	44,183	May 23 04:10 PM
Booth Bruce	Director	Mar 15 '24	Sale	40.46	71,764	2,903,336	806,697	Mar 15 07:23 PM
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151	Mar 15 07:23 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266	Mar 13 07:53 PM
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995	Mar 13 07:52 PM
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830	Mar 13 07:52 PM
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266	Mar 13 07:52 PM
Gollob Jared	Chief Medical Officer	Mar 04 '24	Sale	41.86	3,344	139,967	95,740	Mar 04 06:21 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '24	Sale	41.86	3,934	164,664	142,351	Mar 04 06:12 PM
Albers Jeffrey W.	Director	Feb 21 '24	Option Exercise	10.34	4,385	45,341	4,385	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Option Exercise	10.34	615	6,359	615	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 21 '24	Sale	39.05	4,385	171,227	0	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Sale	39.07	615	24,031	0	Feb 21 06:46 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Option Exercise	2.08	46,137	95,965	120,846	Feb 09 07:47 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Sale	35.50	46,137	1,638,071	74,709	Feb 09 07:47 PM
Albers Jeffrey W.	Director	Jan 23 '24	Option Exercise	10.34	10,000	103,400	10,000	Jan 23 07:37 PM
Albers Jeffrey W.	Director	Jan 23 '24	Sale	30.05	10,000	300,470	0	Jan 23 07:37 PM
Chiniara Ellen	Chief Legal Officer	Jan 04 '24	Sale	22.58	3,295	74,416	34,205	Jan 05 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jan 02 '24	Option Exercise	2.08	9,000	18,720	615,570	Jan 02 05:43 PM
BVF PARTNERS L P/IL	Director	Nov 03 '23	Buy	14.07	197,699	2,781,407	2,656,191	Nov 06 06:07 PM
BVF PARTNERS L P/IL	Director	Nov 02 '23	Buy	11.64	216,406	2,519,918	2,552,306	Nov 06 06:07 PM
Mainolfi Nello	Chief Executive Officer	Nov 03 '23	Option Exercise	2.08	20,000	41,600	606,570	Nov 06 06:00 PM

Open in Screener

LXEO

Lexeo Therapeutics Inc.

Sep 06 • 04:00PM ET

10.90

Dollar change -0.50
Percentage change -4.39	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

LXEO Lexeo Therapeutics Inc. daily Stock Chart

Held by: VTI VXF IWM IWO VTWO IWC VTWG RSSL BTEC URTY

Index	RUT	P/E	-	EPS (ttm)	-2.71	Insider Own	33.63%	Shs Outstand	26.65M	Perf Week	-6.20%
Market Cap	360.35M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	-0.63%	Shs Float	21.94M	Perf Month	-7.00%
Income	-77.22M	PEG	-	EPS next Q	-0.69	Inst Own	66.03%	Short Float	8.82%	Perf Quarter	-37.54%
Sales	0.00M	P/S	-	EPS this Y	77.51%	Inst Trans	-	Short Ratio	6.32	Perf Half Y	-25.75%
Book/sh	4.99	P/B	2.18	EPS next Y	-4.96%	ROA	-60.10%	Short Interest	1.94M	Perf Year	-
Cash/sh	5.29	P/C	2.06	EPS next 5Y	-	ROE	-74.84%	52W Range	9.00 - 22.33	Perf YTD	-18.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-44.60%	52W High	-51.19%	Beta	-
Dividend TTM	-	Quick Ratio	9.38	Sales past 5Y	19.69%	Gross Margin	-	52W Low	21.11%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	9.38	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	39.25	Volatility	5.60% 6.16%
Employees	58	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	22.83
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-27.58%	Payout	-	Rel Volume	0.52	Prev Close	11.40
Sales Surprise	-	EPS Surprise	7.43%	Sales Q/Q	-	Earnings	Aug 12 BMO	Avg Volume	306.29K	Price	10.90
SMA20	-7.14%	SMA50	-15.20%	SMA200	-23.35%	Trades		Volume	159,958	Change	-4.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-13-24	Initiated	Robert W. Baird	Outperform	$28
Jun-06-24	Initiated	H.C. Wainwright	Buy	$22
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Sep-05-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Jul-16-24 11:03AM	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data (Zacks)
Jul-15-24 04:17PM	Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion (Investor's Business Daily) -26.08%
10:11AM	Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout (Investor's Business Daily)
06:36AM	Loading…
06:36AM	Lexeo gene therapy shows signs of heart benefit in small study (BioPharma Dive)
06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire)
Jul-11-24 08:00AM	Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 (GlobeNewswire) +6.08%
Jul-08-24 07:00AM	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors (GlobeNewswire) +5.55%
May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
04:22PM	Loading…
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Richard Nolan	Chief Executive Officer	Aug 12 '24	Option Exercise	2.33	5,000	11,650	125,695	Aug 13 06:34 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 12 '24	Sale	11.53	5,000	57,634	120,695	Aug 13 06:34 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 10 '24	Option Exercise	2.33	5,000	11,650	175,695	Jul 12 04:55 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 11 '24	Sale	17.07	28,031	478,409	120,695	Jul 12 04:55 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 10 '24	Sale	16.50	26,969	444,979	148,726	Jul 12 04:55 PM
Townsend Richard Nolan	Chief Executive Officer	Jun 10 '24	Option Exercise	2.33	5,000	11,650	175,695	Jun 12 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Jun 10 '24	Sale	17.65	5,000	88,264	170,695	Jun 12 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	May 13 '24	Option Exercise	2.33	5,000	11,650	175,695	May 14 04:04 PM
Townsend Richard Nolan	Chief Executive Officer	May 13 '24	Sale	13.22	5,000	66,093	170,695	May 14 04:04 PM
Omega Fund VI, L.P.	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,157,623	Nov 09 08:36 PM
Lundbeckfond Invest A/S	10% Owner	Nov 07 '23	Buy	11.00	227,272	2,499,992	1,835,959	Nov 09 08:33 PM
Longitude Capital Partners IV,	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,567,100	Nov 09 08:32 PM

Open in Screener

CGEM

Cullinan Therapeutics Inc

Sep 06 • 04:00PM ET

17.98

Dollar change +0.05
Percentage change 0.28	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

CGEM Cullinan Therapeutics Inc daily Stock Chart

Held by: VTI XBI IWM VXF IBB IWO SCHA VTWO VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-3.10	Insider Own	33.47%	Shs Outstand	42.90M	Perf Week	-4.67%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-3.26	Insider Trans	-0.37%	Shs Float	38.57M	Perf Month	8.71%
Income	-142.16M	PEG	-	EPS next Q	-0.79	Inst Own	77.55%	Short Float	21.15%	Perf Quarter	-20.23%
Sales	0.00M	P/S	-	EPS this Y	12.51%	Inst Trans	-1.13%	Short Ratio	10.29	Perf Half Y	9.97%
Book/sh	11.34	P/B	1.59	EPS next Y	-0.89%	ROA	-23.63%	Short Interest	8.16M	Perf Year	61.98%
Cash/sh	11.43	P/C	1.57	EPS next 5Y	-	ROE	-24.60%	52W Range	7.64 - 30.19	Perf YTD	76.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-62.42%	ROI	-21.61%	52W High	-40.44%	Beta	-0.09
Dividend TTM	-	Quick Ratio	28.87	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	135.34%	ATR (14)	1.05
Dividend Ex-Date	-	Current Ratio	28.87	EPS Y/Y TTM	7.74%	Oper. Margin	0.00%	RSI (14)	48.62	Volatility	5.85% 5.72%
Employees	85	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	5.32%	Payout	-	Rel Volume	0.48	Prev Close	17.93
Sales Surprise	-	EPS Surprise	-3.43%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	792.71K	Price	17.98
SMA20	1.49%	SMA50	1.09%	SMA200	6.49%	Trades		Volume	383,859	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
05:04PM	Loading…
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Loading…
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
12:01PM	Loading…
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 11:18AM	Why Are Cullinan Oncology Shares Rising Today? (Benzinga) +23.12%
02:00AM	Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taihos Acquisition of Cullinan Pearl (GlobeNewswire)
May-08-22 09:23AM	Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth (Simply Wall St.)
May-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
Apr-27-22 10:00AM	Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-05-22 08:00AM	Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Apr-04-22 04:34PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.55%
Mar-29-22 07:54AM	Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting (Benzinga)
Mar-28-22 04:01PM	Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Mar-17-22 07:08AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
07:00AM	Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 (GlobeNewswire)
Mar-09-22 08:00AM	Cullinan Oncology to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +8.91%
Mar-08-22 05:30PM	Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 (GlobeNewswire)
Feb-28-22 08:00AM	Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors (GlobeNewswire)
Feb-12-22 06:50AM	Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year (Simply Wall St.)
Feb-07-22 06:30AM	Cullinan Oncology to Present at SVB Leerinks 11th Annual Global Healthcare Conference (GlobeNewswire) +6.52%
Jan-10-22 06:30AM	Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment (GlobeNewswire)
Jan-05-22 09:00AM	Cullinan Oncology to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -6.69%
Jan-04-22 07:34AM	Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA (MarketWatch)
07:00AM	FDA Grants Breakthrough Therapy Designation for Cullinan Oncologys CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-16-21 01:04PM	Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients (Benzinga)
06:30AM	Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Dec-13-21 07:00AM	Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JENNIFER MICHAELSON & MARC D M	Officer	Sep 05 '24	Proposed Sale	18.68	16,000	298,880		Sep 05 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 05 '24	Sale	16.33	8,000	130,640	123,942	Jul 09 05:30 PM
Ebeling Thomas	Director	Jun 10 '24	Option Exercise	13.00	18,450	239,850	186,653	Jun 11 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Option Exercise	4.30	50,000	215,000	187,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Option Exercise	4.30	5,606	24,106	135,188	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Sale	28.07	58,000	1,628,159	129,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Sale	30.06	5,606	168,516	129,582	May 08 07:30 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Option Exercise	4.30	40,000	172,000	205,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Sale	16.18	40,000	647,200	165,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Option Exercise	4.30	40,000	172,000	205,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Sale	14.09	40,000	563,600	165,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Option Exercise	4.30	21,316	91,659	187,306	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Option Exercise	4.30	14,559	62,604	184,674	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Sale	12.46	21,316	265,597	165,990	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Sale	12.14	18,684	226,911	165,990	Jan 24 05:00 PM
AHMED NADIM	President and CEO	Dec 26 '23	Sale	9.24	4,272	39,473	111,550	Dec 27 06:30 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 21 '23	Sale	8.50	1,860	15,810	56,191	Dec 22 05:30 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 21 '23	Sale	8.50	1,400	11,900	44,133	Dec 22 05:30 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 21 '23	Sale	8.50	1,920	16,320	83,919	Dec 22 05:30 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 21 '23	Sale	8.50	1,145	9,732	87,582	Dec 22 05:30 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '23	Sale	8.22	386	3,173	58,051	Dec 20 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '23	Sale	8.22	238	1,956	88,727	Dec 20 06:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '23	Sale	8.22	290	2,384	45,533	Dec 20 06:00 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 18 '23	Sale	8.22	398	3,272	85,839	Dec 20 06:00 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 12 '23	Sale	7.81	1,926	15,042	86,237	Dec 13 08:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '23	Sale	7.81	1,068	8,341	88,965	Dec 13 08:00 PM

Open in Screener

GLUE

Monte Rosa Therapeutics Inc

Sep 06 • 04:00PM ET

5.69

Dollar change -0.32
Percentage change -5.32	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

GLUE Monte Rosa Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC ONEQ AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.24	Insider Own	30.23%	Shs Outstand	50.14M	Perf Week	-10.95%
Market Cap	349.20M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	-0.02%	Shs Float	42.82M	Perf Month	57.62%
Income	-130.41M	PEG	-	EPS next Q	-0.47	Inst Own	62.19%	Short Float	6.52%	Perf Quarter	35.80%
Sales	5.76M	P/S	60.62	EPS this Y	27.69%	Inst Trans	0.82%	Short Ratio	12.08	Perf Half Y	-3.23%
Book/sh	3.66	P/B	1.55	EPS next Y	3.77%	ROA	-41.88%	Short Interest	2.79M	Perf Year	-5.79%
Cash/sh	4.27	P/C	1.33	EPS next 5Y	-	ROE	-59.51%	52W Range	2.44 - 8.84	Perf YTD	0.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-96.71%	ROI	-49.11%	52W High	-35.63%	Beta	1.43
Dividend TTM	-	Quick Ratio	6.56	Sales past 5Y	0.00%	Gross Margin	-32.61%	52W Low	133.20%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	6.56	EPS Y/Y TTM	12.96%	Oper. Margin	-2420.91%	RSI (14)	52.81	Volatility	9.13% 12.29%
Employees	133	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-2264.53%	Recom	1.00	Target Price	13.67
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	40.21%	Payout	-	Rel Volume	0.50	Prev Close	6.01
Sales Surprise	255.79%	EPS Surprise	17.50%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	231.01K	Price	5.69
SMA20	3.40%	SMA50	21.38%	SMA200	10.67%	Trades		Volume	116,612	Change	-5.32%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

Aug-28-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.50%
Aug-19-24 07:00AM	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study (GlobeNewswire)
Aug-08-24 08:15AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.25%
07:15AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:36AM	Loading…
Jul-08-24 08:36AM	Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day (GlobeNewswire) +6.87%
Jun-27-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 (GlobeNewswire) -8.40%
Jun-14-24 08:45AM	Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
May-30-24 07:00AM	Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Leadership Team Promotions (GlobeNewswire)
May-21-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease (GlobeNewswire) -13.23%
May-16-24 01:09PM	Monte Rosa Therapeutics Prices $100 Million Public Offering (MT Newswires)
07:00AM	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering (GlobeNewswire)
May-15-24 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-10-24 03:26PM	Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -6.37%
01:55PM	Loading…
May-09-24 01:55PM	GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 04:01PM	Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer (GlobeNewswire) -5.72%
Apr-29-24 10:36AM	UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating (MT Newswires) +5.25%
Apr-10-24 08:50AM	Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why (Zacks) -8.78%
Apr-04-24 09:55AM	Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:50AM	Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-19-24 09:55AM	Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know (Zacks)
Mar-16-24 05:31AM	Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-14-24 01:53PM	GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -8.42%
07:22AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-24 07:00AM	Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1 Pathway Inhibitor (GlobeNewswire)
Jan-31-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:00AM	Loading…
Jan-16-24 09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool) -8.42%
Jan-08-24 07:15AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 (GlobeNewswire) +14.39%
Jan-03-24 07:00AM	Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-23 07:00AM	Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire) -8.31%
Nov-09-23 08:10AM	Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com) -10.57%
07:10AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 10:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases (GlobeNewswire) +6.93%
Oct-27-23 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.20%
Oct-26-23 04:30PM	Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-23 09:35AM	Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE) (Zacks)
Oct-17-23 08:03AM	Roche is stuck on molecular glue (BioPharma Dive) -19.80%
07:00AM	Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors (GlobeNewswire)
Aug-10-23 07:27AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors (GlobeNewswire)
Jul-16-23 09:50AM	We're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.)
May-30-23 04:30PM	Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences (GlobeNewswire) +5.16% +13.19%
May-23-23 07:30AM	Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases (GlobeNewswire)
May-11-23 07:50AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:30AM	Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-23 04:30PM	Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023 (GlobeNewswire)
Mar-23-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors (GlobeNewswire)
Mar-16-23 07:52AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (AP Finance) +7.35%
07:30AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-06-23 08:30AM	Here's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation (Simply Wall St.) -6.94%
Feb-03-23 07:30AM	Monte Rosa Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +15.15%
Jan-25-23 09:55AM	How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46% (Zacks)
Jan-09-23 07:30AM	Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 (GlobeNewswire) -14.32%
Jan-04-23 07:30AM	Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-10-22 07:30AM	Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.26%
Nov-01-22 07:30AM	Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors (GlobeNewswire)
Oct-31-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +5.99%
Oct-20-22 04:30PM	Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium (GlobeNewswire) +5.28%
Sep-06-22 07:30AM	Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader (GlobeNewswire)
Aug-30-22 08:35AM	We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.) -10.32%
Aug-11-22 07:30AM	Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.17%
Jun-14-22 05:16AM	Upcoming 220K-square-foot South End lab project almost fully leased (American City Business Journals) +5.08%
May-11-22 07:30AM	Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.03%
Apr-08-22 01:00PM	Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-29-22 07:30AM	Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates (GlobeNewswire) +16.33%
Mar-23-22 11:32AM	We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-03-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.58%
Jan-25-22 07:30AM	Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders (GlobeNewswire) -9.86%
Jan-04-22 07:30AM	Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-21 07:30AM	Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer (GlobeNewswire)
Nov-22-21 07:30AM	Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-10-21 07:30AM	Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-08-21 07:00AM	Merck KGaA veteran helms immuno-oncology startup with $80M (American City Business Journals)
Oct-20-21 07:30AM	Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit (GlobeNewswire) +5.45%
Oct-07-21 09:00AM	Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer (GlobeNewswire)
Sep-30-21 04:30PM	Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference (GlobeNewswire) -9.92%
Sep-24-21 08:49AM	Here's Why We're Not At All Concerned With Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation (Simply Wall St.)
Sep-10-21 07:30AM	Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Sep-08-21 07:30AM	Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) -13.53%
Aug-12-21 07:30AM	Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress (GlobeNewswire)

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dunn Edmund	Principal Accounting Officer	Jul 05 '24	Sale	3.83	1,610	6,166	13,944	Jul 09 04:15 PM
Dunn Edmund	Principal Accounting Officer	Jun 03 '24	Sale	4.04	1,207	4,876	15,554	Jun 05 04:10 PM

Open in Screener

FENC

Fennec Pharmaceuticals Inc

Sep 06 • 04:00PM ET

5.29

Dollar change -0.08
Percentage change -1.49	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FENC Fennec Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM IWN VTWO IWC IWO VTWV RSSL VTWG URTY

Index	RUT	P/E	134.61	EPS (ttm)	0.04	Insider Own	16.21%	Shs Outstand	27.03M	Perf Week	-4.34%
Market Cap	144.73M	Forward P/E	30.52	EPS next Y	0.17	Insider Trans	-6.47%	Shs Float	22.93M	Perf Month	-8.16%
Income	2.74M	PEG	-	EPS next Q	-0.12	Inst Own	53.05%	Short Float	8.31%	Perf Quarter	-22.77%
Sales	48.89M	P/S	2.96	EPS this Y	118.61%	Inst Trans	0.72%	Short Ratio	19.58	Perf Half Y	-44.95%
Book/sh	-0.05	P/B	-	EPS next Y	55.22%	ROA	6.62%	Short Interest	1.91M	Perf Year	-33.54%
Cash/sh	1.57	P/C	3.36	EPS next 5Y	-	ROE	-	52W Range	5.00 - 11.92	Perf YTD	-52.85%
Dividend Est.	-	P/FCF	6.29	EPS past 5Y	-2.95%	ROI	9.63%	52W High	-55.62%	Beta	0.27
Dividend TTM	-	Quick Ratio	7.75	Sales past 5Y	236.90%	Gross Margin	95.55%	52W Low	5.80%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	8.02	EPS Y/Y TTM	110.07%	Oper. Margin	12.00%	RSI (14)	38.40	Volatility	5.64% 6.13%
Employees	29	Debt/Eq	-	Sales Y/Y TTM	647.88%	Profit Margin	5.59%	Recom	1.17	Target Price	15.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	1.17%	Payout	-	Rel Volume	0.96	Prev Close	5.37
Sales Surprise	-33.91%	EPS Surprise	-700.00%	Sales Q/Q	118.41%	Earnings	Aug 13 BMO	Avg Volume	97.31K	Price	5.29
SMA20	-6.64%	SMA50	-11.88%	SMA200	-37.62%	Trades		Volume	93,714	Change	-1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$9 → $12
Sep-07-22	Initiated	CapitalOne	Overweight	$11
Aug-08-22	Resumed	Craig Hallum	Buy	$14
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-11-18	Initiated	Goldman	Buy

Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
06:15AM	Loading…
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)
May-14-24 10:53AM	FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -26.75%
07:20AM	Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue (MT Newswires)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 06:15PM	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-23-24 08:01AM	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing (MT Newswires)
07:00PM	Loading…
Apr-05-24 07:00PM	Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-27-24 07:00PM	Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-26-24 01:00AM	Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-22-24 09:49AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:04AM	Q4 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 02:52PM	FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-19-24 10:14AM	Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up (Zacks)
06:01AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-17-24 09:00PM	Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand (GlobeNewswire)
Feb-29-24 07:04AM	Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Feb-01-24 05:55AM	FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin (GlobeNewswire)
Jan-06-24 03:01AM	Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc (GuruFocus.com)
Dec-05-23 05:55AM	Fennec Announces Incremental $5 Million Investment from Petrichor (GlobeNewswire)
Nov-09-23 04:50PM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:40AM	Loading…
Nov-07-23 09:40AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:10AM	Q3 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:59AM	Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +15.36%
Oct-30-23 06:45AM	Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Sep-07-23 05:59AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 12:53PM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:59AM	Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.29%
Jul-31-23 05:30AM	Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire) +8.66%
Jun-12-23 05:00PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
Jun-08-23 02:53PM	Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well (Simply Wall St.)
Jun-06-23 05:44AM	Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)
May-11-23 06:01AM	Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-08-23 06:15AM	Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-28-23 09:26AM	When Will Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Become Profitable? (Simply Wall St.)
Apr-01-23 08:12AM	Investors in Fennec Pharmaceuticals (NASDAQ:FENC) have made a notable return of 52% over the past three years (Simply Wall St.)
Mar-31-23 08:03AM	Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)
Mar-30-23 05:55AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Feb-23-23 08:44AM	Why Earnings Season Could Be Great for Adherex Technologies (FENC) (Zacks)
Jan-31-23 06:00AM	Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA (GlobeNewswire) +6.26%
Jan-25-23 07:19AM	Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients (GlobeNewswire) +8.27%
Jan-23-23 11:57AM	RTP drugmaker Fennec sues Cipla over generics effort (American City Business Journals)
Dec-17-22 09:55AM	Institutions own 28% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares but individual investors control 55% of the company (Simply Wall St.)
Nov-11-22 07:10AM	Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-22 10:28AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Are Analysts Optimistic? (Simply Wall St.)
Oct-17-22 08:00AM	Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States (GlobeNewswire)
Sep-26-22 07:35AM	Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor (GlobeNewswire) -8.30%
Sep-21-22 02:19PM	RTP pharma to see $20M infusion on heels of drug winning approval (American City Business Journals) +11.93%
01:05PM	After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss (Benzinga)
07:00AM	Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection) (GlobeNewswire)
06:05AM	U.S. FDA approves Fennec's hearing loss therapy (Reuters)
Aug-22-22 07:04AM	Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor (GlobeNewswire)
Aug-12-22 06:59AM	Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-22 02:59PM	RTP drugmaker secures up to $45M despite regulatory speed bumps (American City Business Journals)
07:30AM	Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor (GlobeNewswire)
Jul-10-22 08:42AM	What Kind Of Shareholders Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC)? (Simply Wall St.)
Jun-14-22 06:00PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-23-22 07:29AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-22 06:00AM	Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-06-22 05:17PM	Inflation crushes market caps of Triangle's biggest public companies except these ones (American City Business Journals)
May-03-22 09:55AM	Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect? (Zacks)
Apr-27-22 06:00AM	Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK (GlobeNewswire) -9.27%
Mar-25-22 07:00AM	Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference (GlobeNewswire)
Mar-24-22 06:00AM	Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark (GlobeNewswire) -6.41%
Feb-28-22 06:00AM	Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update (GlobeNewswire)
Jan-31-22 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire) +5.20%
Jan-27-22 05:38PM	Hartford Financial Management Inc. Buys Exelon Corp, American Electric Power Co Inc, Pinnacle ... (GuruFocus.com) -7.54%
Dec-14-21 07:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC (ACCESSWIRE)
Dec-13-21 10:08AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC (PR Newswire)
Dec-01-21 07:06AM	RTP drugmaker suffers another regulatory setback (American City Business Journals) -11.39%
Nov-30-21 04:20PM	Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down (Zacks) -8.16%
10:57AM	FENC Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. Securities Class Action Investigation (GlobeNewswire)
06:00AM	Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors (GlobeNewswire)
05:49AM	When Will Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Breakeven? (Simply Wall St.)
Nov-29-21 07:23PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC (GlobeNewswire) -50.41%
07:24AM	Fennec Pharmaceuticals Expects FDA Rejection for New Drug (Investing.com)
06:00AM	Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors (GlobeNewswire)
Nov-10-21 06:00AM	Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Oct-05-21 08:30AM	4 Breakout Stocks for Impressive Returns (Zacks)
Sep-29-21 02:27PM	Hedge Funds Are Piling Into Fennec Pharmaceuticals Inc. (FENC) (Insider Monkey)
Sep-09-21 06:00AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-21 06:00AM	Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-21 03:18AM	Is Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Popular Amongst Institutions? (Simply Wall St.)
Jun-29-21 05:30PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
Jun-24-21 06:00AM	Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility (GlobeNewswire) +7.52%
Jun-22-21 07:17AM	Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity (Benzinga) +5.13%
06:00AM	Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK (GlobeNewswire)
Jun-03-21 03:33AM	Here's Why We're Not Too Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn Situation (Simply Wall St.)
May-28-21 06:00AM	Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK (GlobeNewswire) +6.66%
May-13-21 06:00AM	Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haigh Adrian	Director	Sep 05 '24	Proposed Sale	5.00	20,246	101,230		Sep 05 05:02 PM
Raykov Rosty	Director	Sep 04 '24	Sale	5.52	2,431	13,419	66,432	Sep 04 06:48 PM
ROSTISLAV RAYKOV	Director	Sep 04 '24	Proposed Sale	5.52	2,431	13,419		Sep 04 04:05 PM
ROSTISLAV RAYKOV	Officer	Aug 01 '24	Proposed Sale	6.26	2,431	15,206		Aug 01 04:21 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Aug 01 '24	Sale	6.25	2,431	15,206	187,471	Aug 01 04:08 PM
RALLIS CHRIS A	Director	Jul 05 '24	Option Exercise	2.79	1,792	5,000	47,630	Jul 08 04:05 PM
RALLIS CHRIS A	Director	Jul 05 '24	Sale	6.03	1,173	7,073	46,457	Jul 08 04:05 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Jul 02 '24	Sale	6.13	2,431	14,902	187,471	Jul 02 05:55 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Jun 03 '24	Sale	6.76	2,431	16,434	187,471	Jun 03 05:12 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	9.11	2,431	22,152	187,471	May 02 04:59 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 22 '24	Option Exercise	2.31	22,223	51,335	22,223	Apr 22 07:34 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 19 '24	Option Exercise	2.31	22,222	51,333	22,222	Apr 22 07:34 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 19 '24	Sale	9.34	22,222	207,442	0	Apr 22 07:34 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 22 '24	Sale	9.32	22,223	207,029	0	Apr 22 07:34 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 17 '24	Sale	9.91	22,222	220,220	22,222	Apr 18 09:43 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 18 '24	Sale	9.62	22,222	213,776	0	Apr 18 09:43 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 15 '24	Sale	10.30	22,222	228,793	22,222	Apr 16 06:00 PM
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 16 '24	Sale	10.28	22,222	228,389	0	Apr 16 06:00 PM
RALLIS CHRIS A	Director	Apr 15 '24	Option Exercise	10.45	1,389	14,515	45,838	Apr 15 06:15 PM
RALLIS CHRIS A	Director	Apr 15 '24	Sale	10.45	800	8,360	44,449	Apr 15 06:15 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Apr 04 '24	Sale	10.89	44,283	482,400	231,771	Apr 05 04:56 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Apr 05 '24	Sale	10.75	44,300	476,269	187,471	Apr 05 04:56 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Apr 03 '24	Sale	10.78	40,584	437,451	276,054	Apr 03 05:37 PM
RALLIS CHRIS A	Director	Mar 26 '24	Option Exercise	2.31	4,329	10,000	45,249	Mar 27 04:24 PM
RALLIS CHRIS A	Director	Mar 26 '24	Sale	10.97	2,114	23,191	40,920	Mar 27 04:24 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 26 '24	Sale	10.90	13,975	152,346	91,771	Mar 27 04:22 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 25 '24	Sale	11.00	13,975	153,690	105,746	Mar 25 07:31 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 04 '24	Sale	10.64	15,000	159,600	134,721	Jan 05 05:24 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 05 '24	Sale	10.41	15,000	156,150	119,721	Jan 05 05:24 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Dec 28 '23	Option Exercise	1.59	8,540	13,579	291,127	Dec 29 04:30 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Dec 28 '23	Sale	11.55	3,656	42,227	287,471	Dec 29 04:30 PM
RALLIS CHRIS A	Director	Dec 26 '23	Option Exercise	1.59	3,144	4,999	46,178	Dec 28 04:02 PM
RALLIS CHRIS A	Director	Dec 26 '23	Sale	10.90	1,390	15,151	44,788	Dec 28 04:02 PM
RALLIS CHRIS A	Director	Nov 20 '23	Sale	8.25	269	2,219	43,034	Nov 20 09:20 PM
Islam Khalid	Director	Nov 16 '23	Option Exercise	2.06	213,825	441,400	213,825	Nov 16 04:05 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Nov 08 '23	Sale	7.76	25,044	194,267	282,587	Nov 09 04:38 PM
Raykov Rosty	CHIEF EXECUTIVE OFFICER	Nov 03 '23	Option Exercise	1.59	74,793	118,921	307,631	Nov 03 05:19 PM

Open in Screener

APGE

Apogee Therapeutics Inc.

Sep 06 • 04:00PM ET

47.25

Dollar change -0.99
Percentage change -2.05	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

APGE Apogee Therapeutics Inc. daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.28	Insider Own	36.53%	Shs Outstand	37.17M	Perf Week	-4.41%
Market Cap	2.76B	Forward P/E	-	EPS next Y	-3.54	Insider Trans	-0.56%	Shs Float	37.12M	Perf Month	15.61%
Income	-118.48M	PEG	-	EPS next Q	-0.78	Inst Own	76.98%	Short Float	22.05%	Perf Quarter	12.19%
Sales	0.00M	P/S	-	EPS this Y	16.91%	Inst Trans	-	Short Ratio	18.47	Perf Half Y	-27.58%
Book/sh	13.65	P/B	3.46	EPS next Y	-26.63%	ROA	-25.44%	Short Interest	8.19M	Perf Year	99.62%
Cash/sh	11.56	P/C	4.09	EPS next 5Y	-	ROE	-33.41%	52W Range	14.19 - 72.29	Perf YTD	69.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-15.27%	52W High	-34.64%	Beta	2.86
Dividend TTM	-	Quick Ratio	27.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	232.98%	ATR (14)	2.60
Dividend Ex-Date	-	Current Ratio	27.70	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	50.68	Volatility	5.39% 5.61%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	84.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-60.56%	Payout	-	Rel Volume	0.51	Prev Close	48.24
Sales Surprise	-	EPS Surprise	-3.58%	Sales Q/Q	-	Earnings	Aug 12 BMO	Avg Volume	443.27K	Price	47.25
SMA20	1.00%	SMA50	4.00%	SMA200	10.98%	Trades		Volume	225,530	Change	-2.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Today 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Loading…
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
10:13AM	Loading…
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Loading…
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)
Aug-10-23 02:29PM	FMR LLC Acquires New Stake in Apogee Therapeutics Inc (GuruFocus.com)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 07:30AM	Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-02-23 07:30AM	Apogee Therapeutics to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-18-23 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Sep 04 '24	Sale	47.56	6,665	316,969	280,793	Sep 06 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sep 04 '24	Sale	47.62	40,000	1,904,841	1,394,487	Sep 06 08:02 PM
HENDERSON MICHAEL THOMAS	Officer	Sep 04 '24	Proposed Sale	47.62	40,000	1,904,848		Sep 04 01:35 PM
Henderson Jane	Chief Financial Officer	Aug 23 '24	Sale	48.26	6,000	289,560	200,871	Aug 23 08:05 PM
JANE V HENDERSON	Officer	Aug 23 '24	Proposed Sale	48.26	6,000	289,570		Aug 23 04:09 PM
Dambkowski Carl	Chief Medical Officer	Aug 07 '24	Sale	40.67	7,335	298,336	287,458	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Aug 07 '24	Sale	40.62	40,000	1,624,764	1,434,487	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Officer	Aug 07 '24	Proposed Sale	40.62	40,000	1,624,784		Aug 07 01:18 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 05 '24	Sale	37.26	15,000	558,900	1,474,487	Jul 05 08:01 PM
Dambkowski Carl	Chief Medical Officer	Jul 03 '24	Sale	37.60	5,995	225,418	294,793	Jul 05 08:01 PM

Open in Screener

DNA

Ginkgo Bioworks Holdings Inc

Sep 06 • 04:00PM ET

5.65

Dollar change -0.49
Percentage change -7.98	%

Healthcare • Biotechnology • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

DNA Ginkgo Bioworks Holdings Inc daily Stock Chart

Held by: VTI VB VBK VXF IBB VAW SCHA THNQ IDNA VT

Index	-	P/E	-	EPS (ttm)	-18.03	Insider Own	32.54%	Shs Outstand	38.13M	Perf Week	-20.31%
Market Cap	297.08M	Forward P/E	-	EPS next Y	-7.45	Insider Trans	-8.09%	Shs Float	35.47M	Perf Month	-48.52%
Income	-897.68M	PEG	-	EPS next Q	-2.74	Inst Own	44.82%	Short Float	10.81%	Perf Quarter	-74.32%
Sales	184.34M	P/S	1.61	EPS this Y	43.06%	Inst Trans	-	Short Ratio	2.49	Perf Half Y	-88.23%
Book/sh	17.01	P/B	0.33	EPS next Y	28.84%	ROA	-45.83%	Short Interest	3.84M	Perf Year	-93.69%
Cash/sh	13.94	P/C	0.41	EPS next 5Y	31.20%	ROE	-76.83%	52W Range	6.00 - 90.40	Perf YTD	-91.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-69.84%	52W High	-93.75%	Beta	1.06
Dividend TTM	-	Quick Ratio	4.71	Sales past 5Y	104.75%	Gross Margin	45.10%	52W Low	-5.83%	ATR (14)	1.09
Dividend Ex-Date	-	Current Ratio	4.71	EPS Y/Y TTM	35.80%	Oper. Margin	-348.09%	RSI (14)	28.63	Volatility	8.88% 12.93%
Employees	1218	Debt/Eq	0.54	Sales Y/Y TTM	-43.45%	Profit Margin	-486.98%	Recom	3.83	Target Price	36.80
Option/Short	Yes / Yes	LT Debt/Eq	0.54	EPS Q/Q	-17.99%	Payout	-	Rel Volume	1.27	Prev Close	6.14
Sales Surprise	30.28%	EPS Surprise	-42.05%	Sales Q/Q	-30.24%	Earnings	Aug 08 AMC	Avg Volume	1.54M	Price	5.65
SMA20	-33.63%	SMA50	-49.40%	SMA200	-84.55%	Trades		Volume	1,951,907	Change	-7.98%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform	$3.50 → $2.50
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell	$3 → $1.25
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy	$6
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight	$5
May-18-22	Downgrade	BofA Securities	Neutral → Underperform	$3
Mar-02-22	Resumed	Cowen	Outperform	$12
Feb-23-22	Initiated	Goldman	Neutral	$7
Feb-01-22	Initiated	BofA Securities	Neutral	$6
Jan-28-22	Initiated	BofA Securities	Buy	$8
Jan-07-22	Initiated	BTIG Research	Buy	$12
Nov-29-21	Initiated	Jefferies	Buy	$16
Oct-13-21	Initiated	Raymond James	Outperform	$14.50
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy	$14

Show Previous Ratings

Sep-04-24 04:30PM	Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement (PR Newswire)
Aug-30-24 07:00AM	Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire) -5.64%
Aug-19-24 07:56AM	Upcoming Stock Splits This Week (August 19 to August 23) Stay Invested (TipRanks) +5.64%
Aug-08-24 05:01PM	Ginkgo Bioworks Reports Second Quarter 2024 Financial Results (PR Newswire) -5.46%
04:00PM	Global Agriculture Biologicals Testing Market Size To Worth USD 5.61 Billion by 2033 CAGR of 7.20% (GlobeNewswire)
07:00AM	Loading…
Aug-02-24 07:00AM	Ginkgo Bioworks to Hold Special Meeting of Shareholders (PR Newswire) -14.97%
Aug-01-24 07:01AM	Ginkgo Bioworks Announces Date of Second Quarter 2024 Results Presentation (PR Newswire)
Jul-16-24 07:01AM	Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals (Business Wire) +20.65%
Jul-11-24 06:00AM	3 Stocks to Avoid Like the Plague in 2024 (InvestorPlace)
Jul-10-24 04:08PM	3 High-Risk, Sky-High Reward Stocks to Buy for Under $1 (InvestorPlace) +5.35%
06:35AM	Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted (InvestorPlace)
Jul-08-24 07:00AM	7 F-Rated Stocks To Sell in July (InvestorPlace)
Jul-05-24 07:30AM	3 Biotech Stocks to Sell in July Before They Crash & Burn (InvestorPlace) -11.19%
Jun-27-24 03:38PM	Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace) +8.91%
Jun-26-24 12:48PM	Perion Layoffs 2024: What to Know About the Latest PERI Job Cuts (InvestorPlace) -11.31%
12:29PM	Loading…
12:29PM	Ginkgo Bioworks Layoffs Expand to 400 Job Cuts (InvestorPlace)
Jun-24-24 10:52AM	Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears (InvestorPlace) -13.71%
10:31AM	Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts (InvestorPlace)
Jun-20-24 12:31PM	5-Year Fortune Forecast: 3 Penny Stocks Destined for Massive Gains (InvestorPlace)
Jun-19-24 12:00PM	7 Penny Stocks to Sell in June Before They Crash & Burn (InvestorPlace)
Jun-07-24 09:35AM	After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA) (Zacks) -6.53%
May-31-24 07:00AM	3 Sorry Biotech Stocks to Sell in May While You Still Can (InvestorPlace) -5.51%
May-17-24 01:58PM	Hedge Fund and Insider Trading News: Paul Marshall, Ray Dalio, Boaz Weinstein, Bill Ackman, Stanley Druckenmiller, Eisler Capital, Archegos Capital Management, Ginkgo Bioworks Holdings Inc (DNA), Visa Inc (VISA), and More (Insider Monkey)
May-15-24 07:01AM	Ginkgo Bioworks to Participate in Two Conferences in May (PR Newswire)
May-14-24 06:00PM	Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan (PR Newswire)
May-13-24 04:05PM	Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE (PR Newswire) +10.49%
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -17.29%
May-09-24 05:45PM	Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Ginkgo Bioworks Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 01:46PM	3 Meme Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
12:31PM	Loading…
May-07-24 12:31PM	Want $10,000? Invest $1,000 in These 3 Penny Stocks Now (InvestorPlace) -5.48%
11:43AM	16 Best US Stocks To Invest In Under $10 (Insider Monkey)
07:01AM	GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener (PR Newswire)
May-06-24 07:01AM	Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (PR Newswire)
May-02-24 07:00AM	Ginkgo Bioworks Announces Date of First Quarter 2024 Results Presentation (PR Newswire)
Apr-29-24 05:24PM	Is a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock? (InvestorPlace) +15.08% -9.97%
04:01PM	Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors (PR Newswire)
Apr-25-24 08:01AM	AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 (PR Newswire) -8.05%
Apr-16-24 07:02AM	Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products (PR Newswire)
Apr-11-24 07:01AM	Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces 'Lab Data as a Service' (PR Newswire) -6.25%
07:01AM	Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets (PR Newswire)
Apr-10-24 07:02AM	Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain (PR Newswire)
07:01AM	Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks (PR Newswire)
Apr-08-24 07:00AM	IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service (PR Newswire)
Apr-04-24 07:01AM	Ginkgo Bioworks to Host 5th Annual Ferment Conference (PR Newswire)
Apr-03-24 07:02AM	Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing (PR Newswire)
Apr-02-24 07:02AM	Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs (PR Newswire) -6.25%
Mar-28-24 07:02AM	Ginkgo Bioworks Awarded DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments (PR Newswire) +5.45%
Mar-27-24 07:02AM	AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production (PR Newswire)
Mar-26-24 07:02AM	Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins (PR Newswire)
Mar-13-24 05:04AM	ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network (PR Newswire)
Mar-12-24 07:01AM	CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago (PR Newswire)
Feb-29-24 05:01PM	Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire) -15.13%
Feb-28-24 07:12AM	bit.bio Announced as Inaugural Partner of Ginkgo Bioworks New Technology Network (Business Wire)
07:03AM	Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions (PR Newswire)
07:02AM	Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs (PR Newswire)
07:02AM	Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers (PR Newswire)
07:02AM	Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers (PR Newswire)
07:01AM	Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners (PR Newswire)
Feb-27-24 09:00AM	Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones (PR Newswire) +9.29%
07:05AM	Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-22-24 07:00AM	Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation (PR Newswire)
Feb-15-24 07:02AM	Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design (PR Newswire)
07:00AM	BiomEdit Announces Advancement of a First-of-Its-Kind Engineered Bacteria Product into Full Pivotal Development to Combat Necrotic Enteritis in Broiler Chickens (PR Newswire)
Feb-13-24 07:01AM	House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025 (PR Newswire) -10.60%
Feb-01-24 07:00AM	Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval (PR Newswire)
Jan-31-24 07:00AM	Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains (PR Newswire)
Jan-15-24 07:00AM	Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world (PR Newswire)
Jan-10-24 07:35AM	Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference (PR Newswire) -6.62%
Jan-08-24 07:00AM	Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board (PR Newswire)
Jan-04-24 07:00AM	Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform (PR Newswire)
Jan-03-24 07:00AM	Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -7.78%
Dec-20-23 07:00AM	OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product (PR Newswire) -5.03%
Dec-19-23 07:01AM	U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions (PR Newswire) +13.29%
07:01AM	GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals' (PR Newswire)
07:01AM	FGen AG, a Ginkgo Bioworks Subsidiary, Awarded Funding Through European Innovation Council's Pathfinder Programme For Sustainable Milk Protein Production Project (PR Newswire)
Dec-13-23 07:01AM	Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria (PR Newswire) +8.27%
Dec-12-23 07:01AM	Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors (PR Newswire)
Dec-08-23 09:00AM	Alveolus Bio Enters Into Strategic Collaboration with BiomEdit (PR Newswire)
07:02AM	Agrivalle and Ginkgo Bioworks Enter Multiyear Strategic Partnership to Accelerate Next-Gen Ag Biological Products (PR Newswire)
Dec-06-23 05:00PM	Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan (PR Newswire)
Nov-30-23 12:25PM	Freight Farms Emerges as Global AgTech Leader with Small-Scale Solutions (IPO-Edge.com) -7.19%
Nov-27-23 07:00AM	Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins (PR Newswire)
Nov-14-23 04:30PM	XWELL, Inc. Reports Third Quarter 2023 Results (GlobeNewswire) +12.50% +8.33%
Nov-11-23 01:55PM	Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 07:01AM	Foremost Farms Selects Ginkgo Bioworks to Develop Technology for Upcycling Dairy Co-products (PR Newswire) -15.44%
Nov-08-23 05:01PM	Ginkgo Bioworks Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-06-23 07:00AM	Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens (PR Newswire) -7.32%
Nov-01-23 09:00AM	BiomEdit Awarded Grant to Develop Microbiome-Based Solution to Reduce Methane Emissions and Enhance Production Efficiency of Cattle in Africa and South Asia (PR Newswire)
07:00AM	Ginkgo Bioworks Announces Date of Third Quarter 2023 Results Presentation (PR Newswire)
Oct-24-23 07:00AM	Concentric by Ginkgo Partners with Penn State University on Zoonotic Disease Biosurveillance Research Supported by USDA Grant (PR Newswire) +5.37%
Oct-19-23 04:01PM	Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus (PR Newswire) -5.45%
Oct-17-23 07:01AM	Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit (PR Newswire)
Oct-16-23 07:01AM	Zenfold Leverages Ginkgo Enzyme Services to Enable Veterinary Active Ingredient Development with Sustainable Biology (PR Newswire)
Oct-12-23 07:01AM	QL AG Announces Partnership with Ginkgo Bioworks to Develop Dairy Proteins (PR Newswire) -7.43%
Oct-05-23 07:00AM	Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting (PR Newswire) +5.49%
Oct-02-23 07:01AM	Nosh.bio Leverages Ginkgo Strain Optimization Services to Enhance Meaty Taste of Mycoprotein (PR Newswire) -5.52%
Sep-29-23 07:00AM	Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover (PR Newswire) +5.23%
Sep-28-23 09:54AM	Too Cheap to Ignore: Cathie Wood Snaps Up These 2 Stocks Under $5 (TipRanks)
07:01AM	Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing (PR Newswire)

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Che Austin	Officer	Sep 06 '24	Proposed Sale	6.06	99	600		Sep 06 09:47 AM
Che Austin	Officer	Sep 05 '24	Proposed Sale	6.24	99	618		Sep 05 10:50 AM
Che Austin	Officer	Sep 04 '24	Proposed Sale	6.00	99	594		Sep 04 10:43 AM
Che Austin	Officer	Sep 03 '24	Proposed Sale	6.57	99	650		Sep 03 12:59 PM
Che Austin	Officer	Aug 30 '24	Proposed Sale	7.24	99	717		Aug 30 10:31 AM
Che Austin	Officer	Aug 29 '24	Proposed Sale	7.19	99	712		Aug 29 10:31 AM
Che Austin	Officer	Aug 28 '24	Proposed Sale	7.45	99	738		Aug 28 11:25 AM
Che Austin	Officer	Aug 27 '24	Proposed Sale	7.77	99	769		Aug 27 10:01 AM
Che Austin	Officer	Aug 26 '24	Proposed Sale	8.08	99	800		Aug 26 11:51 AM
Che Austin	Officer	Aug 23 '24	Proposed Sale	8.38	396	3,318		Aug 23 10:46 AM
Che Austin	Officer	Aug 19 '24	Proposed Sale	0.23	3,968	915		Aug 19 11:05 AM
Che Austin	Officer	Aug 16 '24	Proposed Sale	0.25	3,968	982		Aug 16 11:23 AM
Che Austin	Officer	Aug 15 '24	Proposed Sale	0.24	3,968	932		Aug 15 11:59 AM
Che Austin	Officer	Aug 14 '24	Proposed Sale	0.28	3,968	1,108		Aug 14 10:10 AM
Che Austin	Officer	Aug 13 '24	Proposed Sale	0.26	3,968	1,034		Aug 13 10:33 AM
Che Austin	Officer	Aug 12 '24	Proposed Sale	0.27	3,968	1,057		Aug 12 09:57 AM
Che Austin	Officer	Aug 09 '24	Proposed Sale	0.31	3,968	1,230		Aug 09 12:37 PM
Che Austin	Officer	Aug 08 '24	Proposed Sale	0.30	3,968	1,182		Aug 08 10:14 AM
Che Austin	Officer	Aug 07 '24	Proposed Sale	0.29	3,968	1,149		Aug 07 10:38 AM
Coen Steven P.	See remarks	Aug 02 '24	Sale	0.29	17,486	5,018	207,318	Aug 06 04:39 PM
Dmytruk Mark E.	See remarks	Aug 02 '24	Sale	0.29	63,567	18,244	1,088,186	Aug 06 04:37 PM
Che Austin	Officer	Aug 06 '24	Proposed Sale	0.30	3,968	1,190		Aug 06 10:12 AM
Che Austin	Officer	Aug 05 '24	Proposed Sale	0.27	3,968	1,052		Aug 05 11:05 AM
Dmytruk Mark E.	Officer	Aug 02 '24	Proposed Sale	0.29	63,567	18,225		Aug 02 03:56 PM
Che Austin	Officer	Aug 02 '24	Proposed Sale	0.34	3,968	1,349		Aug 02 10:22 AM
Che Austin	Officer	Aug 01 '24	Proposed Sale	0.38	3,968	1,502		Aug 01 01:49 PM
Che Austin	Officer	Jul 31 '24	Proposed Sale	0.37	3,968	1,450		Jul 31 10:39 AM
Che Austin	Officer	Jul 30 '24	Proposed Sale	0.37	3,968	1,470		Jul 30 11:17 AM
Che Austin	Officer	Jul 29 '24	Proposed Sale	0.38	3,968	1,508		Jul 29 10:34 AM
Che Austin	Officer	Jul 26 '24	Proposed Sale	0.33	3,968	1,326		Jul 26 09:56 AM
Coen Steven P.	See remarks	Jul 02 '24	Sale	0.33	13,520	4,408	195,058	Jul 05 04:02 PM
Dmytruk Mark E.	See remarks	Jul 02 '24	Sale	0.33	49,162	16,027	1,043,626	Jul 05 04:01 PM
Coen Steven P.	See remarks	Jun 03 '24	Sale	0.55	13,440	7,379	178,832	Jun 05 05:06 PM
Dmytruk Mark E.	See remarks	Jun 03 '24	Sale	0.55	48,866	26,827	984,662	Jun 05 05:04 PM
DEKKERS MARIJN E	Director	May 16 '24	Sale	0.83	265,000	220,030	5,515,364	May 20 04:54 PM
Sankar Shyam	Director	May 15 '24	Buy	0.82	625,000	514,750	2,356,874	May 16 05:08 PM
SLOAN HARRY	Director	May 14 '24	Buy	0.91	297,619	271,815	718,540	May 14 05:16 PM
DEKKERS MARIJN E	Director	May 14 '24	Sale	0.93	1,727,056	1,606,162	281,217	May 14 05:13 PM
Dmytruk Mark E.	See remarks	May 02 '24	Sale	0.84	47,806	40,396	925,400	May 06 04:55 PM
Coen Steven P.	See remarks	May 02 '24	Sale	0.84	131,928	111,479	162,527	May 06 04:53 PM
Dmytruk Mark E.	See remarks	Apr 02 '24	Sale	1.05	51,169	53,727	865,079	Apr 04 04:40 PM
Dmytruk Mark E.	See remarks	Mar 04 '24	Sale	1.26	38,826	48,765	808,125	Mar 06 05:08 PM
Dmytruk Mark E.	See remarks	Feb 02 '24	Sale	1.21	39,569	47,799	761,737	Feb 06 05:06 PM
Kelly Jason R	See remarks	Jan 04 '24	Sale	1.55	100,000	155,500	3,894,680	Jan 05 05:11 PM
Kelly Jason R	See remarks	Jan 03 '24	Sale	1.54	100,000	154,400	3,994,680	Jan 05 05:11 PM
Dmytruk Mark E.	See remarks	Jan 03 '24	Sale	1.54	45,794	70,523	716,098	Jan 05 05:09 PM
Canton Barry	10% Owner	Dec 20 '23	Sale	1.79	37,650	67,582	12,374,554	Dec 22 04:59 PM
Canton Barry	10% Owner	Dec 21 '23	Sale	1.74	37,650	65,398	12,374,544	Dec 22 04:59 PM
Kelly Jason R	See remarks	Dec 20 '23	Sale	1.79	100,000	179,400	4,194,680	Dec 22 04:57 PM
Kelly Jason R	See remarks	Dec 21 '23	Sale	1.74	100,000	173,700	4,094,680	Dec 22 04:57 PM
Shetty Reshma P.	See remarks	Dec 20 '23	Sale	1.79	37,650	67,582	12,374,554	Dec 22 04:55 PM
Shetty Reshma P.	See remarks	Dec 21 '23	Sale	1.74	37,650	65,398	12,374,544	Dec 22 04:55 PM
Canton Barry	10% Owner	Dec 14 '23	Sale	1.63	37,650	61,257	12,412,194	Dec 15 05:07 PM
Canton Barry	10% Owner	Dec 13 '23	Sale	1.34	36,829	49,351	12,413,025	Dec 15 05:07 PM
Canton Barry	10% Owner	Dec 14 '23	Sale	1.48	821	1,215	12,412,204	Dec 15 05:07 PM
Kelly Jason R	See remarks	Dec 14 '23	Sale	1.62	100,980	164,092	4,294,680	Dec 15 05:05 PM
Kelly Jason R	See remarks	Dec 13 '23	Sale	1.34	99,020	132,786	4,395,660	Dec 15 05:05 PM
Shetty Reshma P.	See remarks	Dec 14 '23	Sale	1.63	37,650	61,257	12,412,194	Dec 15 05:02 PM
Shetty Reshma P.	See remarks	Dec 13 '23	Sale	1.34	36,829	49,351	12,413,025	Dec 15 05:02 PM
Shetty Reshma P.	See remarks	Dec 14 '23	Sale	1.48	821	1,215	12,412,204	Dec 15 05:02 PM
Canton Barry	10% Owner	Dec 06 '23	Sale	1.32	37,650	49,811	12,449,854	Dec 08 05:17 PM
Canton Barry	10% Owner	Dec 07 '23	Sale	1.31	37,650	49,510	12,449,844	Dec 08 05:17 PM
Kelly Jason R	See remarks	Dec 06 '23	Sale	1.32	100,000	132,300	4,594,680	Dec 08 05:15 PM
Kelly Jason R	See remarks	Dec 07 '23	Sale	1.31	100,000	131,300	4,494,680	Dec 08 05:15 PM
Shetty Reshma P.	See remarks	Dec 06 '23	Sale	1.32	37,650	49,811	12,449,854	Dec 08 05:14 PM
Shetty Reshma P.	See remarks	Dec 07 '23	Sale	1.31	37,650	49,510	12,449,844	Dec 08 05:14 PM
Dmytruk Mark E.	See remarks	Dec 04 '23	Sale	1.39	42,402	58,812	676,844	Dec 06 05:09 PM
Shetty Reshma P.	See remarks	Nov 29 '23	Sale	1.45	37,650	54,592	12,487,504	Dec 01 05:02 PM
Shetty Reshma P.	See remarks	Nov 30 '23	Sale	1.35	37,650	50,940	12,487,494	Dec 01 05:02 PM
Kelly Jason R	See remarks	Nov 29 '23	Sale	1.45	100,000	145,200	4,794,680	Dec 01 04:59 PM
Kelly Jason R	See remarks	Nov 30 '23	Sale	1.35	100,000	135,300	4,694,680	Dec 01 04:59 PM
Canton Barry	10% Owner	Nov 29 '23	Sale	1.45	37,650	54,592	12,487,504	Dec 01 04:54 PM
Canton Barry	10% Owner	Nov 30 '23	Sale	1.35	37,650	50,940	12,487,494	Dec 01 04:54 PM
Canton Barry	10% Owner	Nov 24 '23	Sale	1.42	37,650	53,275	12,525,144	Nov 27 05:00 PM
Canton Barry	10% Owner	Nov 22 '23	Sale	1.40	37,650	52,785	12,525,154	Nov 27 05:00 PM
Kelly Jason R	See remarks	Nov 24 '23	Sale	1.41	100,000	141,300	4,894,680	Nov 27 04:58 PM
Kelly Jason R	See remarks	Nov 22 '23	Sale	1.40	100,000	140,400	4,994,680	Nov 27 04:58 PM
Shetty Reshma P.	See remarks	Nov 24 '23	Sale	1.42	37,650	53,275	12,525,144	Nov 27 04:57 PM
Shetty Reshma P.	See remarks	Nov 22 '23	Sale	1.40	37,650	52,785	12,525,154	Nov 27 04:57 PM
Canton Barry	10% Owner	Nov 15 '23	Sale	1.54	37,650	58,132	12,562,804	Nov 17 04:59 PM
Canton Barry	10% Owner	Nov 16 '23	Sale	1.45	37,650	54,705	12,562,794	Nov 17 04:59 PM
Kelly Jason R	See remarks	Nov 15 '23	Sale	1.54	100,000	154,200	5,194,680	Nov 17 04:56 PM
Kelly Jason R	See remarks	Nov 16 '23	Sale	1.45	100,000	145,200	5,094,680	Nov 17 04:56 PM
Shetty Reshma P.	See remarks	Nov 15 '23	Sale	1.54	37,650	58,132	12,562,804	Nov 17 04:53 PM
Shetty Reshma P.	See remarks	Nov 16 '23	Sale	1.45	37,650	54,705	12,562,794	Nov 17 04:53 PM
Shetty Reshma P.	See remarks	Nov 08 '23	Sale	1.50	37,650	56,626	12,600,454	Nov 13 08:02 AM
Shetty Reshma P.	See remarks	Nov 09 '23	Sale	1.29	37,650	48,531	12,600,444	Nov 13 08:02 AM
Kelly Jason R	See remarks	Nov 08 '23	Sale	1.50	100,000	150,200	5,394,680	Nov 13 08:01 AM
Kelly Jason R	See remarks	Nov 09 '23	Sale	1.29	100,000	129,100	5,294,680	Nov 13 08:01 AM
Canton Barry	10% Owner	Nov 08 '23	Sale	1.50	37,650	56,626	12,600,454	Nov 13 08:00 AM
Canton Barry	10% Owner	Nov 09 '23	Sale	1.29	37,650	48,531	12,600,444	Nov 13 08:00 AM
HENRY CHRISTIAN O	Director	Nov 02 '23	Sale	1.39	4,500	6,255	1,234,378	Nov 06 05:23 PM
Dmytruk Mark E.	See remarks	Nov 02 '23	Sale	1.50	37,229	55,918	634,206	Nov 06 05:21 PM
Shetty Reshma P.	See remarks	Nov 02 '23	Sale	1.52	37,650	57,077	12,638,094	Nov 03 05:09 PM
Shetty Reshma P.	See remarks	Nov 01 '23	Sale	1.34	37,650	50,564	12,638,104	Nov 03 05:09 PM
Canton Barry	10% Owner	Nov 02 '23	Sale	1.52	37,650	57,077	12,638,094	Nov 03 05:04 PM
Canton Barry	10% Owner	Nov 01 '23	Sale	1.34	37,650	50,564	12,638,104	Nov 03 05:04 PM
Kelly Jason R	See remarks	Nov 02 '23	Sale	1.52	100,000	151,600	5,494,680	Nov 03 05:01 PM
Kelly Jason R	See remarks	Nov 01 '23	Sale	1.34	100,000	134,200	5,594,680	Nov 03 05:01 PM
Shetty Reshma P.	See remarks	Oct 25 '23	Sale	1.48	37,650	55,609	12,675,754	Oct 27 04:56 PM

Open in Screener

DNLI

Denali Therapeutics Inc

Sep 06 • 04:00PM ET

25.25

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

DNLI Denali Therapeutics Inc daily Stock Chart

Held by: VTI IWM VB VXF XBI VBK IBB IWO SCHA IWN

Index	RUT	P/E	-	EPS (ttm)	-2.85	Insider Own	16.89%	Shs Outstand	138.39M	Perf Week	3.48%
Market Cap	3.61B	Forward P/E	-	EPS next Y	-2.68	Insider Trans	-0.72%	Shs Float	118.98M	Perf Month	16.47%
Income	-419.65M	PEG	-	EPS next Q	-0.62	Inst Own	84.17%	Short Float	7.03%	Perf Quarter	18.49%
Sales	1.27M	P/S	2846.29	EPS this Y	-139.57%	Inst Trans	-0.74%	Short Ratio	7.56	Perf Half Y	22.99%
Book/sh	9.69	P/B	2.61	EPS next Y	-5.70%	ROA	-29.89%	Short Interest	8.36M	Perf Year	2.23%
Cash/sh	6.26	P/C	4.03	EPS next 5Y	-	ROE	-32.61%	52W Range	14.56 - 25.90	Perf YTD	17.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.99%	ROI	-29.39%	52W High	-2.51%	Beta	1.36
Dividend TTM	-	Quick Ratio	12.46	Sales past 5Y	264.19%	Gross Margin	-570.72%	52W Low	73.42%	ATR (14)	1.09
Dividend Ex-Date	-	Current Ratio	12.46	EPS Y/Y TTM	-173.06%	Oper. Margin	-39085.40%	RSI (14)	59.58	Volatility	3.86% 4.28%
Employees	445	Debt/Eq	0.04	Sales Y/Y TTM	-99.63%	Profit Margin	-33121.86%	Recom	1.13	Target Price	39.77
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-145.07%	Payout	-	Rel Volume	0.57	Prev Close	25.25
Sales Surprise	-100.00%	EPS Surprise	13.96%	Sales Q/Q	-100.00%	Earnings	Aug 01 BMO	Avg Volume	1.11M	Price	25.25
SMA20	5.19%	SMA50	8.80%	SMA200	25.35%	Trades		Volume	628,703	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85
Sep-01-21	Initiated	SMBC Nikko	Outperform	$78
May-18-21	Initiated	UBS	Buy	$70
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$80 → $95
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$105
Nov-11-20	Reiterated	H.C. Wainwright	Buy	$65 → $80
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight	$35
Aug-20-20	Reiterated	H.C. Wainwright	Buy	$28 → $45
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform	$20

Show Previous Ratings

Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
06:45AM	Loading…
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
07:00AM	Loading…
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%
Feb-27-24 08:31AM	Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +38.25%
08:05AM	Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Loading…
08:00AM	Denali Therapeutics Announces $500 million Private Placement Equity Financing (GlobeNewswire)
06:53AM	Denali, fresh off study setback, gets $500M lift (BioPharma Dive)
Feb-16-24 08:39AM	UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal (Reuters) -7.30%
08:22AM	Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (Reuters)
07:13AM	ALS drug from Denali, Sanofi falls short in mid-stage study (BioPharma Dive)
Feb-07-24 08:00AM	Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium (GlobeNewswire)
Feb-01-24 08:00AM	Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium (GlobeNewswire)
Jan-31-24 11:04PM	Baillie Gifford Reduces Stake in Denali Therapeutics Inc (GuruFocus.com)
Jan-26-24 10:00AM	Denali's (DNLI) Pipeline Progresses Despite Stiff Competition (Zacks)
Jan-11-24 01:11PM	40 Cities with the Lowest Life Expectancy in the US (Insider Monkey)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 08:00AM	Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire) +5.27%
06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace)
Dec-22-23 06:22AM	40 Cities with the Highest Life Expectancy in the US (Insider Monkey)
Dec-21-23 09:55AM	Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect? (Zacks)
Dec-07-23 11:31AM	Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report? (Zacks)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
09:55AM	Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High? (Zacks)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) -5.11%
Nov-07-23 05:50PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-06-23 09:55AM	Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet (Zacks)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-06-23 04:41AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains? (Zacks)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire)
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report? (Zacks)
Aug-30-23 08:30AM	Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-11-23 11:36AM	20 Countries that Have the Most Billionaires Per Capita (Insider Monkey)
Aug-10-23 12:02PM	Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues (Zacks)
06:03AM	Pinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right Now (Simply Wall St.)
Aug-08-23 06:05PM	Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-29-23 05:13AM	Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now (InvestorPlace)
Jun-27-23 02:23PM	In the wake of Denali Therapeutics Inc.'s (NASDAQ:DNLI) latest US$402m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Jun-26-23 10:00AM	Salt Lake City Ups the Ante in Bid to Become a Fintech Hub (The Wall Street Journal)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
06:00AM	Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs (PR Newswire)
Jun-20-23 04:20PM	Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker (Benzinga)
07:00AM	Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) (GlobeNewswire)
Jun-09-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? (Zacks)
Jun-08-23 11:30AM	Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report? (Zacks)
Jun-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report? (Zacks)
Jun-05-23 06:15PM	Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure (Benzinga)
May-31-23 01:30PM	Denali Therapeutics (NASDAQ:DNLI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire) -8.49%
May-15-23 04:31PM	Why Shares of Denali Therapeutics Are Up Monday (Motley Fool) +14.52%
May-09-23 01:24PM	Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus (Zacks)
May-08-23 05:15PM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 01:21PM	Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 40% Undervaluation? (Simply Wall St.)
May-01-23 10:00AM	Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline (Zacks)
Apr-27-23 10:02AM	Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-14-23 07:03AM	Denali Therapeutics' (NASDAQ:DNLI) investors will be pleased with their 28% return over the last five years (Simply Wall St.)
Apr-12-23 08:00AM	Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta (GlobeNewswire)
Apr-10-23 08:00AM	Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-29-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report? (Zacks)
Mar-04-23 07:35AM	The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically (Simply Wall St.)
Feb-28-23 09:01AM	Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus (Zacks)
Feb-27-23 05:35PM	Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Feb-23-23 11:15AM	Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study (Benzinga) -8.45%
Feb-22-23 04:33PM	Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium (GlobeNewswire)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Sep 03 '24	Sale	25.00	3,080	77,007	116,176	Sep 04 06:26 PM
Watts Ryan J.	President and CEO	Aug 20 '24	Sale	23.79	2,260	53,765	235,807	Aug 22 04:16 PM
Krognes Steve E.	Director	Aug 20 '24	Sale	23.79	1,727	41,085	32,677	Aug 22 04:15 PM
Schuth Alexander O.	COFO and Secretary	Aug 20 '24	Sale	23.65	5,806	137,286	180,613	Aug 22 04:14 PM
Schuth Alexander O.	COFO and Secretary	Aug 21 '24	Sale	24.78	2,547	63,115	178,066	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 21 '24	Sale	24.57	20,005	491,571	118,810	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 20 '24	Sale	23.79	2,453	58,357	138,815	Aug 22 04:14 PM
CAROLE HO	Officer	Aug 21 '24	Proposed Sale	23.65	20,005	473,118		Aug 21 04:42 PM
ALEXANDER SCHUTH	Officer	Aug 21 '24	Proposed Sale	23.65	2,547	60,237		Aug 21 04:40 PM
Krognes Steve E.	Director	Aug 20 '24	Proposed Sale	23.79	1,727	41,085		Aug 20 08:09 PM
Schuth Alexander O.	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,357		Aug 20 08:09 PM
Watts Ryan J.	Director	Aug 20 '24	Proposed Sale	23.79	2,260	53,765		Aug 20 08:08 PM
Ho Carole	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,356		Aug 20 08:08 PM
ALEXANDER SCHUTH	Officer	Aug 20 '24	Proposed Sale	23.95	3,353	80,304		Aug 20 04:27 PM
Schuth Alexander O.	COFO and Secretary	Aug 13 '24	Sale	22.89	2,272	52,006	186,419	Aug 15 04:10 PM
Ho Carole	Chief Medical Officer	Aug 13 '24	Sale	22.89	2,337	53,494	141,268	Aug 15 04:09 PM
Schuth Alexander O.	Officer	Aug 13 '24	Proposed Sale	22.89	2,272	52,006		Aug 13 08:37 PM
Ho Carole	Officer	Aug 13 '24	Proposed Sale	22.89	2,337	53,494		Aug 13 08:36 PM
Krognes Steve E.	Director	Jul 01 '24	Sale	22.12	30,000	663,668	34,404	Jul 03 09:13 PM
Krognes Steve E.	Director	Jun 13 '24	Sale	21.79	688	14,992	52,620	Jul 03 09:13 PM
SATO VICKI L	Director	Jul 01 '24	Sale	22.14	3,080	68,204	119,256	Jul 03 09:13 PM
Cook Jennifer E.	Director	Jun 06 '24	Sale	21.73	1,458	31,682	20,038	Jun 10 08:06 PM
SATO VICKI L	Director	May 15 '24	Sale	20.39	1,674	34,133	116,369	May 17 04:28 PM
SATO VICKI L	Director	Apr 15 '24	Sale	18.29	1,666	30,471	118,043	Apr 17 05:14 PM
Krognes Steve E.	Director	Apr 01 '24	Sale	20.50	92,500	1,896,250	47,341	Apr 02 06:07 PM
SATO VICKI L	Director	Mar 15 '24	Sale	20.10	1,666	33,487	119,709	Mar 19 04:27 PM
SATO VICKI L	Director	Feb 15 '24	Sale	18.37	1,666	30,604	121,375	Feb 20 05:38 PM
Krognes Steve E.	Director	Feb 13 '24	Sale	17.29	2,750	47,548	139,841	Feb 15 09:16 PM
Watts Ryan J.	President and CEO	Feb 13 '24	Sale	17.29	9,589	165,794	238,067	Feb 15 09:15 PM
Ho Carole	Chief Medical Officer	Feb 13 '24	Sale	17.29	2,784	48,135	145,010	Feb 15 09:14 PM
Ho Carole	Chief Medical Officer	Feb 14 '24	Sale	17.79	1,405	24,995	143,605	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 14 '24	Sale	17.66	20,128	355,460	187,341	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 13 '24	Sale	17.29	2,716	46,960	207,469	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 08 '24	Option Exercise	0.68	50,000	34,000	210,185	Feb 12 04:48 PM
SATO VICKI L	Director	Jan 16 '24	Sale	18.42	1,666	30,688	123,041	Jan 18 06:26 PM
Ho Carole	Chief Medical Officer	Jan 10 '24	Sale	19.02	4,668	88,785	147,794	Jan 12 08:18 PM
Watts Ryan J.	President and CEO	Jan 09 '24	Sale	19.78	7,818	154,640	2,268,363	Jan 11 05:28 PM
Ho Carole	Chief Medical Officer	Jan 05 '24	Sale	19.43	9,972	193,756	198,777	Jan 09 07:35 PM
Krognes Steve E.	Director	Jan 05 '24	Sale	19.43	3,208	62,331	142,591	Jan 09 07:34 PM
Schuth Alexander O.	COFO and Secretary	Jan 05 '24	Sale	19.43	9,972	193,756	539,307	Jan 09 07:34 PM
Watts Ryan J.	President and CEO	Jan 05 '24	Sale	19.43	17,483	339,695	2,276,181	Jan 09 07:33 PM
SATO VICKI L	Director	Dec 15 '23	Sale	23.39	1,666	38,968	124,707	Dec 18 07:30 PM
SATO VICKI L	Director	Nov 15 '23	Sale	19.13	1,666	31,871	126,373	Nov 16 06:14 PM
SATO VICKI L	Director	Oct 16 '23	Sale	20.66	1,666	34,420	128,039	Oct 18 04:44 PM
SATO VICKI L	Director	Sep 15 '23	Sale	23.62	1,666	39,348	129,705	Sep 19 04:45 PM

Open in Screener

BEAM

Beam Therapeutics Inc

Sep 06 • 04:00PM ET

23.31

Dollar change -0.87
Percentage change -3.60	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

BEAM Beam Therapeutics Inc daily Stock Chart

Held by: ARKK VTI VB IWM ARKG XBI VBK VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	13.15%	Shs Outstand	81.63M	Perf Week	-13.15%
Market Cap	1.92B	Forward P/E	-	EPS next Y	-4.66	Insider Trans	-1.60%	Shs Float	71.58M	Perf Month	-4.70%
Income	-143.01M	PEG	-	EPS next Q	-1.19	Inst Own	81.50%	Short Float	15.62%	Perf Quarter	-3.16%
Sales	352.57M	P/S	5.45	EPS this Y	-173.05%	Inst Trans	-0.68%	Short Ratio	9.15	Perf Half Y	-36.93%
Book/sh	10.37	P/B	2.25	EPS next Y	0.84%	ROA	-10.94%	Short Interest	11.18M	Perf Year	-5.47%
Cash/sh	12.23	P/C	1.91	EPS next 5Y	-3.70%	ROE	-17.17%	52W Range	16.95 - 49.50	Perf YTD	-14.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-14.21%	52W High	-52.91%	Beta	1.87
Dividend TTM	-	Quick Ratio	5.81	Sales past 5Y	43297.50%	Gross Margin	93.24%	52W Low	37.52%	ATR (14)	1.51
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.81	EPS Y/Y TTM	60.97%	Oper. Margin	-52.31%	RSI (14)	39.62	Volatility	5.99% 5.21%
Employees	436	Debt/Eq	0.19	Sales Y/Y TTM	339.83%	Profit Margin	-40.56%	Recom	1.88	Target Price	50.14
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-2.01%	Payout	-	Rel Volume	0.38	Prev Close	24.18
Sales Surprise	-16.95%	EPS Surprise	1.52%	Sales Q/Q	-41.48%	Earnings	Aug 06 BMO	Avg Volume	1.22M	Price	23.31
SMA20	-7.19%	SMA50	-10.59%	SMA200	-15.36%	Trades		Volume	467,199	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$85
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight	$47 → $90
Feb-16-21	Initiated	Wells Fargo	Overweight	$145

Show Previous Ratings

Sep-05-24 11:31AM	Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? (Zacks)
Aug-14-24 10:27AM	Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology (Insider Monkey)
Aug-09-24 10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-07-24 10:50AM	Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss (Zacks)
Aug-06-24 01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
07:45AM	Loading…
07:45AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-26-24 07:43AM	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-24-24 06:28PM	Beam Therapeutics Stock Earns RS Rating Jump To 85 (Investor's Business Daily) +7.92%
08:53AM	CRISPR Therapeutics Nears 52-Week Low. Time to Buy? (TipRanks)
08:23AM	Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 (InvestorPlace)
Jul-22-24 04:45PM	3 Gene Editing Stocks Shaping the Future of Medicine (InvestorPlace) +12.09%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 10:12AM	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines (Zacks) +6.52%
Jul-15-24 06:30AM	Beam Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
12:56PM	Loading…
Jul-11-24 12:56PM	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now (Zacks) +8.01%
Jul-09-24 12:00PM	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:25AM	3 Stocks With the Potential to 10X Your Money (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:26AM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study (Zacks)
Jun-26-24 06:30AM	Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jun-14-24 03:00AM	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report? (Zacks)
May-30-24 06:30AM	Beam Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 04:00PM	Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey) +12.98%
May-09-24 06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
10:52AM	Loading…
May-08-24 10:52AM	Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss (Zacks)
06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference (GlobeNewswire)
May-07-24 09:02PM	Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview (GuruFocus.com)
01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:17AM	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47% -8.66%
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98% -9.14%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 01:04PM	Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates (Zacks)
Nov-08-23 06:30AM	Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire) -8.36%
06:30AM	Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-01-23 05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +10.62%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)
10:00AM	After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? (Motley Fool)
06:00AM	Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:18AM	5 Reasons Beam Therapeutics Remains a Risky Stock (Motley Fool)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-25-23 06:30AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT (GlobeNewswire)
05:50AM	Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? (Motley Fool)
01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-21-23 08:45AM	Beam Therapeutics Stock: Bear vs. Bull (Motley Fool)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
09:37AM	SolarEdge downgraded, Crocs upgraded: Wall Street's top analyst calls (The Fly)
Oct-19-23 09:03AM	UPDATE 2-Beam Therapeutics to cut 20% of workforce as part of restructuring plan (Reuters) -11.73%
08:54AM	Beam Therapeutics to cut 20% of workforce (Reuters)
08:45AM	Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline (GlobeNewswire)
Oct-18-23 09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool) -6.60%
Oct-05-23 08:45AM	2 Cathie Wood Stocks I'm Bullish On (Motley Fool)
Oct-03-23 06:27AM	Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? (Motley Fool)
Sep-29-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Sep-27-23 08:30AM	2 Magnificent Growth Stocks to Buy On the Dip (Motley Fool)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM
Evans John M.	CEO	Jun 27 '24	Sale	24.50	60,000	1,470,156	998,343	Jun 28 04:15 PM
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 03 '24	Sale	26.42	1,907	50,383	80,495	Jan 05 04:30 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Option Exercise	7.22	10,000	72,200	92,402	Nov 22 04:05 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Sale	30.50	10,000	305,000	82,402	Nov 22 04:05 PM
Simon Amy	Chief Medical Officer	Oct 30 '23	Sale	18.70	3,448	64,478	65,469	Nov 01 04:30 PM
Ciaramella Giuseppe	President and CSO	Oct 20 '23	Option Exercise	0.67	90,900	60,903	139,150	Oct 24 04:05 PM
Bellon Christine	Chief Legal Officer	Oct 02 '23	Sale	22.85	388	8,866	82,402	Oct 04 04:30 PM

MRNA

EDIT

RGNX

IMVT

RXRX

IPSC

TWST

HALO

PCVX

ATYR

ARTV

BCLI

ALVR

VCEL

CADL

ADVM

FDMT

ACLX

NBIX

TARA

RVMD

KYMR

LXEO

CGEM

GLUE

FENC

APGE

DNA

DNLI

BEAM

Upgrade your FINVIZ experience